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Abstract 
Diabetes mellitus (DM) is prevalent among older adults and leads to disability, frailty, 
and dependency. In care homes, multimorbidity and polypharmacy may further 
complicate the management of DM and increase the risk of adverse events. This thesis 
aims to investigate the prevalence and management of DM in care homes, with special 
emphasis on medicines and blood glucose measurements.  
Paper I was a cross-sectional study of 742 residents from 19 Norwegian nursing homes 
(NHs). We found a DM prevalence of 16 % (n=116), and that 74 % of residents with 
DM used blood glucose-lowering medicines. CBGM the last four weeks was 
registered for 73 % of the residents, frequency varied from daily to monthly. Six out of 
ten residents had at least one blood glucose reading <6.0 mmol/L. An HbA1c value the 
last twelve months was recorded for 77 % of residents, with a mean of 57 mmol/mol 
(7.3 %) and a range of 28-112 mmol/mol (4.7-12.4 %). 
Paper II was a retrospective study of 826 residents from 30 English care homes, using 
baseline data from the CAREMED study. For residents with type 2 DM (T2DM), we 
described comorbidities and prescriptions, and identified potentially inappropriate 
medicines (PIMs). Of the 106 residents with T2DM, 76 % used blood glucose-
lowering medicines. The number of comorbidities, prescriptions, and residents using 
≥5 medicines was higher among residents with T2DM compared to residents without 
DM. We identified 346 PIMs, and nine out of ten residents with T2DM had at least 
one PIM. Of the 67 PIMs in the 20 % resident sample for validation, a care home 
physician agreed that 26 and 40 of them could be directly discontinued or considered 
discontinued, respectively. 
Paper III was a qualitative study exploring the perspectives of NH staff on the use and 
usefulness, procedures, and potential challenges of CBGM in Norwegian NHs. We 
conducted three profession-specific focus groups, including five physicians, four 
registered nurses, and three auxiliary nurses, using a semi-structured interview guide. 
All professional groups found CBGM necessary when caring for residents with DM, 
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but tried to minimise its use to ease the strain on the residents. The participants 
mentioned access to and familiarity with procedures, equivalent practice, explicit 
documentation routines, and sufficient training in DM and its symptoms as means by 
which to promote the appropriate use of CBGM and ensure patient safety. Currently, 
one or several of these factors were lacking.    
In conclusion, the research in this thesis shows that care home residents with DM 
suffer a high burden of medicines in general and use of DM medicines in particular. 
Patient safety may be further compromised by the lack of training and procedures in 
regard to CBGM and recognising deviant blood glucose concentrations. Thus, the 
potential to optimise medicine use and improve blood glucose-monitoring practices 
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‘So you’re diabetic?’ 
‘I prefer pancreatically challenged’. 
~ Internet meme 
1.1 Diabetes mellitus – a rising challenge 
1.1.1 Classification and diagnosis 
Diabetes mellitus (DM) is not one disease, but rather a group of complex metabolic 
diseases characterised by hyperglycaemia, which results from deficiencies in insulin 
secretion and/or response to insulin action. The specific aetiologies of DM have yet to 
be elucidated, but experts agree that a progressive loss or dysfunction of pancreatic β-
cells responsible for producing insulin is the principal component. Disease 
mechanisms and progression, as well as clinical presentation, may vary from person to 
person, but broadly speaking, there are two major categories of DM: type 1 diabetes 
mellitus (T1DM) and type 2 diabetes mellitus (T2DM). The latter accounts for 
approximately 90 % of all cases of DM. Gestational diabetes and other specific types 
of diabetes (e.g. monogenic diabetes) are not discussed in this thesis. The risk of 
developing DM is associated with a strong genetic predisposition, but various 
environmental factors may also contribute to onset and progression of the disease (1, 
2).  
Both DM types can become manifest over a wide range of age groups, but T1DM 
typically presents itself in childhood or early adulthood, while T2DM often becomes 
manifest later in life. In T1DM, the pancreatic β-cells are destroyed through 
autoimmune processes, which ultimately lead to absolute insulin deficiency. In the 
more prevalent T2DM, the mechanisms for disease are more complex, mainly 
involving different degrees of reduced insulin sensitivity and deficient insulin 
secretion. These effects have long been attributed to an age-related decline in β-cell 
function together with an increase in adipose tissue, resulting in increased hepatic 
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glucose production and impaired glucose uptake in muscle (3, 4). However, during the 
last decade, the following have been recognised as contributing factors to the 
hyperglycaemia of T2DM (5, 6):  
- increased glucagon secretion due to pancreatic α-cell dysfunction;  
- deficiency and resistance to gut hormones (incretins glucagon-like peptide-1 
(GLP-1) and gastric inhibitory polypeptide (GIP)) responsible for glucose-
dependent insulin secretion and slowing down gastric emptying;  
- impaired glucose reabsorption in the renal tubuli, due to upregulation of 
transport proteins (sodium glucose-linked transporter 2 (SGLT2));  
- increased appetite, due to neurotransmitter dysfunction in the brain.  
Recently, systemic low-grade inflammation and changes to the microbiota have also 
been suggested as parts of the pathogenesis picture. Although adding to the complexity 
of the pathophysiology of T2DM, these insights have resulted in new targets for 
medicines and warrant greater individualisation of therapy. 
DM can be diagnosed based on either the measurement of plasma glucose or glycated 
haemoglobin (HbA1c) (2, 7). When measuring plasma glucose, venous sampling of 
the fasting plasma glucose (FPG) or the two-hour plasma glucose (2h PG) after an oral 
glucose tolerance test (OGTT) can be applied. HbA1c is a measure of the proportion 
of haemoglobin (Hb) in the red blood cells that is glycated, i.e. bound to glucose. The 
build-up of glycated haemoglobin reflects the average level of glucose to which the 
red blood cell (RBC) has been exposed during its life span (7). The average RBC life 
span is approximately 120 days; however, an HbA1c change toward treatment goal 
value takes between 25 and 30 days to reach 50 %, and 50 to 70 days to reach 80 % 
(8). HbA1c is expressed as the ratio of glycated Hb to total Hb in a unit of mmol/mol, 
which has recently replaced percent as the commonly used unit in Norway (7).  
The hyperglycaemia limits that make up the criteria for diagnosis are listed in Table 1. 
If classic symptoms of hyperglycaemia are present, one affirmative test result or a 
random plasma glucose measurement ≥11.0 mmol/L is sufficient. If the patient 
displays no clinical symptoms of hyperglycaemia, two affirmative tests of the FPG, 2h 
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PG, or the HbA1c are required to confirm the diagnosis (Table 1)  (2, 7). In the clinical 
practice recommendations issued by the American Diabetes Association (ADA), it is 
stated that the two tests can either come from the same sample or from two separate 
samples. If using separate samples, it is recommended that the second test be 
performed without delay (2). Norwegian guidelines, however, state that the diagnosis 
is confirmed if the patient presents with any of the first three values in Table 1 in two 
separate samples, taken on two separate days, within a period of two weeks (7). 
For the FPG, the patient should have had no caloric intake and avoid smoking for at 
least eight hours prior to measurement. In the OGTT, the patient fasts for 8-14 hours 
before drinking 75 g of glucose dissolved in water. The plasma glucose is measured 
two hours thereafter (7). Compared to the FPG and the 2h PG, the HbA1c 
measurement is more convenient as it does not require fasting. In addition, it has better 
pre-analytical stability and is relatively robust regardless of acute changes in glucose 
levels (2, 9). Thus, HbA1c testing was recommended by the World Health 
Organization (WHO) as the preferred method of diagnosing DM in 2011 (9). Shortly 
thereafter, in 2012, HbA1c became the primary diagnostic criteria in the Norwegian 
guidelines as well (10). 
Table 1. Criteria for diagnosing diabetes mellitus (2, 7) 
FPG (no caloric intake for ≥8 h)* ≥7.0 mmol/L 
OR 




HbA1c performed in a laboratory using a NGSP-certified method 
standardised or traceable to the results in the DCCT* 
48 mmol/mol (≥6.5 %) 
OR 
Random PG in a patient presenting with classic hyperglycaemia 
symptoms or a hyperglycaemic crisis 
≥11.1 mmol/L 
*If there is no display of hyperglycaemia symptoms, diagnosis should be confirmed by additional testing. 
2h PG = two-hour plasma glucose, DCCT = Diabetes Control and Complications Trial, FPG = fasting plasma 
glucose, HbA1c = glycated haemoglobin, NGSP = National Glycohemoglobin Standardization Program, OGTT = 
oral glucose tolerance test, PG = plasma glucose 
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1.1.2 Hyperglycaemia and its consequences 
If not treated, hyperglycaemia will have several negative impacts on the body. Early 
on, symptoms such as polyuria, polydipsia, fatigue, blurred vision, and frequent 
infections can occur (1). In the long term, uncontrolled hyperglycaemia may result in 
macrovascular and microvascular complications. More specifically, high levels of 
circulating glucose will over time cause damage to blood vessels, affecting the heart, 
kidneys (nephropathy), eyes (retinopathy), and nerves (neuropathy) (11). This could in 
turn lead to complications such as hypertension, stroke, renal failure, impaired vision, 
sexual dysfunction, foot ulcers and amputation. DM is also associated with a higher 
risk of developing or exacerbating other diseases, such as thyroid disease, coeliac 
disease, cancer, fractures, dementia, mental health disorders and various infectious 
diseases (12). 
The high disease burden that accompanies DM is in fact responsible for the greater 
proportion of the direct medical costs attributed to DM, according to a 2017 
population-based analysis from the United States (US) (13). It was estimated that 
people with DM incur one in four of all healthcare dollars and that they have more 
than twice the healthcare expenditures compared to people without DM. When 
adjusted for inflation and diabetes prevalence, the average cost of diabetes had 
increased by 13 % since 2012 (13). Updated cost numbers from Norway are scarce, 
but an assessment from 2011 estimated that the total medical costs attributable to DM 
ranged from €516-589 million (14). The majority part of these costs was related to 
prevention of microvascular and macrovascular complications, rather than to treatment 
of complications. In terms of medicine use and medical supply materials, a person 
with DM was found to have an annual average excess cost of €2730 compared to a 
person without DM. However, the total national expenses attributable to DM had not 
risen since 2005, when the cost was estimated at €535 million. (14).  
In the US, the annual cost of resources spent on DM increases by age, and 61 % of all 
healthcare expenditures attributed to DM are utilised by those ≥65 years of age (13). 
Likewise, the DM prevalence is highest among older age groups. On a global level it 
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was estimated that in 2017, DM affected 451 million people between the ages of 18-99 
years, where those aged ≥65 years accounted for 123 million (27 %). The total figure 
is expected to increase to 693 million by 2045, and the highest increase is expected 
among those aged ≥65 years, increasing to 253 million (36 %) (1). 
1.2 Diabetes in old age 
1.2.1 Pathogenesis 
In developed countries, 65 years is generally used as the conventional cut-off to define 
old age. This is most likely a social construct that corresponds roughly to the 
retirement age in many countries. Although there is broad agreement that the 
biological processes which increase the susceptibility to disease and death are not 
connected to a specific chronological age, this definition of old age is also applied in 
health research, as exemplified in the two previous paragraphs. 
There are several reasons why DM, and primarily T2DM, is prevalent in the older 
population. Advanced age is associated with sarcopenic obesity, including 
deteriorating functional ability due to loss of muscle mass and strength, as well as with 
increased adiposity resulting from changes in fat distribution and physical inactivity 
(15). Depletion of skeletal muscle, which is mainly responsible for insulin-mediated 
glucose disposal, greatly influences insulin sensitivity (15), while excess adipose tissue 
leads to elevated levels of free fatty acids (FFAs) (16). FFAs impair insulin-mediated 
vasodilation of endothelial tissue and stimulate inflammatory pathways, both of which 
contribute to increased insulin resistance and thereby reduced glucose disposal (15-
17). Furthermore, subcellular defects, such as a reduced mitochondrial oxidative 
capacity and insulin receptor deficiency, have been suggested as contributing factors to 
insulin resistance in advanced age (15, 17).  
In younger adults, an increased insulin resistance prompts the β-cells to increase the 
insulin response in order to restore normoglycaemia. However, due to the progressive 
β-cell failure with age, β-cell function is impaired and compensatory 
hyperinsulinaemia does not occur (3). In addition, β-cell sensitivity to incretin 
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hormones may be reduced, further compromising insulin secretion (3). Other co-
existing diseases and a number of medicines, commonly presented in the older 
population, could also have a negative impact on both glucose metabolism and insulin 
secretion (3, 15, 17). This interplay between altered insulin action and reduced insulin 
secretion could trigger an already genetic predisposition for the disease, causing 
diabetes to manifest (Figure 1).  
Figure 1. Age-related risk factors contributing to insulin resistance (orange) and decreased 
insulin secretion (green), which together with impaired β-cell function leads to development of 
impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM). Adapted with permission 
from Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003; 
284(1): E7-12. 
There is evidence that lean older persons with DM have a relatively preserved insulin 
sensitivity, and that the main metabolic deficiency is a reduced insulin secretion (18). 
In contrast, obese older persons with DM have a relatively preserved insulin secretion, 
presenting with insulin resistance as the principal defect (19). This is different from 
middle-aged persons with DM, where both obese and lean persons present with 
relative deficiencies in both insulin secretion and insulin sensitivity (18, 19). 
1.2.2 Clinical features and complications  
Hyperglycaemia 
The renal threshold for glucose increases with age, so despite hyperglycaemia, 
glycosuria seldom occurs. Polydipsia is also uncommon, due to decreased thirst 
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perception (20). Thus, symptoms of DM may be absent, unspecific, or confused with 
common age-related symptoms such as confusion and incontinence (20, 21). This may 
lead to a failure in the detection and treatment of hyperglycaemia. 
Furthermore, several medicines commonly used in advanced age may worsen 
symptoms of pre-existing hyperglycaemia or induce it. For example, it is well known 
that statins have a diabetogenic effect, although this effect may differ with the type and 
dose of the statin. Thiazide diuretics, beta blockers, glucocorticoids, and some 
antidepressants are also associated with an increased risk of hyperglycaemia. The main 
mechanisms of medicine-induced hyperglycaemia are diminution of insulin secretion 
and/or production, peripheral insulin sensitivity and/or promotion of weight gain, 
promotion of hepatic gluconeogenesis and/or glycogenolysis, or direct cytotoxic 
effects on pancreatic cells (22).  
Persistent and untreated hyperglycaemia in the older person carries an additional risk 
compared to the general risk attributed to this in the younger person with DM. For 
instance, dehydration and electrolyte disturbances pose serious risks to the older 
person, and also contribute to dizziness and a greater probability of falling in addition 
to increasing the risk of hyperglycaemic emergencies, such as diabetic ketoacidosis 
(DKA) or hyperosmolar hyperglycaemic states (HHS). Infections, oral health 
problems and urinary incontinence may also result from persistent hyperglycaemia, 
further deteriorating health and quality of life (21, 23, 24). 
Hypoglycaemia 
The risk of hypoglycaemia is also increased in old and frail individuals with DM (25, 
26). Hypoglycaemia is associated with a range of diverse symptoms that occur at an 
abnormally low plasma glucose concentration, usually below 4.0 mmol/L (Table 2) 
(27-30).  
Although all of the symptoms in Table 2 are associated with hypoglycaemia, their 
presentation, pattern, and intensity generally vary between individuals (29, 30). 
Moreover, hypoglycaemia may have unusual symptom presentation in older patients 
compared to younger patients (30-33), and could therefore be misinterpreted, for 
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instance as cerebrovascular or cardiovascular events (30, 33, 34). Examples of unusual 
symptoms are dilated pupils, abnormal movements, and sudden mood changes (35).  
 
Age-related declines in renal function, hepatic metabolism, and blood flow (36) may 
be contributing factors to the increased hypoglycaemia risk seen in this population. As 
a result of the renal and hepatic dysfunction, medicines will accumulate in the body, 
increasing the risk of adverse effects. In addition, DM in itself can also compromise 
renal function over time, further increasing hypoglycaemia risk.  
Moreover, the ability to hear, remember, and understand instructions, as well as vision 
and dexterity, are fundamental for management of a sometimes complex diabetes 
medicine regime and capillary blood glucose measurements (CBGM). As one or 
several of these abilities diminish with age, so will the individual’s capacity to 
identify, treat, and report hypoglycaemia (36). In addition, hypoglycaemia 
unawareness, meaning that the patient is unable to detect the first warning signs of 
hypoglycaemia (Table 2), is more prevalent in old age (28, 37). This symptom 
alteration of hypoglycaemia is commonly attributed to a long duration of diabetes, 
antecedent hypoglycaemia and metabolic changes (28, 30). For instance, older adults 
have a decreased secretion of one or more counter-regulatory hormones for 
neutralising hypoglycaemia (28, 38). 
Table 2. Symptoms of hypoglycaemia (27-30) 
Autonomic symptoms (first warning signs) Neuroglycopenic symptoms 
Sweating 











Loss of concentration / Difficulty thinking 
Lightheadedness / Dizziness 
Unsteadiness 
Tiredness / Drowsiness  
Difficulty speaking 
Visual disturbances 
Abnormal behaviour (agitation, aggressiveness) 
Confusion 
Coma 
Symptoms in parentheses are not considered autonomic, but are often listed amongst the first warnings signs of 
hypoglycaemia 
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Physical and cognitive deterioration from hypoglycaemia are not only apparent in the 
actual emergency. Studies have shown that repeated episodes of hypoglycaemia are 
associated with several cardiovascular events (30) and moderate to severe impairment 
of a patient’s general health status (26). Especially severe hypoglycaemia may 
exacerbate cognitive function (27, 29, 39), increase the risk of falls and fractures (29), 
hospitalisation and premature death, as well as other adverse events (40, 41). 
Comorbidities and clinical complexity 
Studies have found that older persons with DM have a median of five comorbid 
conditions (interquartile range (IQR) 3-8) and that they also are more likely to 
experience physical symptoms, such as acute pain and shortness of breath (42, 43). 
Some of the comorbidities contributing to this, such as ischaemic heart disease, 
hypertension, and peripheral neuropathy are directly related to DM. However, gastro-
oesophageal reflux disease, depression, chronic airway disease, chronic pain, and 
inflammation are also among the common comorbidities in these patients (42).  
The metabolic disturbances, complications, and symptom burden following DM 
contribute to high clinical complexity, disability, ill health, and reduced quality of life 
in older people (15, 44-47). For instance, an acceleration or increased risk of cognitive 
decline or dementia in older patients with DM has been reported (48-51), although the 
link between the two has not been fully established. Other geriatric syndromes such as 
depression, urinary incontinence, and falls are also more frequent in those with DM 
compared to those without DM (52, 53). Several studies link an increased risk of falls 
to diabetes complications such as retinopathy and neuropathy (54-56). In addition, 
muscle strength and quality also deteriorate faster in older persons with DM compared 
to older persons without DM (42, 57). 
In summary, DM, its complications, and its treatment are all associated with a 
progressive decline in both physical and cognitive function, resulting in a deterioration 
of the capacity for self-care. Thus, DM is a common cause of the utilisation of nursing 
and residential care services (13, 58, 59), mediated by clinical, cognitive, and 
functional impairment (58, 59). 
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1.3 Diabetes in care homes 
1.3.1 Definition of care homes 
The provision and regulation of care-home services vary across countries. We define 
care homes as institutions that are staffed 24 hours a day and offer accommodation and 
care to older people who are unable to live at home, for shorter or longer periods. Care 
homes include both nursing homes and residential homes. Nursing homes provide 
nursing care in addition to personal care, and hence should always have qualified 
nursing staff on site. The research in this thesis was carried out in Norway and the 
United Kingdom (UK), where the organisation of care-home services differs. In 
Norway, residential and nursing homes are normally separated from each other, with 
some exceptions. In the UK, it is more common that the two exist within the same care 
home. The term care home is mainly used throughout this thesis, except for when it is 
relevant to distinguish nursing homes from residential homes. 
1.3.2 Prevalence and burden of DM in care homes 
In the last two decades, multiple studies have investigated DM prevalence in care 
homes across Europe (60-79). The latest studies (data from 2011-2014) indicate a DM 
prevalence in care homes of 14-22 % (72-79). In high-income countries outside 
Europe, the most recent prevalence numbers vary from 18 % in Australia (80) to 24 % 
in Canada (81), whilst in the US numbers as high as 35 % have been reported (82). For 
additional details of studies reporting DM prevalence in care homes across Europe and 
outside Europe, please see Appendix 1 and Appendix 2, respectively. 
The UK has been among the leading countries describing the DM field in care homes, 
reporting prevalence, clinical characteristics, and current level of care for residents 
with DM (60, 63, 64, 68, 69, 73, 83-87). Recently-reported prevalence numbers for 
diagnosed DM in UK care homes were 16-22 % (68, 69, 73). In contrast, exploration 
of DM prevalence and management in Norwegian care homes has been scarce. A 
study from the Tromsø area in 2006 reported that 20 % of older people aged >69 years 
who received nursing care within an institution or in their own homes had a DM 
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diagnosis (88). However, this study excluded those with severe illness or dementia, 
and did not report which patients lived in a nursing home or which patients lived at 
home. Three newer studies, the first investigating characteristics of cancer patients in 
cognitively-intact nursing home residents, the second the characteristics of nursing 
home residents with dementia, and the third investigating whether management of DM 
in nursing homes was in accordance with guideline recommendations, found a DM 
prevalence of 16.7 %, 15.3 %, and 15.2 %, respectively (77, 89, 90). 
Advanced age, dementia, cognitive impairment, functional impairment, and increased 
number of prescriptions are all major reasons for care-home residency (91). As such, 
care home residents have a high burden of disability, comorbidity, and polypharmacy, 
and are frequent users of healthcare resources (92). For residents with DM, the burden 
may be greater than for non-DM residents. Most studies comparing the two groups 
report that residents with DM are younger (73, 79, 93-96), have more comorbidities 
(73, 93, 96-98) and prescriptions (73, 79, 93-96), and experience more emergency 
department visits or hospitalisations (72, 73, 95-97), than do residents without DM. 
Experience of daily or persistent pain is also common (73, 93, 99, 100); however, there 
are conflicting results as to whether pain is more frequent in residents with DM 
compared to residents without DM (73, 79, 99, 100). 
1.4 Clinical practice recommendations for DM management 
The increasing prevalence and metabolic distinction of DM in old age have prompted 
the development of several guidelines, consensuses, and reviews specifically targeting 
older adults, including care home residents (Table 3). The recommendations have 
been, and still are, pragmatic and based on the best available evidence and clinical 
expertise, reflecting the lack of robust studies including older adults and the 
heterogeneity of this patient group. As the majority of patients have T2DM and the 
evidence for management of T1DM in older adults is especially limited, most 
recommendations apply to the former. However, recommendations for T1DM are 
included where appropriate.  
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Table 3. Overview of recommendations for DM management in older adults and care home 




American Diabetes Association (ADA) 
 Standards of medical care in diabetes: 12. Older adults (101) 2019 Consensus report 2012 
(23), included in 
standards 2015 
 Management of diabetes in long-term care and skilled nursing 






American Geriatrics Society (AGS) 
 Guidelines abstracted from the American Geriatrics Society 
Guidelines for improving the care of older adults with diabetes 
mellitus: 2013 update (102) 
2013 First published 2003 
Diabetes UK 





Building on document 
published 1997 
Diabetes Canada 
 Diabetes in older people (104) 2018  
European Diabetes Working Party for Older People (EDWPOP) 
  An international position statement on the management of frailty in 





 Diabetes mellitus in older people: position statement on behalf of 
the International Association of Gerontology and Geriatrics (IAGG), 
the European Diabetes Working Party for Older People 






 European Diabetes Working Party for Older People 2011 clinical 
guidelines for type 2 diabetes mellitus. Executive summary (107) 
 
2011 First published 2004 
International Diabetes Foundation (IDF) 




 McKellar guidelines for managing older people with diabetes in 





including general and 
specialist healthcare 
professionals  
 Pragmatic diabetes management in nursing homes: individual care 
plan (France) (35) 
 
2013 
 Evidence-informed guidelines for treating frail older adults with type 
2 diabetes: from the Diabetes Care Program of Nova Scotia 
(DCPNS) and the Palliative and Therapeutic Harmonization 






The newest recommendations compile and highlight key aspects of the earlier 
recommendations, but also incorporate new insights from the ever-growing body of 
DM research. There has also been a development towards including topics that are 
recognised as increasingly important in the care of older adults, such as deprescribing 
and inter-professionalism.  
In Norway, national guidelines for diabetes only recently included recommendations 
for older adults and care home residents with DM (7). However, the information is 
limited to targets for glycaemic control and blood pressure. A general clinical 
procedure for diabetes care in nursing homes, primarily meant to aid registered nurses, 
was developed and published in 2011 (111). This procedure covers eight areas of care: 
diagnosis, assessment on admission, treatment goals and algorithms, care planning, 
injection techniques and blood glucose measurements, preventing and treating 
complications, hyperglycaemia, and hypoglycaemia. Additionally, clinical procedures 
for nursing home physicians were published in 2015, and revised in 2018. These 
include recommendations for management of DM treatment, hypoglycaemic and 
hyperglycaemic emergencies (112).  
Due to close agreement between the recommendations listed in Table 3, the documents 
from the ADA (24, 101) and the International Diabetes Foundation (IDF) (108) will 
serve in the following as the main resources to sum up the recommendations. Other 
recommendation documents will be cited when relevant. 
1.4.1 Approach to care guided by health characteristics 
Rather than distinguish by age group, the recommendations highlight comorbidity, 
cognitive and physical function, and life expectancy as important when making care 
decisions. Despite slight differences in how the recommendations group the patients, 
three major classes of older patients with DM can be identified and serve as a 
framework for considering treatment goals and care requirements: 1) patients who are 
relatively healthy and/or functionally independent; 2) patients with one or more 
medical, cognitive and/or functional problems, which can make self-care difficult; and 
3) those with significant comorbidity, cognitive and/or functional impairment, and/or 
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who reside in a long-term care facility (24, 101, 108). Distinct recommendations have 
also been developed for end-of-life patients/palliative patients with DM (24, 101, 103, 
108, 109), but these are not the focus of this thesis and thus will not be discussed 
further. 
When consulting frameworks such as these, one should bear in mind that the resident’s 
health status may change over time, and also that not all care home residents 
necessarily fall into the third group. Consequently, recommendations encourage care 
homes to develop their own policies for diabetes care, and make use of individual care 
planning on admission, following care transitions and during annual reviews (24, 101, 
103, 107-109).  
Various assessment tools and procedures can aid determination of the patient’s 
requirements and help organise the care plan. There is no consensus on which data 
should be collected; however, information about functional and cognitive capacity 
should be included as a minimum. Additional measures can be applied to gain 
information about other factors that are relevant to determine the resident’s health 
status. Frailty is amongst the more commonly suggested measures, as it increases the 
risk of sarcopenia, falls, complications, and death in these patients. By some, the 
degree of frailty is specifically used as a defining feature to guide correct placement of 
the patient into the care classes outlined above (104, 108). There is no one definition 
of frailty, but there is broad agreement that it occurs due to a combination of decline in 
physical function (e.g. restriction in mobility and strength), and reduced ability to 
resist to clinical, functional, or psychosocial stressors (101, 104, 105, 108). Weight 
loss or inadequate nutritional intake are thought to increase the risk of frailty, and are 
sometimes included as part of the definition (101, 104, 108). The Clinical Frailty 
Scale, a 9-point scale, is one way to determine the degree of frailty (104, 108).  
1.4.2 Treatment rationale and targets 
Table 4 gives an overview of the general recommendations made for treatment 
rationale and targets for HbA1c, blood pressure, and lipids in the three patient 
categories defined above, based on several sources (24, 35, 101, 102, 104, 107-109). 
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The targets provided in Table 4 serve as broad guidelines and should be individualised 
according to each patient’s specific requirements and disease features. A high degree 
of frailty and short expected life span entail that strict treatment targets and rigid 
recommendations may have limited benefit (45, 46), and thus, more relaxed goals are 
recommended for care home residents compared to those recommended for healthier 
older adults and younger adults (23, 35, 108).  
Table 4. Objectives and recommended treatment goals for older adults with diabetes grouped 
by health characteristics 






(mmHg) LDL-C (mmol/L)  
 
Group 1 
Relatively healthy and 
independent 
 
Treatment and care should 
consider a longer remaining 
life expectancy and thus 
prevent cognitive and 
functional decline, falls and 



























Treatment and care should 
consider an intermediate 
remaining life expectancy, 
high treatment burden, risk of 
hypoglycaemia and falls 
Focus should be on 
preserving functional status 
and prevent complications 
(within reason) 
 












and/or residing in 
nursing care 
 
Treatment and care should 
consider a limited remaining 
life expectancy and thus risk-
benefit evaluations should be 
made 
Focus should be on quality of 
life, monitoring and 
preventing dehydration, 
malnutrition, hypoglycaemia, 
HHS and DKA. Minimal 







based on goal for 
group 1 
CV=cardiovascular, DKA=diabetic ketoacidosis, DM=diabetes mellitus, HHS=hyperosmolar hyperglycaemic 
state, LDL-C=Low density lipoprotein cholesterol 
*Lower targets may be appropriate if patient is healthy and has low risk of hypoglycaemia 
The table is developed based on frameworks and recommendations issued by the American Diabetes 
Association (24, 101), the American Geriatrics Society (102), the European Diabetes Working Party for Older 
People (107), the International Diabetes Federation (108), Benetos et al. (35), and Dunning et al. (109) 
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Ismail-Beigi et al. (113) were the first to propose a framework for which factors to 
consider when individualising patients’ glycaemic treatment targets. This framework 
was later adapted by the ADA and the European Association for the Study of Diabetes 
(EASD) (114). The ADA adaption of this framework is presented in Figure 2 (with 
permission from the ADA). 
 
Figure 2. Factors to consider when individualising glycaemic target. Reprint from the American 
Diabetes Association, 6. Glycemic targets: Standards of Medical Care in Diabetes—2019, 
American Diabetes Association, 2019. Copyright and all rights reserved. Material from this 
publication has been used with the permission of the American Diabetes Association. 
Beyond the fact that the potential advantages of tight glycaemic control are of less 
importance in older patients with a limited life span, evidence exists that stringent 
HbA1c goals may even be harmful in this population. Firstly, incidence of 
hypoglycaemia increases substantially with age in patients with HbA1c <53 mmol/mol 
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(7.0 %) (115). Secondly, prevalence of falls is also the highest in patients with HbA1c 
<53 mmol/mol (7.0 %), with the exception of those aged ≥85 years, where an HbA1c 
>75 mmol/mol (9.0 %) is associated with the highest fall prevalence (115). Finally, the 
risks of a major cardiovascular event and all-cause mortality are the highest in patients 
with a median HbA1c level 46 mmol/mol [range 13-50] (6.4 % [range 3.3-6.7]) and 86 
mmol/mol [range 85-154] (10.5 % [range 9.9-16.2]) (116). In general, an HbA1c level 
<53 mmol/mol (7.0 %) is discouraged in frail, older patients, and should be viewed as 
an alert to overtreatment (35, 108). A group of Canadian experts encourages an even 
more relaxed line in regard to glycaemic targets, stressing that values below 64 
mmol/mol (8.0 %) warrant decreasing or discontinuing antidiabetic pharmacotherapy 
in these patients. They further endorse HbA1c values up to 108 mmol/mol (12.0 %) as 
acceptable if the patient is otherwise asymptomatic (110). 
Beyond glycaemic control, recommendations also emphasise the value of treating 
hypertension in older adults, as there is strong clinical evidence that this results in a 
reduction in cardiovascular morbidity and mortality (101, 108). Choice of 
antihypertensive therapy follows the same principles as for younger adults, but 
treatment targets should be individualised and special consideration given to potential 
detrimental side effects and interactions with other medicines and/or diseases (104, 
108, 117). There is limited evidence to support blood pressure (BP) targets <140/90 
mmHg (Table 4), and systolic BP <130 mmHg and diastolic BP <67 mmHg may 
increase mortality in older adults with diabetes (104). 
There is less evidence of the benefits of lipid-lowering therapy, especially in patients 
aged >80 years. Statins, especially in high doses or with higher potency, hold a greater 
risk of adverse effects such as myopathy and cognitive impairment, which may 
outweigh potential benefits (108, 118). There seems to be an agreement that statins (or 
other lipid-lowering therapy where appropriate) could be indicated when clinically 
relevant, i.e. where life expectancy of the resident at least equals the time frame for 
expected benefit (101, 108). For primary prevention, the benefit of statins on CVD in 
older people is somewhat uncertain, but some have shown an increase in effect after 
five years of therapy. The benefit of statins has been shown for prevention of new 
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cardiovascular events in people with established CVD (secondary prevention). 
However, those aged >80 years, those with severe physical or cognitive impairment, or 
those with a life expectancy <12 months, are unlikely to benefit from statins (108). 
There is also less agreement on setting specific goals for lipids, as no optimal level of 
cholesterol has been established for octogenarians with diabetes (118). Thus, lipid 
targets are generally extrapolated from those given for the younger population, but 
with the suggestion that they can be relaxed in the more functionally dependent groups 
(104, 108).  
Overall, the aims for care home residents are to avoid hypoglycaemia and 
symptomatic hyperglycaemia, minimise complications that can deteriorate function, 
and enhance quality of life. Hence, the care plan should consider all aspects of care, 
not just clinical targets for glycaemic control, blood pressure, and lipids. For instance, 
it is encouraged to include management plans for fluid intake, hypoglycaemia, 
hyperglycaemia, diabetes complications, physical activity, and medicine regimen with 
review dates. Assessments of and strategies to improve comorbidities or geriatric 
syndromes closely associated with DM, e.g. cognitive dysfunction, depression, 
malnutrition, urinary incontinence, falls, skin problems, and oral health problems, are 
also emphasised (24, 101-104, 108, 109, 111). 
1.4.3 Blood glucose monitoring and glucose levels 
There is broad agreement that an adequate overview and handling of glycaemic control 
will improve care for care home residents with DM and prevent acute events such as 
hypo- and hyperglycaemia (24, 35, 101-104, 108-111). Unfortunately, studies have 
reported findings that indicate that glucose monitoring may do more harm than good. 
Incorrect sampling leading to pathogen transmission is probably the most serious 
shortcoming (119-121). Lack of protocols and agreement on when to perform CBGM 
(122-127) may be the reason CBGM fails to be performed based on individual needs 
(87, 128, 129), and uncertainty of how to make use of the results (65) may explain 
why blood glucose logs are sometimes incomplete (122, 130). For glucose monitoring 
to be of value, it should have a clear purpose, resident and/or staff should be trained in 
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appropriate sampling and be able to review and act upon the results, and an analytical 
quality assurance system should be in place. 
A few of the recommendations state that all residents with DM have an HbA1c 
measurement taken a minimum of every six months, and more often if needed or 
indicated (102, 103, 111). However, HbA1c may not always be a reliable measurement 
for glycaemic control in this population. Conditions or treatments affecting the life 
span of the erythrocytes are not uncommon in older adults with DM and may give 
false readings of HbA1c (2, 101, 109). For instance, anaemias of chronic disease, iron 
deficiency, or other nutritional deficiencies increase with age and are especially 
common in care home residents (131). Depending on the cause of the anaemia, the 
HbA1c value could be either falsely low or high (132). Furthermore, evidence exists 
that HbA1c readings are significantly lower in patients with advanced chronic kidney 
disease (CKD) compared to those without CKD, at comparable levels of blood glucose 
measured by continuous glucose monitoring (CGM) (133). Lastly, while HbA1c 
reflects the resident’s average level of glycaemic control, the glycaemic variability 
may be much wider in an older person compared to a younger person, especially if the 
patient’s condition is unstable, or acute illness or dehydration occur (24, 101, 104, 
134). Thus, CBGM should be used to complement or substitute HbA1c measurements 
when appropriate (24, 101, 104).  
CBGM is commonly applied to monitor day-to-day fluctuations in blood glucose. 
CBGM can alert nursing staff to detrimental fluctuations in blood glucose levels that 
may require action in the form of adjustment of therapy, intake of fluids or food, or 
closer follow-up for a period. CBGM is especially important in detecting and treating 
hypoglycaemia. The threshold for hypoglycaemia is defined as a blood glucose level 
<4.0 mmol/L by most recommendations (24, 101, 106, 108, 111), with the exception 
of the Australian McKellar guidelines, which define hypoglycaemia as a blood glucose 
level <6.0 mmol/L (109). However, the recommended ideal glucose range for frail 
patients, in order to minimise risk of hypoglycaemia and avoid symptoms of 
hyperglycaemia, varies between sources. Most agree that avoiding glucose levels <6.0 
mmol/L is necessary to prevent hypoglycaemia (101, 103, 106, 108, 109, 111), whilst 
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there is generally a wider interval for what is an acceptable upper limit to minimise the 
risk of dehydration, electrolyte imbalance, urinary incontinence, dizziness, falls, and 
hyperglycaemic emergencies. The International Association of Gerontology and 
Geriatrics (IAGG) and the European Diabetes Working Party for Older People 
(EDWPOP) advocate keeping glucose levels below the renal threshold for glycosuria 
(~11.0 mmol/L) (106), but the majority accept that random glucose levels between 12-
14 mmol/L generally do not cause symptomatic hyperglycaemia (24, 101, 110, 112). 
The McKellar guidelines state that a blood glucose level >15 mmol/L should be 
considered hyperglycaemia, which can turn into a medical emergency if consistently 
elevated and the resident is feeling unwell (109). A Canadian expert committee 
support glucose levels up to 20 mmol/L, if these are not associated with bothersome 
hyperglycaemic symptoms and the patient has a short life expectancy (110).  
For residents with T2DM, there is no consensus regarding which residents should 
receive CBGM and the appropriate frequency of measurement, but there exists an 
awareness to avoid unnecessary monitoring. Most recommendations thus do not 
discourage CBGM in any resident; they state that it should be decided on a case-to-
case basis founded on the goals for care, complexity of treatment regimen and risk of 
hypoglycaemia. They put special emphasis on that residents using pharmacotherapy 
with high hypoglycaemia-risk, such as insulin, sulfonylureas (SU) or meglitinides, 
should have a management plan that includes a schedule for CBGM (24, 102-104, 108, 
111, 112). The ADA proposes block testing: fasting/pre-prandial glucose 
measurements on some days, postprandial and bedtime glucose measurements on other 
days as a means to provide a pattern for glycaemic variability without multiple daily 
measurements (24). Less invasive procedures, such as flash glucose monitoring 
(FGM), has been investigated in older long-term care residents, but inaccuracy in 
detecting lower glucose values currently limits its use in this population (135).  
In contrast, guidelines from France, Canada and Australia are more specific regarding 
which residents should receive CBGM, and how often (35, 109, 110). The French and 
Australian recommendations state that CBGM should be performed at reasonable 
intervals during the day (e.g. fasting, postprandial and 4 pm), daily to monthly 
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depending on residents’ stability and risk of hypoglycaemia, at least for those using 
insulin or SU (35, 109). For residents with stable blood glucose levels using other 
treatment, the Australian recommendations still advocate for CBGM (109), whilst the 
French recommendations state that the monitoring of HbA1c is sufficient (35). In 
contrast, the Canadian recommendations argue that even for residents who are stable 
on basal insulin alone, there is no need for routine CBGM. Furthermore, they conclude 
that residents who receive both basal and mealtime insulin should have CBGM 
performed once daily, at alternate times, if they have remained stable on this regimen 
(110). All three advocate for more frequent CBGM if the resident is unstable, has 
acute illness or dehydration, or if his or her behaviour and/or cognition changes (35, 
109, 110). The Canadian recommendations propose the following situations where 
CBGM should be performed more frequently: when the resident experiences 1) acute 
illness; 2) a major change in health status (e.g. substantial functional or cognitive 
decline); 3) significant change in oral intake; when there is 4) a suspicion of 
detrimental glucose levels (high or low); 5) an adjustment of treatment for DM; 6) an 
initiation of or change in oral steroid use (110).  
Equally important as monitoring schedules and detailed instructions for management 
of hyper- and hypoglycaemia, is the appropriate documentation of CBGM readings 
and other changes in treatment, food and fluid intake, and behaviour that could have 
consequences for, or be related to, blood glucose levels (35, 103, 108). This 
information is essential as a reference for everyone who cares for the resident, 
especially staff that is unfamiliar with the resident (35). Diabetes UK recommends that 
the care home should define those responsible for CBGM and that no member of staff 
without training in CBGM and adequate knowledge of diabetes, its symptoms, and 
how to act on deviant readings, perform CBGM. Whilst they specifically state that the 
resident should be involved in decisions on monitoring frequency and glycaemic 
targets, they advise that preferably only registered nurses should undertake the task of 
performing CBGM (103). On another note, the IDF and the McKellar guidelines 
encourage care homes to provide adequate support for the resident to self-manage 
blood glucose monitoring where appropriate (108, 109). Subsequently, the physician 
should have the main responsibility in supervising and following up any deviations or 
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other concerns (35) and review at least annually the need and frequency for CBGM 
(109). As care homes may use the same meter for several residents, procedures for 
hygiene and correct sampling should also be in place, together with protocols for 
maintenance and external quality assurance of equipment (103, 109).  
1.4.4 Pharmacologic management of diabetes 
The overall aims for managing care home residents with DM should also be normative 
when choosing medicines. Thus, focus is put on avoiding hypoglycaemia and 
overtreatment together with maintaining quality of life. One should consider the 
potential for medicine-disease interactions, medicine-medicine interactions, impact on 
weight, other adverse events, the need to involve care givers, and other patient-related 
factors that may influence choice of therapy (101, 103, 108, 109). 
Metformin is considered the first-line therapy in residents with T2DM, unless the 
estimated glomerular filtration rate (eGFR) is below 30 ml/min/1.73 m2, due to the risk 
of lactic acidosis (101, 108, 136). When the eGFR is between 30 and 60 ml/min/1.73 
m2, metformin is still considered safe with dose reduction and closer monitoring of 
renal function and adverse events (23, 102, 108, 136). Caution should also be 
exercised in patients with impaired hepatic function or heart failure, and temporarily 
discontinuing metformin should be considered during acute illness, dehydration, or 
other conditions that may compromise renal or hepatic function (101, 136).  
With newer medicines and insights into the pathophysiology of T2DM, the potential 
for individualising therapy has increased. If metformin is contraindicated or not 
tolerated, there is no defined alternative option. Likewise, the options for second- and 
third-line therapies are not clearly stated, but should be chosen based on patient- and 
medicine-specific factors (101, 104, 136). Thus, providing guidance based on factors 
such as cardiovascular disease (CVD), CKD, promoting weight loss, avoiding 
hypoglycaemia, and minimising medication costs have replaced fixed algorithms for 
treatment selection in T2DM (136).  
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For individualisation to be beneficial, sound knowledge of the advantageous and 
disadvantageous properties of the various antidiabetic medicines is crucial (24, 35, 
101, 104, 136). For instance, several of the recommendations advise caution when 
prescribing SU due to the increased risk of hypoglycaemia with age (24, 101, 102, 
104, 108). Other therapies could also be disadvantageous for certain patients. An 
overview of properties for each type of medicine, as well as the precautions when 
prescribing these for care home residents, are listed in Table 5 (pages 36-38). The 
McKellar guidelines present a glucose-lowering medicine (GLM)-related adverse 
event risk assessment tool, which they recommend be used together with other quality 
indicators for use of medicines, to minimise risk and increase benefit (109). 
Regarding insulin therapy, simplification of the insulin regimen is promoted (24, 35, 
101, 104, 108). A regimen with basal insulin once daily, preferably in the morning 
rather than at bedtime, is considered effective and safe in terms of hypoglycaemia risk 
and resident comfort (24, 101, 106). Insulin analogs, such as detemir and glargine, 
may provide a more predictable and consistent glycaemic effect compared to human 
insulin (104). Mealtime insulin may still be necessary for some residents, especially 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.4.5 Optimising medicines through deprescribing 
Optimisation and simplification of therapy should not only be considered when first 
prescribing, but also in the subsequent monitoring of the therapy (137). 
Deprescribing, defined as ‘the process of withdrawal of an inappropriate 
medication, supervised by a health care professional with the goal of managing 
polypharmacy and improving outcomes’ (138), is crucial in this process. The goal of 
deprescribing is to avoid unnecessary treatment with unlikely benefits and potential 
harmful effects (139).  
Different frameworks for optimising prescribing and aiding deprescribing in patients 
aged ≥65 years have existed for some time. These are sometimes referred to as 
prescribing quality indicators (PQI). Well-known examples include the US Beers 
criteria for Potentially Inappropriate Medication Use in Older Adults (140); 
Screening Tool to Alert doctors to the Right Treatment (START) and Screening Tool 
of Older Persons’ potentially inappropriate Prescriptions (STOPP), both developed in 
Ireland (141); and the Norwegian General Practice (NorGeP) criteria (142). These 
criteria have been formed as explicit standard indicators, based on expert consensus, 
following examination of available evidence on recommended and problematic 
medicines in older people. Still, the degree to which they incorporate other clinical 
information, such as comorbidities and functional dependency, is low. It has therefore 
been argued that these criteria may not be appropriate for use in care-home settings, 
where patients have multiple illnesses and/or disabilities, and a limited life 
expectancy (143, 144).  
More recently, updates have been done to make the aforementioned criteria more 
applicable to care-home settings, exemplified by STOPPFrail (144) in 2017 and 
NorGeP-NursingHomes (NorGeP-NH) in 2015 (145). At the time of our research, 
these were not available. However, the UK’s National Health Service (NHS) 
PrescQIPP programme had developed the pragmatic, evidence-based decision aid 
Optimising Safe and Appropriate Medicine Use (OSAMU) (146), which was updated 
in 2016 to Improving Medicines and Polypharmacy Appropriateness Clinical Tool 
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(IMPACT) (147). Sectioned into drug classes as presented in the British National 
Formulary (BNF) chapters, OSAMU sought to stop or continue therapy based on 
whether the therapy had a valid indication, and was safe and beneficial for the 
individual considering comorbidities and remaining life expectancy. Using OSAMU 
and similar pragmatic approaches demonstrated that deprescribing in general was safe 
in care home residents and seldom led to reactions that required medicines to be 
restarted (148-150). In addition, deprescribing contributed to a decrease in medicine 
cost and administration time (148-150). 
Increased awareness of the high risk and detrimental impact of potential medicine-
medicine interactions, medicine-disease interactions, hypoglycaemia, and other 
adverse events care home residents with DM face, has resulted in recommendations 
urging clinicians to regularly review the complexity of the resident’s medicine regime 
and reduce or stop medicines when appropriate (101, 103, 104, 108, 109). Currently, 
several of the recommendations for DM management in older people and care home 
residents also provide practical guidance to aid prescribing decisions, including the 
deprescribing of blood glucose-lowering therapy (101, 104, 106, 110). For instance, 
EDWPOP and IAGG recommend not starting blood glucose-lowering medicines until 
fasting blood glucose is consistently ≥7.0 mmol/L (106), whilst a Canadian expert 
committee advise that a random glucose reading <7.0 mmol/L should trigger a 
reduction in blood glucose lowering therapy, and glucose readings frequently >20.0 
mmol/L call for an increase in treatment (110). Both the ADA and Diabetes Canada 
promote ways to simplify an insulin regimen or switch medicines to avoid 
hypoglycaemia (101, 104). The ADA also highlights specific situations where the 
simplification, deintensification or deprescribing of antidiabetic therapy may be 
required (101). 
A recent review exploring patient characteristics of those for whom deintensification 
or deprescribing of blood glucose-lowering therapy is appropriate, identified among 
other things dementia, old age, impaired renal function, multiple comorbidities, 
significant weight loss, tight glycemic control, and frequent hypoglycaemia (151). 
Several studies have in fact shown that blood glucose-lowering treatment can safely 
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be simplified, reduced, or withdrawn in frail older patients with DM, including care 
home residents, without causing adverse events or leading to poor glycaemic control 
(66, 152, 153). One study that switched multiple-dose insulin regimens to once daily 
insulin glargine with or without non-insulin agents in 65 T2DM patients aged ≥65 
years, also found that the simplification resulted in significantly less hypoglycaemia 
and improvement in DM-related distress score (153). In addition, a particularly 
telling case from the US has been described by Lekarcyk et al. (31): 
An 88-year old woman with T2DM, dementia, and CKD was transferred from one 
care home to another. The woman had a history of aggressive behaviour, delirium, 
and hypoglycaemia unawareness, and experienced extreme variations in her pre-
breakfast blood glucose levels (from 2.3 mmol/L to 17.3 mmol/L). Upon transfer, her 
DM therapy were 68 units of insulin glargine at bedtime in addition to 5-12 units of 
sliding-scale insulin lispro before meals. Her weight was 63 kg and her most recent 
HbA1c was 54 mmol/mol (7.1 %). She refused CBGM the first days following 
transfer. Her aggressive behaviour was initially attributed to her progressing 
dementia, but a diabetes care provider suspected that it could be caused by 
hypoglycaemia due to the mismatch between the insulin dose, the resident’s weight, 
and her HbA1c value. To verify this, her insulin glargine dose was gradually reduced. 
At 38 units, they noticed an improvement in her mental status, a decrease in 
hyperglycaemia, and the woman also became less combative towards CBGM. CBGM 
showed an association between hypoglycaemia and escalating aggressive behaviour, 
and her insulin dose was further reduced. At seven units insulin glargine in the 
morning, she no longer experienced hypoglycaemia and had no need for correction 
doses using insulin lispro. Further, her aggressive episodes were significantly 
decreased and she was able to interact socially with staff and other residents (31). 
This case report not only exemplifies how harmful overtreatment can be, and the 
benefits of deprescribing, but also highlights the challenges and complexity entailed 
in treating frail older patients with DM. The case report also highlights the 
importance of increasing the knowledge of and focus on blood glucose-lowering 
therapy, glycaemic control, and blood glucose measurements in this population. 
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2. Research aims 
‘My name is Sherlock Holmes. It is my business to know what other people do not know.’ 
~ Arthur Conan Doyle, from The Adventure of the Blue Carbuncle 
The overall aim of this research was to investigate the prevalence and management of 
DM in care homes for older people, with an emphasis on medicines and blood 
glucose measurements. To explore this, three studies with the following objectives 
were undertaken: 
Study I 
The purpose of this study was to determine the prevalence of DM; and investigate the 
use of blood glucose-lowering medicines, frequency of CBGM and HbA1c 
measurements, and level of glycaemic control in Norwegian nursing homes.  
Study II 
The purpose of this study was to describe the comorbidities and medicine use in UK 
care home residents with T2DM and the number of potentially inappropriate 
medicines (PIMs) in these residents using a medicines optimisation tool. An 
additional objective was to describe the clinical applicability of the medicines 
optimisation tool used. 
Study III 
The purpose of this study was to explore the perspectives of physicians, registered 
nurses and auxiliary nurses on the use, usefulness, procedures, and potential 




3. Subjects and methods 
‘I like to envision the whole world as a jigsaw puzzle … If you look at the whole picture, it is 
overwhelming and terrifying, but if you work on your little part of the jigsaw and know that people 
all over the world are working on their little bits, that’s what will give you hope.’ 
~ Jane Goodall, ethologist, known for her close and lengthy study of wild chimpanzees in Tanzania 
The research in this thesis is based on three studies with different study populations, 
examined through different methodological approaches. An overview for each of the 
studies is given in Table 6. 
Table 6. Methodological overview of the three studies included in the thesis 





742 long-term care 
nursing home residents 
19 nursing homes 
Western Norway 
Age, gender, diabetes (yes/no) collected for 
all residents 
Details of current blood glucose-lowering 
medicines, capillary blood glucose 
measurements the last four weeks and 
HbA1c measurements the last twelve 
months collected from the medical records 
of all residents with a diagnosis of diabetes 
35 CBGM observations followed by external 
quality control 
Descriptive statistics applied 
II Descriptive, cross-
sectional study 
826 older care home 
residents 
30 care homes  
East Anglia UK 
Details of active medical problems and 
current prescriptions collected from the 
medical records of all residents 
Potentially inappropriate medicines 
identified for residents with T2DM using the 
tool ‘Optimising Safe and Appropriate 
Medicine Use’ 
Applicability of tool evaluated by 
experienced care home physician  
Descriptive statistics applied 
III Qualitative study 3 auxiliary nurses 
4 registered nurses 
5 physicians 
Employees of nursing 
homes  
Western Norway 
Three profession-specific focus group 
interviews regarding capillary blood glucose 
measurements in nursing homes 
Analysed in accordance with Malterud’s 
principles of systematic text condensation 
(154) 
CBGM = capillary blood glucose measurements, T2DM = type 2 diabetes mellitus 
44 
 
3.1 Study I 
3.1.1 Study population and data collection 
In the first study, we wanted to examine the prevalence and medical management of 
DM in Norwegian nursing homes. Based on what we knew about DM prevalence in 
nursing homes from other European countries, we aimed to include a total population 
of a thousand residents to ensure a representative sample of approximately 100 
residents with DM. To meet this requirement, and yet keep the data collection within 
a reasonable limit in regard to time and travel, we drew a random sample of 20 
nursing homes from a geographical area that was well-defined, but also diverse in 
population density and composition, namely the geographical area of the Western 
Norway Regional Health Authority (counties Rogaland, Hordaland, and Sogn og 
Fjordane). The number of nursing homes that was invited from each county differed 
due to population density and the total number of nursing homes within each county. 
To reach our goal of 20 nursing homes, we randomly selected and invited another 
nursing home from the same county in cases where one of the nursing homes first 
approached rejected our invitation. In total, we invited 26 nursing homes: nine from 
Rogaland, eleven from Hordaland, and six from Sogn og Fjordane. Of the 20 nursing 
homes that agreed to participate, one later withdrew from the study due to time 
constraints. The final sample consisted of six nursing homes from Rogaland, nine 
from Hordaland, and four from Sogn og Fjordane.  
Prior to the candidate visiting the nursing homes to collect data, nursing home staff 
was asked to register year of birth, gender, and whether or not the resident had a 
registered diagnosis of DM, for all long-term care residents (Appendix 3). 
Furthermore, they assessed the capacity of the residents with DM to consent, before 
distributing information and collecting written consent to participate in the study 
from the residents or their families (Appendix 4). For consenting residents, the 
candidate was given access to collect information from residents’ medical records 
about blood glucose-lowering treatment, CBGM the last four weeks, and HbA1c 
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measurements the last twelve months (Appendix 5). Data collection took place 
between February and August 2012. 
Observations of any scheduled CBGM at the nursing homes while visiting, with the 
intention to assess the quality of the nursing home procedure of CBGM, was 
originally part of the study. Due to the limited number of observations available, we 
chose not to pursue this objective further. However, these observations brought up 
questions about the benefits and appropriateness of CBGM in nursing homes, which 
provided the basis for Study III.  
3.1.2 Analysis 
Considerations for analysis 
All blood glucose-lowering medicines were sorted according to A10 – ‘Drugs used in 
diabetes’ in the Anatomical Therapeutic Chemical (ATC) classification system (155). 
Hypoglycaemia was defined as any blood glucose concentration <4.0 mmol/L, and a 
risk for hypoglycaemia as a fasting blood glucose concentration <6.0 mmol/L. 
Hyperglycaemia was defined as any blood glucose concentration >11.0 mmol/L.  
Statistical analysis 
To compare means for the normally distributed continuous variables, 95 % 
confidence intervals (CIs) were estimated. Pearson’s chi-squared test was applied to 
compare dichotomous categorical variables (gender, capacity to consent), whilst 
categorical data with three or more variables (e.g. blood glucose-lowering medicine 
regime) were compared by estimating 95 % CIs for the percentages. The 95 % CIs for 
the percentages were estimated by a bootstrapping method, simulating 10,000 
datasets for each CI. Non-overlapping CIs and p-values <0.05 were considered 
statistically significant. The statistical software IBM SPSS Statistics 20.0 (IBM, 
Armonk, NY) and Microsoft Excel 2010 (Microsoft, Redmond, WA, USA) were 




The study was presented for ethical approval by the Norwegian Regional Committee 
for Medical and Health Research Ethics serving the geographical region of Rogaland, 
Hordaland, and Sogn og Fjordane (REC West), which did not have any objections or 
remarks to the study protocol. As nursing home staff collected resident information 
and consent forms from the participating residents before the candidate came to visit, 
the confidentiality of each resident was guaranteed. To avoid exposing frail patients 
to unnecessary testing, we chose only to observe scheduled CBGM, rather than ask 
all nursing homes to perform glucose measurements during our visit. 
3.2 Study II 
3.2.1 Study population and data collection 
The study population for this study was the baseline population from a cluster 
randomised controlled trial named CAREMED, conducted between March 2011 and 
March 2013. A UK study set in 30 care homes across East Anglia (counties Norfolk 
and Cambridgeshire), CAREMED aimed to investigate the impact of a multi-
professional medication review service (156). At the time of the study, the School of 
Pharmacy at the University of East Anglia (UEA) and the Centre for Pharmacy at the 
University of Bergen (UIB) had a teaching collaboration, with an ambition to develop 
this connection to include joint research projects. Therefore, a research project with a 
DM-related focus based on the CAREMED data was agreed on. The candidate gained 
access to the CAREMED database through a one-month overseas exchange to the 
UEA. 
We extracted data on demographics, active medical problems, and name, strength, 
dosage, and duration of current prescriptions registered at baseline for all the 826 
residents included in the CAREMED study. Baseline data for the CAREMED study 
was collected between April 2011 and January 2012. The baseline data also included 
information on laboratory tests for blood pressure and eGFR. However, as these 
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variables were incomplete for some residents, we decided not to include them in 
further analysis. 
3.2.2 Analysis 
Considerations for analysis 
Extracting only baseline data for the 826 residents included, we performed a cross-
sectional sub-analysis, using information about their current conditions and 
prescriptions. All conditions had been classified into the main chapters (level 1) of 
the International Statistical Classification of Diseases and Related Health Problems 
10th revision (ICD-10) Version 2010 (157) by the technical staff on the CAREMED 
study. Many, but not all, were also classified further into the major blocks under each 
chapter (level 2), and some were classified down to single disease codes (level 3). In 
addition to the recorded diagnosis, we made use of the first level classifications. All 
prescriptions were classified according to the ATC classification system (155) for the 
purpose of this study by the candidate. 
Residents with T2DM were identified by having T2DM as a recorded diagnosis in the 
medical records. Residents with other DM diagnoses were excluded from the study 
population and further analysis. Polypharmacy was defined as having registered ≥five 
unique medicines, i.e. ATC codes. 
In addition, we performed a theoretical medicines optimisation review for all 
residents with T2DM, using the NHS PrescQIPP document OSAMU (146) as a 
decision aid. Based on the limited information from the residents’ medical records, 
we identified that 35 out of the 46 areas or drug classes in the OSAMU document 
were applicable to our population. To allow for a descriptive analysis, the document’s 
stated considerations to optimise medicines use were conveyed into explicit criteria 
(score 0 = negative or 1 = positive) by the candidate (appendices 6 and 7). In total, 50 
explicit criteria were formulated. The candidate used a mix of statistical and visual 
analysis to review the residents’ medicines. A score of 1 was defined as the medicine 
being potentially inappropriate and therefore eligible for deprescribing. The identified 
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PIMs were validated and reviewed for deprescribing for a random sample of 20 % of 
the residents, by a physician with clinical and research expertise on medicines 
optimisation from Norwegian nursing homes. 
Statistical analysis 
Due to small numbers and skewed distributions, continuous variables were only 
calculated as medians with range. To compare medians for the continuous data and 
percentages for the categorical data, 95 % CIs were estimated. The CIs were 
estimated by a simple bootstrap, simulating 10,000 datasets for each CI. Non-
overlapping CIs were considered statistically significant. IBM SPSS Statistics 22.0 
(IBM, Armonk, NY) was used for statistical analysis, apart from bootstrapping, 
where Python 2.7 was used to aid analysis. 
3.2.3 Ethics 
The CAREMED study received ethical approval by the NHS Norfolk Research 
Ethics Committee within the UK Health Departments’ Research Ethics Service. All 
data extracted for the purposes of this study was depersonalised when the candidate 
received it. 
3.3 Study III 
3.3.1 Study population and data collection 
The observations of CBGM in Study I revealed that the procedure itself, who was 
allowed to perform it, and when it was performed varied from nursing home to 
nursing home. Furthermore, nursing home staff often posed questions about the 
appropriateness of this procedure to the candidate upon visit. It was this that 
prompted the candidate to explore these concerns by interviewing physicians, 
registered nurses, and auxiliary nurses working in nursing homes, about their 
perspectives regarding this commonly used procedure.  
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Focus group interviews use the interaction between the participants to investigate 
their common experiences, priorities, and attitudes (158), making this approach 
suitable to answer our research questions. To gain a credible response to the question 
in hand, we aimed to explore the perspectives of all professional groups involved in 
the procedure, in profession-specific interviews. Therefore, we set out to include: 
x Physicians with a licence to practice and a full-time or part-time engagement 
working in a nursing home, as well as experience in managing CBGM in 
nursing homes. 
x Registered nurses with a licence to practice and a full-time or part-time 
engagement in a nursing home, as well as experience in performing CBGM in 
nursing homes. 
x Auxiliary nurses with a licence to practice and a full-time or part-time 
engagement in a nursing home, as well as experience in performing CBGM in 
nursing homes. 
To recruit auxiliary nurses and registered nurses, we contacted managers in three 
nursing homes in proximity of our institution that were also in geographical 
proximity of each other. The reason for this was that we had planned to chair the 
interviews at one of the nursing homes, to reduce travel time and expenses for the 
participants. The nursing home managers helped with recruitment and distributing 
information, and reported back to us how many had agreed to participate. For one of 
the three nursing homes, none of the nurses had volunteered for participation. 
To recruit physicians, we contacted the local organising committee of a continuing 
professional education meeting for nursing home physicians that took place 
approximately once a month. Verbal and written information about the study was 
given by the candidate at one of the meetings, whilst recruitment of participants was 
done at the following meeting. 
Originally, five auxiliary nurses and four registered nurses, all women, had agreed to 
participate. However, two of the auxiliary nurses failed to show up to the interview, 
without informing us in advance that they were unable to attend. From the 
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physicians’ continuing education meeting, five participants were recruited, three 
women and two men. The interviews with the nurses took place on two dates in June 
2014, whilst the physician interview took place in September 2014. Each interview 
was moderated by the candidate in addition to one or two of her supervisors, 
following a semi-structured interview guide (Appendix 8). The interviews were 
audiotaped, lasted between 60 and 75 minutes, and the themes discussed covered 
perspectives on the use, documentation, interpretation, consequences, and challenges 
of CBGM in nursing homes (see Table 1 in Paper III). 
3.3.2 Analysis 
Qualitative analysis was used to categorise the data into patterns following a 
systematic method. We applied Malterud’s principles of systematic text condensation 
(STC) to our data (154). STC is divided into four steps, which are presented below as 
defined by Malterud (154) together with an account of how we applied them to our 
data:  
1) From chaos to themes – all authors read all the transcripts to obtain an 
overview and then agreed on initial themes to aid coding. 
2) From themes to codes – the candidate searched the transcripts iteratively to 
identify units of meaning and sort or code these according to the initial themes.  
3) From code to meaning – all authors evaluated the content in each code group 
and identified sub themes or sub groups. The candidate thereafter condensed 
the content of each sub group into an artificial quote.  
4) From condensation to descriptions and concepts – the candidate collected and 
transformed the artificial quotes within each code group to an analytical text 
with illustrative quotes. All authors compared the final text against the original 
transcripts to validate the findings, and finally agreed on categories for 
presenting the results. 





Volunteering for the focus groups was understood as consent, and all participants also 
received an information leaflet describing details of the study, and that consent could 
be withdrawn at any time up until participating in the interviews (Appendix 9). To 
protect the privacy of the participants and throughout the study process, no names of 
either participants or nursing homes were linked to the interview data or identified in 
the transcripts. Audio recordings were deleted as soon as the transcripts were 
completed. The confidentiality of their colleagues, and patients or family, as well as 
the importance of professional confidentiality were emphasised both in the 
information leaflet and by the moderator before the interviews.  
The Norwegian Social Science Data Services (NSD) was consulted about the study, 
but advised that the study was not subject to notification, as no personal data from the 
participants were registered or stored during data collection. The guidelines for 
notification have later changed, so that today studies where interviews are audiotaped 
will generally be subject to notification.   
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4. Summary of results 
‘The reward of the young scientist is the emotional thrill of being the first person in the history of the 
world to see something or to understand something. Nothing can compare with that experience.’ 
~ Cecilia Payne-Gaposchkin, astronomer, astrophysicist, and the first to describe that stars were 
composed primarily of hydrogen and helium 
4.1 Study I 
Paper I 
Andreassen LM, Sandberg S, Kristensen GBB, Solvik UO, Kjome RLS. Nursing 
home patients with diabetes: Prevalence, drug treatment and glycemic control. 
Diabetes Res Clin Pract 2014, 105(1):102-109. 
This cross-sectional study examined the known prevalence of DM in long-term care 
in Norwegian nursing homes, as well as medicines and glycaemic control among 
residents with a DM diagnosis.  
Within the total study population of 742 nursing home residents from 19 nursing 
homes in the western part of Norway, 116 residents (15.6 %) had registered a known 
DM diagnosis. The residents with DM were on average 85.2 years [95 % CI: 83.8, 
86.6] and the majority were women (male:female ratio 0.49). Of the 100 residents 
who consented to further participation in the study, 52 could give informed consent 
themselves. Blood glucose-lowering medicines were prescribed for 74 residents, 47 
of these received insulin. The probability of being prescribed medicines for DM was 
significantly higher for residents with the capacity to consent (p = 0.04). 
CBGM and HbA1c records existed for 73 and 77 residents, respectively. CBGM 
readings from the last four weeks showed that 60 % of the residents had documented 
at least one episode of hypoglycaemia (<4.0 mmol/L) or risk of hypoglycaemia (<6.0 
mmol/L fasting). Risk of hypoglycaemia was recorded for all residents using insulin, 
48 % of those only using oral antidiabetic drugs (OADs), and for none of those 
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without medical treatment for DM.  Frequency of CBGM was also treatment-related; 
residents using insulin had significantly more frequent measurements than residents 
who did not (p < 0.01). The latest HbA1c values ranged from 28 mmol/mol (4.7 %) 
to 112 mmol/mol (12.4 %), with a mean of 57 mmol/mol [95 % CI: 53, 60] (7.3 % 
[95 % CI: 7.0, 7.7]). The average HbA1c value was significantly higher for residents 
on insulin (64 mmol/mol [95 % CI: 58, 70] (8.0 % [95 % CI: 7.4, 8.6])) compared to 
residents using only OADs (52 mmol/mol [95 % CI: 46, 57] (6.7 % [95 % CI: 6.4, 
7.4])) and residents not on blood glucose-lowering medicines (46 mmol/mol [95 % 
CI: 40, 53] (6.4 % [95 % CI: 5.8, 7.0])). Distribution of HbA1c values according to 
treatment is depicted in Figure 3. A total of 35 residents (45 %) had an HbA1c <53 
mmol/mol (7.0 %).  
 
Figure 3. Distribution of last recorded HbA1c value in mmol/mol (%) from 77 residents with 





























Includes residents with insulin only and residents with insulin and OADs 
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4.2 Study II 
Paper II 
Andreassen LM, Kjome RLS, Solvik UO, Houghton J, Desborough JA. The 
potential for deprescribing in care home residents with Type 2 diabetes. Int J 
Clin Pharm 2016; 38(4): 977-84. 
This cross-sectional study examined the comorbidities and prescriptions in UK care 
home residents with T2DM, in addition to the number of potentially inappropriate 
medicines and the proportion of these eligible for deprescribing. 
The study population of 823 residents from 30 care homes included 106 residents (13 
%) with T2DM. The residents with T2DM differed from the residents without DM in 
that they were younger and had a greater number of active medical problems and 
prescriptions. In addition, a larger proportion of residents with T2DM experienced 
polypharmacy (≥5 unique medicine substances). The most common diabetes 
treatment was OADs alone (n = 56), whilst only 14 residents (13 %) were prescribed 
insulin. The remaining 36 residents did not receive blood glucose-lowering 
medicines.  
Using the tool Optimising Safe and Appropriate Medicines Use, we identified a total 
of 346 PIMs for 96 of the residents with T2DM (90.6 %). Among these, the number 
of PIMs ranged from one to nine, and 70 % had ≥3 PIMs. Four out of the five most 
frequent PIMs concerned absence of a valid indication, including statins, laxatives, 
antidepressants, and H2 blockers / proton pump inhibitors. The remaining PIM was 
potentially excessive prescribing of antihypertensives.  
A total of 67 PIMs were available for validation in the 20 % random sample of 
residents. The care home physician agreed that 26 of these (39 %) could be 
discontinued without further question, and that a further forty medicines (60 %) could 
potentially be discontinued, but additional clinical data would be needed to confirm 
or refute this. A change of medicines was recommended for the final PIM.   
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4.3 Study III 
Paper III 
Andreassen LM, Granas AG, Solvik UO, Kjome RLS. ‘I try not to bother the 
residents too much’ – the use of capillary blood glucose measurements in 
nursing homes. BMC Nurs 2016, 15:7. 
This qualitative study explored the perspectives of physicians, registered nurses and 
auxiliary nurses in regard to the use, usefulness, procedures, and challenges of 
CBGM in Norwegian nursing homes. The main findings are summarised in Table 8. 
Table 8. Main findings from Study III 
Main category with 
subcategories Findings 
Premises for CBGM All groups considered CBGM useful: the physicians for following 
up and adjusting treatment, and the nurses for confirming or 
disproving whether a clinical change could be attributed to 
fluctuations in blood glucose.  
‘If a resident with diabetes falls ill in any way whatsoever, our first 
thought is, okay, we should at least check the blood sugar level, to 
rule it out, you know. (…) We always check it, because it is such 
an easy and quick thing to do.’ RN2. 
To promote the well-being and safety of the residents, all groups 
agreed that CBGM should be kept to a minimum, special diets 
should be avoided and blood glucose levels should be relaxed. 









The resident perspective 
Professional competence 
and understanding of roles 
The nurses knew which symptoms would call for additional CBGM 
or notification of the physician, and the physicians confirmed that 
hypoglycaemia generally was appropriately managed. However, 
managing borderline low or high blood glucose values was 
associated with more uncertainty.  
The nurses stated that little or no training had been given in 
diabetes care and that they were expected to acquire and maintain 
the necessary knowledge themselves. The physicians confirmed 
this. All groups wished for inter-professional courses to ensure that 
everyone has the same information and follows the same 
guidelines. 
‘In my experience, it is often very useful to attend [the nurses’] 
training. (…) There are often totally different approaches for the 
nurses compared to the physicians, you know. And they often 
benefit from seeing it from both angles.’ P3. 
 
Training and responsibility 
 
Awareness and 
assessment of symptoms 
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Table 8 continued. Main findings from Study III 
Record keeping Some of the nurses said that they kept a paper record of the 
residents’ CBGM readings readily available at the ward, in addition 
to registering them in the electronic patient records system. The 
physicians viewed this as unnecessary, but to the nurses the 
paper records were essential for easily spotting deviations in 
readings and documentation. 
 
‘(…) We do also have a paper form where we register [the values]; 
it’s kept in the resident’s kardex. But we also register it in the 
electronic patient records system that we use. (…) We do register 
it both places, and that’s also because we need it to be available 
on the ward, easily accessible, you know? To look back at how 
[the blood glucose levels] have been earlier.’ RN3. 
None of the participating nurses was familiar with any written 
template or procedure for how to carry out a CBGM or manage 
acute glycaemic events. This surprised the physicians, who 
believed the local authority guidelines to be well-known. Still, the 
nurses said that a common understanding for how to manage 
unexpected symptoms, deviations or acute events existed among 
them. 
 




Official guidelines or 
common procedures? 






5.1 Methodological considerations 
‘The world is noisy and messy. You need to deal with the noise and uncertainty.’ 
~Daphne Koller, professor in computer science, researching the application of artificial intelligence 
in biomedical science 
The studies in this thesis make use of both quantitative and qualitative methods. 
These two approaches complement each other and are more and more often used 
alongside each other in health services research (159). Quantitative methods take a 
positivist, or objective, approach, where the goal is to describe one or several 
measurable phenomena or a cause-effect relationship between them. Core questions 
for this type of research are ‘what’, ‘how many’ and ‘why’. Qualitative methods 
belong in the post-positivist tradition, where observations are considered fallible and 
biased by cultural, social, historical, and individual backgrounds. This approach is 
referred to as constructivism, the belief that we construct our view of reality based on 
our perceptions of it. The goal of qualitative methods is to provide a wider 
explanation or understanding of a phenomenon, using questions such as ‘why’ and 
‘how’ (159).  
As the framework and applicability differ between the two methodologies, different 
criteria have been developed to assess their scientific rigour (159-162). Where 
quantitative researchers refer to internal validity – how accurately the findings reflect 
the phenomena of study, or how confident we and the readers of our research can be 
of our conclusions – the equivalent are referred to as trustworthiness or credibility by 
qualitative researchers. The quantitative criteria of external validity and reliability – 
the generalisability of the findings and replicability of the methods used – relate to 
the qualitative criteria of transferability and dependability (159, 160). Furthermore, 
reflexivity is another aspect that may affect qualitative research (159, 161, 162). In 
contrast to quantitative research, the researcher cannot detach herself from the 
58 
 
process, and must account for her preconceptions of the area studied and how these 
influence the research process, in order to ensure objectivity. This approach 
acknowledges that there may be different, but equally valid, versions of knowledge. 
To account for one’s motives, background and beliefs in advance of the study and 
make use of cross-checks for different explanations and participant validation 
(member checking) of data, or interpretations of data, are techniques to enhance 
reflexivity (159, 161). 
5.1.1 Study I 
Internal validity 
Long-term care residents are the largest group of patients within Norwegian nursing 
homes, comprising 80 % of the total patient population (163). In addition to being a 
more consistent population than the residents in intermediate care in regard to age, 
gender distribution, and burden of comorbidities and medicines, they are also the 
most vulnerable patients. Hence we decided to exclude residents other than those in 
long-term care. Although we specified this condition to the nursing home staff that 
recorded birth year, gender, DM diagnosis and capacity to consent, there is a 
possibility that some have recorded residents outside our inclusion criteria. Still, the 
chance that this has happened is considered small. In addition, the impact of 
accidental inclusion of residents outside our inclusion criteria on the results will also 
be small, as the majority of residents will be in long-term care, and because a DM 
diagnosis generally implies a high burden of comorbidity and dependency. 
As we decided to collect information only on treatment specific to DM, we lack 
information on possible confounders for CBGM and HbA1c readings. Several 
clinical factors, such as renal disease, blood diseases, infections, and nutritional 
disturbances may influence the reliability of these readings. Likewise, information 
about renal function and other diseases and disorders could have contributed to a 
wider understanding of the blood glucose-lowering treatment given. Furthermore, we 
lack information about whether the high and low blood glucose values we registered 
resulted in clinical symptoms for the residents. Hence the interpretations and 
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conclusions we draw based on the limited information we included, may have 
explanations other than the ones suggested.  
External validity and reliability 
Being an understudied area, we wanted to examine the prevalence and medical 
management of diabetes in Norwegian nursing homes. Therefore, ensuring the 
generalisability of the findings is of special importance. The randomised approach, 
and the diversity of ownership, location, and number of beds in the nursing homes 
included, increase the external validity, making our results generalisable to the 
Norwegian nursing home population overall.  
However, as the study was cross-sectional, the generalisability across time may 
diminish due to changes in population and immigration patterns, the increases in both 
the older population and the number of people developing DM, new developments in 
pharmacotherapy, and changes in guidelines and healthcare provision for these 
patients. Heterogeneity of the study population in regard to types of comorbidities, 
functional and cognitive abilities, and remaining life expectancy may have an 
influence on choice of treatment and blood glucose readings. 
The cross-sectional nature of the study will influence reliability and objectivity in the 
same way as it does the generalisability. The method section of the study provides 
sufficient information to repeat the measurement and findings elsewhere, but the 
heterogeneity of the population and possible confounding factors to use of medicines, 
CBGM, and HbA1c measurements may produce different data if repeated at a 
different point in time.  
Our use of both CBGM and HbA1c readings to assess glycaemic control contributes 
to better construct validity than if we used only one. In addition, we used evidence-
based guidelines to define cut-offs for hypoglycaemia, hyperglycaemia, and HbA1c 
values that may be detrimental to quality of life in these patients (35, 101, 103, 106, 
108, 111). However, as the study was cross-sectional, this information was not 
complete for all residents, nor was it collected at specific points in time, e.g. at 
admission and after three months. Although CBGM and HbA1c readings give an 
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estimate of the glycaemic control in nursing homes, a longitudinal study could say 
more about how it changes from admission and during the stay.  
5.1.2 Study II 
Internal validity 
This was a data-driven research approach using baseline data from the CAREMED 
study – a randomised controlled trial with a different purpose to the one we wanted to 
focus on. This was disadvantageous because information that could have been of 
particular interest when investigating the subpopulation of residents with DM, e.g. 
HbA1c values, was not available. However, the researcher got access to the trial 
protocol (156) and documents displaying the structure of the database, before the 
objectives were finally decided. This included careful mapping of the variables 
available, and identifying any missing information that could potentially be of 
importance to our research questions and further analysis. Certain variables required 
recoding to ensure proper statistical analysis due to missing values. In addition, the 
researcher created an additional variable for analysis purposes, by sorting all 
medicines according to the ATC system (155). Based on this work, we could define 
some objectives that would be achievable and also provide information that would 
complement the other studies in this thesis. In this process, the researcher 
collaborated closely with both the lead researcher and the main research technician 
for the original study to ensure that the data used in this study was suitable for its 
objectives and interpreted correctly. 
The tool we used to identify PIMs was developed for use in clinical settings (146). As 
we applied it to an already existing data set with limited information of laboratory 
values, medical history, and prescribing history, we could only evaluate certain types 
of therapy in a theoretical manner. This puts a restriction on the conclusions we can 
draw from our results. However, by involving a physician with clinical and research 
expertise in medicines optimisation for care home residents when validating our 




External validity and reliability 
The CAREMED data gave us an opportunity to get a broader picture of the 
comorbidity and medicine burden of residents with DM, a useful supplement to the 
results in our first study. This was a randomised controlled trial of 30 care homes in a 
well-defined geographical area of the UK, with demographics similar to that of the 
overall UK care-home population (92). Hence, the results should be transferable to 
similar care-home settings across the UK. However, as the data was originally 
collected for a different purpose and in a different country from the two other studies, 
there are some issues to address as to whether the results are transferable to a 
Norwegian setting.  
Firstly, the UK care-home sample consisted of both residential homes and nursing 
homes, and the proportion of nursing home residents was less than a fourth. In 
Norway, nursing home residents make up close to 98 % of the total care home 
population (164). This is due to differences in organisation of the care sector, where 
Norwegian residential homes have largely been replaced with people receiving home-
care services (164). Secondly, differences may exist based on which resources have 
been available in the two countries, as the initiatives towards improvement of DM 
care in this population has been evident in the UK (165, 166), but less so in Norway. 
Finally, treatment traditions and the availability of blood glucose-lowering medicines 
may be different in the two countries. Still, the prevalence of DM and the age and 
gender distribution of the residents in this study are comparable to what we found in 
the Norwegian study. Furthermore, international guidelines and consensuses for care 
of older patients with DM form the basis on which Norwegian guidelines are built, 
and the results from this study could serve as a useful supplement to the two 
Norwegian studies, giving an idea of the comorbidities and medicine burden faced by 
care home residents with DM. 
62 
 
5.1.3 Study III 
Credibility (internal validity) and reflexivity 
Searching for different explanations for the data, looking for cases that do not fit the 
pattern, and participant validation (member checking) are all techniques to enhance 
credibility (160-162). The method of STC ensures the former, in that the researcher 
searches iteratively for subjects of meaning (154). The latter was partly 
accommodated in that a brief account of the main points discussed by the participants 
was given by the moderators at the end of each interview. The participants were then 
asked to give feedback on these preliminary interpretations, correct any 
misinterpretation or give additional information if they found it appropriate. This 
aspect could have been strengthened by letting one or several participants from each 
interview group read through and give feedback on the transcripts and/or the 
manuscript.  However, to ensure participant confidentiality and privacy, we did not 
register or store personal information, such as names and email addresses, as part of 
the data collection. Participant validation is also limited in that participants have an 
individual role in the research process, whilst the researcher’s goal is to give an 
interpretation for a wider audience (162). Thus, participant validation is a way to 
reduce error, but may also generate more data, which in turn require interpretation 
(162). 
Theoretical frameworks are sometimes used by qualitative researchers as a way to 
illustrate how interpretations relate to, or are constructed based on, individual, social, 
or historical contexts (159, 161). However, in qualitative research in medical 
sciences, a theoretical framework is not always applied. Reflexivity, i.e. providing a 
frame of reference, or a thorough account of personal and intellectual biases, attends 
to the construction of knowledge in a similar way and enhances credibility of the 
findings (161, 162). As previously mentioned, the CBGM observations and additional 
measurements originally investigated as a part of Study I were too few to give any 
robust results for the quality of CBGM in nursing homes. However, the observations 
provided the springboard for the research questions in Study III. The thoughts that 
emerged from the observations and visits were documented in a field journal by the 
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candidate.  These notes were used to write a document of her preconceptions of the 
field, including hypotheses of what the study would find (Appendix 10). This helps 
maintain reflexivity by distinguishing which experiences and opinions were brought 
into the field in advance by the researcher. Designing, analysing, and interpreting 
data may also result in different, but equally valid, presentations of the area studied, 
depending on a researcher’s personal and professional background. In this study, 
additional researchers (AGG, GBBK, RLSK, and UØS) took part in both the design 
and analysis of data, providing several opportunities to both supplement and 
challenge the beliefs of the candidate.  
Transferability and dependability (external validity and reliability) 
The inclusion of several professions to share their perspectives on CBGM in care 
homes was a strength in this study. This purposeful sampling is a technique to 
develop a theory or explanation of a subject, which includes a range of factors that 
might affect variability of behaviour and may enhance transferability (159, 160). 
However, as stated in Paper III, we experienced difficulty in recruiting nurses, which 
resulted in limited sample sizes in these two focus groups. Nor did we make use of 
saturation, where data are analysed concurrently with data collection, and where 
saturation is reached and data collection can cease when no new themes emerge 
(159). However, the dynamic in all three groups was good, and the participants did 
not seem to be reluctant to disclose opposing views. Although additional perspectives 
on the subject could have emerged from a wider sample, our findings still present 
some important and relevant aspects regarding the use and usefulness of CBGM in 
care homes from the perspective of healthcare personnel.  
A clear account of preconceptions, and how data was collected and analysed will 
increase the dependability and confirmability of a qualitative study, in addition to 
enabling readers to assess the applicability of the findings to their setting (159, 160, 
162). We gave an account of the premises for the study and a brief overview of each 
author’s background in the paper. Furthermore, STC facilitates dependability and 
confirmability through its systematic approach that allows for transparency, inter-
subjectivity, and reflexivity throughout the process (154, 161).  
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In this study, three additional researchers with varying professional backgrounds 
(UØS, GBBK, and RLSK) gave input on development on the interview guide and co-
moderated the interviews together with the candidate. All authors (LMA, AGG, UØS, 
and RLSK) contributed to the first step of analysis, and the candidate discussed with 
several of the authors during the other steps of analysis as well. This provides a form 
of critical appraisal throughout the process, which could help uncover whether the 
interpretations are applicable to a broader audience, i.e. increase transferability, and 
also helps to enhance dependability and confirmability (160). 
5.2 Discussion of findings 
‘All sorts of things can happen when you’re open to new ideas and playing around with things.’ 
~ Stephanie Kwolek, the chemist who invented Kevlar 
5.2.1 Care home residents with DM – undervalued and 
overtreated? 
Our findings of a total DM prevalence of 16 % in Norwegian nursing homes in 2012 
and a T2DM prevalence of 13 % in UK care homes in 2011-12, correspond to the 
DM prevalence numbers of 14-22 % for care homes across Europe during the same 
time period (69, 71-77, 90). The age and gender distribution of the study population, 
and the proportion of pharmacologically-treated residents, are also comparable (67-
69, 71-75).  
While large cohort studies have found that the incidence of T2DM has declined in all 
age groups between 2009 and 2014 in Norway (167), and that it has remained 
relatively stable in the UK population between 2005 and 2013 (168), the prevalence 
has increased in both countries in this time period, especially in the oldest age groups 
(167, 168). The prevalence of DM found in Study I and Study II shows that DM is a 
common diagnosis among care home residents in both Norway and the UK, affecting 
approximately every sixth resident. These findings alone illustrate that care home 
residents with DM should be considered an area of priority. Unfortunately, several of 
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our research findings point towards suboptimal care on the topics of medicine use and 
blood glucose measurements.  
Study I found a high number of residents with low HbA1c values and CBGM 
readings consistent with hypoglycaemia, and nine out of ten residents in Study II 
were prescribed at least one PIM. Medicines for prevention of cardiovascular disease 
were among the top five PIMs in this population, which a physician agreed could be 
directly discontinued or considered discontinued. Thus, Study I and II demonstrate 
that care home residents have a high burden of medicines in general and of DM-
related medicines in particular, and reveal a major potential for optimising DM 
treatment. In Study III we further explored the findings from Study I. This study 
uncovered that the challenges of optimising DM treatment and avoiding 
hypoglycaemia go beyond correct use of CBGM, in that participants identified a lack 
of training and procedures for DM care in general. Participants also spoke of the 
struggle to provide patient-centred care and enhance patient participation. 
5.2.2 Targeting hypoglycaemia through HbA1c goals 
The ADA and IDF guidelines emphasise care home residents’ vulnerability to 
hypoglycaemia (24, 101, 108). Previous studies have found that between 10 % and 69 
% of care home residents experience hypoglycaemia (61, 62, 66, 68, 75, 78, 80, 87, 
96, 127, 169-171).  This is in line with the results in Study I, where six out of ten 
residents had at least one recorded blood glucose concentration consistent with 
hypoglycaemia or high risk of hypoglycaemia. All of the residents prescribed insulin 
had at least one such recording. Whilst we did not have information about glycaemic 
control in Study II, we found that nine out of ten residents with T2DM were 
prescribed five or more medicines. This is defined as polypharmacy and is considered 
an independent risk factor for hypoglycaemia (172).  Register-based studies from the 
UK found that between 1998 and 2014, the number of hospital admissions for 
hypoglycaemia increased and remains high, especially in the oldest age groups (173, 
174). For adults with T2DM ≥65 years of age, the incidence of hospitalisations for 
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hypoglycaemia increased from 1.12 to 3.52 per 1000 person-years between 1998 and 
2013 (173). 
As an HbA1c level <53 mmol/mol (7.0 %) has been shown to increase the risk of 
hypoglycaemia and other unfavourable events in older patients (115, 116), this has 
been proposed as a threshold measure of possible overtreatment (35, 108). Following 
this, deintensification or deprescribing of diabetes treatment could be considered for 
45 % of the residents in Study I. HbA1c levels <53 mmol/mol (7.0 %) are generally 
common in the care-home population, reported for between 36 % and 89 % of 
residents (62, 65-67, 71, 74, 80, 96, 115, 169, 175-178), indicating that overtreatment 
is prevalent.  
The need for alleviating HbA1c goals to target hypoglycaemia in very old care home 
residents is supported by the findings in an observational study of 583 residents ≥65 
years of age in 117 US nursing homes (115). The researchers found that in residents 
≥85 years with an HbA1c value <53 mmol/mol (7.0 %), the incidence of 
hypoglycaemia was close to twice as high compared to that of those with higher 
HbA1c levels. This trend was not found in the younger age groups (115), and also 
stands in contrast to other studies that have not found significant differences in risk 
and duration of hypoglycaemia between patients grouped by different HbA1c levels 
(78, 179, 180). CGM has also revealed that nocturnal hypoglycaemia, registered 
between 10 pm and 6 am, was frequent regardless of different HbA1c levels (180).  
In addition, using CGM data from 90 patients ≥70 years to investigate the 
relationship between HbA1c values and blood glucose levels raised the concern that 
HbA1c values may not accurately reflect glycaemic variability in these patients (134). 
The linear correlation between blood glucose levels and the HbA1c values that has 
been established for adults aged <70 years, sometimes referred to as estimated 
average glucose (eAG), is also less evident for older adults, according to the same 
study. Thus, the authors conclude that HbA1c should be interpreted with caution in 
regard to treatment changes, and fluctuations in blood glucose should always be taken 
into account (134).  
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Nonetheless, simplification of insulin treatment has shown to significantly reduce 
hypoglycaemia duration and hypoglycaemia excursions (153, 180). Additionally, 
high clinical complexity, defined as an age of ≥75 years, dementia, or end-stage renal 
disease, or ≥3 serious chronic conditions, has also been found to increase the risk of 
severe hypoglycaemia in patients with an HbA1c <53 mmol/mol (7.0 %) treated with 
one or more blood glucose-lowering medicines (181). Thus, one can advocate that the 
HbA1c value gives some indication of hypoglycaemia risk, but it cannot and should 
not be used as the sole measure of whether a resident is prone to overtreatment.  
5.2.3 Recognising hypoglycaemia – easier said than done 
In DM, point-of-care testing (POCT) is widely available for monitoring and 
optimising treatment. Study III found that the focus group participants appreciated 
CBGM as a tool to guide both on-site clinical decisions and follow-up of care home 
residents with DM. Still, the findings from Study I suggest suboptimal use of CBGM.  
In detail, findings in our studies raise the concern that not all hypoglycaemia is 
detected by CBGM alone. For instance, 15 % of the total CBGM readings in Study I 
were <6.0 mmol/L and only 3 % were defined as hypoglycaemia (<4.0 mmol/L). This 
may suggest that CBGM is generally done as a routine, and that clinical 
circumstances and events that may warrant additional CBGM are few or not as easily 
picked up on by the care home staff. The nurses participating in Study III stated that 
they were attentive towards symptoms that would require additional measurements, 
but also expressed uncertainty about how to appropriately act upon readings of 
‘borderline low’ values. These findings agree with what was described in focus group 
interviews with home care nurses in Norway, who cared for elderly people with DM 
(126). They also expressed a wish for more guidance in the signs and symptoms to 
look for, in order to tailor the care to the individual patient: ‘I would like to have [the 
specialists] come [to the users] and see how their blood glucose is and be guided 
exactly in relation to each user’ (126).  
According to the physicians participating in Study III, they tried to support proper 
management of DM by setting a treatment target and giving precise orders for 
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CBGM. However, a cross-sectional study of 16 nursing homes in Norway and 
Iceland found that an individual treatment goal (HbA1c) or individual routines for 
CBGM were registered in very few patient records (77). In the UK, a national audit 
of diabetes care in care homes undertaken in 2012-13 revealed that 56 % of the care 
homes either did not keep or did not know if they kept documentation of the HbA1c 
value for residents with DM (165). Furthermore, assessment for hypoglycaemia and 
written policies for management of hypoglycaemia were lacking in over a third of the 
care homes (165).  
Recognising hypoglycaemia in care home residents is challenging, as cited and 
exemplified by Lekarcyk et al. (31) in the introduction of this thesis. Clinical 
complexity and dementia contributes to an unusual presentation of hypoglycaemia 
symptoms, as the resident is unable to act or report on the detrimental events she is 
experiencing, and staff experience confusion around the cause of these symptoms 
(31). Although most guidelines acknowledge this and thus recommend assessment of 
a resident’s risk of hypoglycaemia as a prevention measure, the McKellar guidelines 
for managing older people with diabetes in residential and other care settings in 
Australia is the only one to give specific guidance on how and when to assess 
hypoglycaemia risk (109). In addition to presenting a risk assessment tool, they list 
medicines other than blood glucose-lowering ones that could increase the risk of 
hypoglycaemia, outline the symptoms that mild and severe hypoglycaemia can 
present with in this population, and provide specific protocols on how to manage 
them. They recommend using risk assessment tools in care planning and stress the 
importance of involving the resident as much as possible (109).  
The importance of involving the resident in risk assessment and care planning, rather 
than simply relying on set limits for hypoglycaemia, is illustrated by a quote from one 
of the physicians participating in Study III, who stated that ‘it’s a surprisingly wide 
spectrum for […] when [the residents] experience hypoglycaemia’. A study 
interviewing 61 DM patients aged >75 years about the lowest tolerable blood glucose 
level they felt well at and below which symptoms of hypoglycaemia developed, 
found this to be >4 mmol/L in all patients (mean 6.7 mmol/L (standard deviation 
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(SD) 1.3)) (182). The study found no significant differences in age, gender, number 
of comorbidities or medication, insulin therapy, living status, or caring provision 
between patients that experienced hypoglycaemia at a lower level (≤6.0 mmol/L) 
compared to a higher level (>6.0 mmol/L) (182). The mean HbA1c value of 60 
mmol/mol (7.6 %), and range 29-107 mmol/mol (4.8-11.9 %), were comparable to 
what we reported for the residents in Study I. Even though we did not investigate 
whether the CBGM readings <6.0 mmol/L in Study I were accompanied by clinical 
symptoms of hypoglycaemia for the residents, many of them will likely have 
experienced discomfort without necessarily presenting with textbook hypoglycaemia 
symptoms.   
5.2.4 From ‘what’s the matter?’ to ‘what matters to you?’ 
There has been a development of clinical guidelines and a steady increase of research 
and improvement initiatives for care home residents with DM over the last two 
decades. Despite this, a recent review found that access to guidelines, availability of 
protocols, monitoring of DM and its complications, staff training and knowledge of 
DM, and involvement of residents in DM management are still suboptimal (166). The 
balance between providing high quality care, as stated by the guidelines, whilst 
considering the complexity of the resident and the wish to allow for the resident to 
have a personal choice, was identified as challenging by UK care home staff in a 
focus group study (84). 
In an attempt to correct this, new management approaches that shift the focus from a 
disease-specific approach to that of a holistic, multidisciplinary, and patient-centred 
approach have emerged (183, 184). Moving the focus from ‘what’s the matter?’ to 
‘what matters to you?’ entails uncovering the patients’ individual goals and including 
patients in treatment decisions (185). In addition to empowering patients by 
recognising their wishes and enhancing the quality of life through improving 
functional status, these approaches also warrant close collaboration and 
communication between several professional disciplines. In Scotland, ‘what matters 
to you?’ is used as a key question in the healthcare sector to help staff shift from a 
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paternalistic ‘we know best’ culture towards more person-centred care, enabling the 
patient to have a meaningful life (185). 
A study investigating 62 care home residents’ quality of life and satisfaction with 
care found that dignity, spiritual well-being, and food enjoyment were significant 
predictors of overall satisfaction with the nursing home (186). Experiencing a higher 
level of dignity was also a significant predictor of residents’ satisfaction with the 
staff. Within the study population, 37 % of the residents had a DM diagnosis. The 
authors discuss that enhancement of dignity can be done through daily life 
interactions; one example being that staff members explain to residents what they are 
doing in different situations of care. This agrees with what nurses participating in 
Study III reported regarding talking the resident through the CBGM process as they 
were performing it. 
In a review of DM in older people from 2015, the authors argue that the interplay 
between DM, frailty, and disability underpin the need to put function first when 
assessing, planning, and managing DM (183). With similar reasoning, a 2019 
consensus opinion from primary care clinicians and diabetes specialists presents 
recommendations for holistic assessment and management of older people with 
T2DM (184). In addition to advocating shared decision making and identifying and 
prioritising clinically-dominant conditions, they particularly emphasise targeting 
therapeutic inertia, i.e. failure to intensify or de-intensify treatment as appropriate, to 
avoid overtreatment and adverse events.  
The findings from Study I and Study II suggest a major potential for the 
deprescribing of DM-related treatment, and others have demonstrated that 
deprescribing both blood glucose-lowering medicines (66, 152) and antihypertensives 
(187) is safely obtainable in care home residents. In general, using evidence-based 
decision aids that consider the clinical complexity of care home residents has 
demonstrated that deprescribing in this population seldom leads to reactions that 
require medicines to be re-initiated and contributes to a decrease in medicine cost and 
administration time (148-150).  
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Sometimes deintensification, simplification, or temporarily pausing medication may 
be more appropriate than deprescribing directly, and be a way to ease into 
deprescribing. As the name of the tool we used to guide deprescribing in Study II 
(OSAMU) indicates, the overall focus should be on optimising or improving 
treatment (146, 147). Considering the limited amount of historic and clinical data 
available to us in Study II, it was difficult to approach optimisation of therapy in any 
other respect than identifying inappropriate treatment in regard to the resident’s age, 
current diagnoses, and concurrent therapy.  
There are still questions on how best to arrange for optimisation of medicines in 
regard to which approach produces the most favourable effects on outcomes such as 
adverse events and hospitalisations (188). Also, among the barriers to optimising 
medicines revealed in qualitative studies are fragmented care, incomplete 
information, and uncertainty about which benefits or harms continuing or 
discontinuing specific medicines will produce (188). Some patients or their carers 
may think that fewer medicines equal poorer quality of care, and good 
communication skills are vital when introducing the patient and their relatives to the 
idea of deprescribing. In addition, it is important to remember that other therapies, 
such as analgesics, may be underused in care home residents with DM (99).   
The previously-mentioned 2019 consensus opinion suggests an algorithm for how to 
carry out a holistic review of DM management in the older person, incorporating two 
pragmatic mnemonics; NEWMEDS for the initiation or change of any medication 
and DEINTENSIFY for when, how, and for whom deintensification or simplification 
of blood glucose-lowering medicines may be warranted (184). The DEINTENSIFY 
mnemonic has been directly adapted from Abdelhafiz and Sinclair (151). The 
Australian Deprescribing Network (ADeN), comprising a wide range of healthcare 
professionals and researchers interested in promoting deprescribing, has developed a 
general deprescribing protocol and algorithm (188). The ADeN underlines that the 
deprescribing process is about more than just discontinuing inappropriate medicines, 
including close agreement between the patient, clinician, and pharmacist when 
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reviewing medicine lists, and training initiatives for healthcare personnel involved in 




‘I once wrote a lecture for Manchester University called « Moments of Discovery » in which I said 
that there are two moments that are important. There's the moment when you know you can find out 
the answer and that's the period you are sleepless before you know what it is. When you've got it and 
know what it is, then you can rest easy.’ 
~ Dorothy Crowfoot Hodgkin, chemist and winner of the 1964 Nobel Prize for Chemistry, who 
determined the structure of vitamin B12 and insulin through her work with X-ray crystallography  
The prevalence of DM in Norwegian nursing homes was found to be 16 % and the 
majority of these residents used blood glucose-lowering medicines. Close to half of 
the residents were prescribed insulin and all of these residents had at least one 
recorded episode of a blood glucose level <6.0 mmol/L during the last four weeks, 
considered to be at a high risk of hypoglycaemia. Frequency of CBGM varied 
greatly, but residents using insulin had CBGM performed significantly more often. 
Regardless of treatment, six out of ten residents with DM had registered blood 
glucose levels <6.0 mmol/L. Three-quarters of the residents had measured HbA1c in 
the last twelve months. Mean HbA1c was 57 mmol/mol (7.3 %), and 45% had an 
HbA1c below 53 mmol/mol (7 %) (Study I). 
UK care home residents with T2DM had a significantly higher number of 
comorbidities and prescriptions compared to residents without DM. Additionally, a 
higher percentage of residents with T2DM were treated with five or more medicines. 
Among the 106 residents with T2DM we identified 346 PIMs. Nine out of ten 
residents with T2DM had at least one PIM. The medicines optimisation tool used in 
this study was well suited to identify PIMs in this population (Study II). 
Physicians, registered nurses, and auxiliary nurses working in Norwegian nursing 
homes regarded CBGM as necessary in the management of DM. The participants in 
our study tried to limit the strain they associated with frequent CBGM in this 
population and emphasised the importance of quality of life. However, the 
participants also acknowledged the challenges in recognising and evaluating deviant 
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blood glucose concentrations and pointed to deficiencies in training and procedures 
limiting the usefulness of CBGM (Study III). 
In summary, the research in this thesis shows that there is a major potential for 
deprescribing or optimisation of medicines in care home residents with DM, as 
evident by both medication lists and blood glucose data. Although the staff seem to 
be aware of the needs and challenges of this group of patients, the complexities of the 
disease and treatment make management difficult, and the insufficiency of guidelines 
and training fosters uncertainty and may lead to unfavourable treatment.  
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7. Implications and further research 
‘I don’t know where I’m going from here, but I promise it won’t be boring.’  
~ David Bowie 
This thesis investigates a part of DM management in care homes, where we mainly 
applied a descriptive and explorative approach. Through this, we uncovered that 
medicine use in general and use of DM medicines in particular could pose a risk to 
patient safety. We also found that there is room for improvement of the rationale for 
and use of CBGM in nursing homes.  
Due to the time constraints of a PhD project and the limitations of the data collected, 
there were several questions regarding DM management that we were unable to 
answer in this thesis. The explorative nature of our studies also resulted in findings 
that warrant follow up and new questions that emerged during the research process. 
Future studies should look into interventions to optimise medicine use, including 
deprescribing, as an attempt to lessen the polypharmacy burden and risk of 
hypoglycaemia, and promote evidence-based and rational prescribing for this 
vulnerable group of patients.  
An especially important topic to explore further is how to include the patient 
perspective. Around 80 % of residents in Norwegian care homes are afflicted with 
cognitive impairment, which can make it challenging to involve them in decision 
making. Thus, future research should focus on the best ways to identify what matters 
most to the resident. This will point towards a reasonable and valuable place to start 
improving care, and should form the basis for treatment choices and care planning, 
rather than an HbA1c value that is considered appropriate. As noted in an interview 
study of older home-dwelling people with T2DM, the participants expressed 
healthcare goals in social and functional terms, rather than biomedical terms (189). 
The future also holds great potential when it comes to improved ways of monitoring 
the disease. New blood glucose-monitoring technologies such as CGM and FGM may 
currently not be readily available for use in the care-home population, both due to 
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cost and lack of sufficient studies documenting the value in older people with DM. 
Research and development in this field is therefore necessary. The new technologies 
can possibly alleviate the invasiveness blood glucose monitoring can entail, which 
could ease the strain on both the resident and the healthcare personnel responsible for 
the measurements. Further, they can provide a better overview of the diurnal blood 
glucose variability and the factors that influence this in care home residents with DM. 
Also, CGM or FGM could possibly provide better opportunities to alert caregivers of 
deviant blood glucose levels. This information can in turn help tailor treatment and 
aid nursing home staff in gaining a better understanding of when a particular resident 
is prone to hypo- and hyperglycaemia.  
Finally, CGM and FGM can enable patients to become more independent, in that 
these technologies could make it easier to monitor their disease. Maintaining 
independence and the ability to carry out activities were among the main self-reported 
healthcare goals of home-dwelling people with T2DM (189) and are also stated 
governmental goals in Norway regarding caring for the older population (190). For 
many people, this entails being able to live at home for as long as possible (190, 191). 
Thus, the research focus on frail, older people with DM should be expanded to 
include home-dwelling people with DM, and the possibilities various types of 
assistive technology could provide for these patients. In these matters, it is also of 
great importance to discuss ethical considerations, including privacy, autonomy, 
stigmatisation, individualisation, human contact, and affordability (191). 
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a b s t r a c t
Aims: Determine prevalence of diabetes, and describe use of blood glucose lowering (BGL)
drugs and glycemic control in Norwegian nursing homes.
Methods: In this cross-sectional study we collected details of BGL drugs, capillary blood
glucose measurements (CBGM) in the last four weeks and HbA1c measurements in the last
12 months from the medical records of patients with diabetes, within a population of 742
long-term care patients from 19 randomly selected nursing homes in Western Norway.
Descriptive statistics were applied, and Pearson’s chi-squared (P ! 0.05) or non-overlapping
95% confidence intervals were interpreted as significant effects.
Results: 116 patients (16%) had diabetes, 100 of these gave informed consent and medical
data were available. BGL treatment was as follows: (1) insulin only (32%), (2) insulin and oral
antidiabetics (OADs) (15%), (3) OADs only (27%) and (4) no drugs (26%). Patients with
cognitive impairment were less likely to receive medical treatment (P = 0.04). CBGM and
HbA1c measurements were performed for 73% and 77% of patients, respectively. Mean
HbA1c was 7.3% (57 mmol/mol), 46% of patients had an HbA1c <7.0% (53 mmol/mol), and
CBGM consistent with risk of hypoglycemia was found for 60% of these patients.
Conclusions: Prevalence of diabetes and BGL treatment in Norwegian nursing homes is
comparable to other European countries. Although special care seems to be taken when
choosing treatment for patients with cognitive impairment, there are signs of overtreat-
ment in the population as a whole. The strict glycemic control unveiled may negatively
affect these frail patients’ quality of life and increase the risk of early death.
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1. Introduction
The prevalence of diabetes is increasing worldwide, with the
highest rise in the population "60 years of age [1]. Diabetes in
the elderly is metabolically distinct from younger patients [2],
associated with an accelerated progression of both functional
and cognitive decline [3–5] and is a common cause of nursing
home admissions [6]. The reported prevalence of diabetes in
nursing homes varies from 11 to 36% around the world [7–13].
The majority of nursing home patients receive multiple
drug therapy and drug-related problems (DRPs) are common
[14]. Patients with diabetes have a higher burden of comorbid-
ities compared to patients without diabetes [10,15], further
complicating management of care. Hypoglycemic episodes
occur frequently, due to both an overly intensive drug regime
[7,11,16] and concurrent diseases [17,18]. Symptoms of
hypoglycemia in the elderly are often unspecific and less
marked compared to in younger patients [19,20] and may be
mistaken for symptoms of their cognitive or functional
impairment, or even stroke [20,21]. Hypoglycemia is associat-
ed with an increased risk of adverse clinical outcomes, such as
cardiovascular disease, dementia and death [22,23]. Lack of
guidelines for blood glucose monitoring [7,24], poor recogni-
tion of clinical symptoms that may call for unscheduled
measurements [9], and unclear limits of blood glucose
concentrations where the physician should be notified [24],
may further increase the risk and impact of hypoglycemia.
Guidelines for treatment have, until recently, been sparse
for frail, older patients. However, the new recommendations
concerning treatment of diabetes in this population have a
strong focus on reducing the risk of hypoglycemia in addition
to limiting hyperglycemia, both through reducing excessive
medical treatment and providing appropriate and sufficient
blood glucose monitoring. [25,26].
In Norway, a study from the Tromsø area that examined
subjects >69 years of age either receiving nursing care at home
or in an institution found a known diabetes prevalence of 20%
[27]. However, this study did not discriminate between
patients that received nursing care at home and patients
who were staying in an institution; neither did they include
patients with severe illness or dementia. Hence, diabetes
prevalence in Norwegian nursing homes has not been studied
exclusively, and the quality of diabetes care has not previously
been investigated for these patients. This study aims to
determine the prevalence of diabetes in Norwegian nursing
homes, and investigate the use of blood glucose lowering
drugs, frequency of capillary blood glucose measurements
(CBGM) and HbA1c measurements, and glycemic control in
this population. In addition, these aspects of diabetes care are
compared with the newer recommendations for diabetes
treatment and follow-up.
2. Subjects, materials and methods
2.1. Study design and participants
This cross-sectional study was performed within a population
of long-term care patients in nursing homes between February
and August 2012. Long-term care patients were defined as
patients admitted for a stay of "3 months. We drew a random
sample from all nursing homes (n = 180) within the geograph-
ical area of the Western Norway Regional Health Authority. A
total of 26 nursing homes were invited to participate and 20 of
these accepted, of which one withdrew after data collection
had begun. The 19 nursing homes were located in both rural
and urban areas, with a median long-term care population of
29 patients (range 8–136). Sixteen of the nursing homes were
owned by the municipality, whereas three were owned by
private foundations.
To ensure patients’ confidentiality nursing home staff
collected depersonalized data about year of birth, sex, and
which patients had a diagnosis of diabetes. Nursing home staff
also assessed diabetes patients’ capacity to give consent and
collected written, informed consent from patients. In cases
where patients themselves lacked capacity to consent, their
next of kin was asked to give consent on their behalf. The
study was approved by a regional committee for medical
research ethics (REK Vest).
The researcher (LMA) examined the nursing home medical
records of all consenting diabetes patients and registered any
blood glucose lowering drugs. They were defined as all drugs
within code A10 –‘‘Drugs used in diabetes’’ in the Anatomical
Therapeutic Chemical (ATC) classification system [28]. The
researcher also collected information on number of measure-
ments and concentrations of capillary blood glucose and
HbA1c within the last four weeks and twelve months,
respectively. In this population, we define hypoglycemia as
a blood glucose concentration <4.0 mmol/L and risk of
hypoglycemia as a fasting blood glucose concentration
<6.0 mmol/L [26]. Hyperglycemia is defined as a blood glucose
concentration >11.0 mmol/L [26].
2.2. Statistical analyses
Descriptive statistics for normally distributed continuous
variables are expressed as means with 95% confidence
intervals (CI). Non-overlapping confidence intervals are inter-
preted as significant effects. Continuous variables with a
skewed distribution are presented as median with range.
Categorical variables are presented as frequencies and
percentages. The 95% CI for the percentages were estimated
by the 2.5 and 97.5 percentiles from non-parametric boot-
strapped data (10,000 datasets were simulated for each CI).
Pearson’s chi-squared were used to test for significant effects.
P-values ! 0.05 were considered statistically significant. Sta-
tistical analyses were carried out using IBM SPSS Statistics 20.0




A total of 742 long-term care patients lived within the 19
participating nursing homes. Of these, 116 had a diagnosis of
diabetes (16%). Patients with diabetes did not differ from the
patients without diabetes in mean age (85.2 y [CI: 83.8, 86.6] vs.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 5 ( 2 0 1 4 ) 1 0 2 – 1 0 9 103
86.0 y [CI: 85.3, 86.7]) or in male to female ratio (0.49 vs. 0.37,
P = 0.22).
The study population consisted of 100 consenting patients
with diabetes, of which 52 were able to give informed consent
themselves. The 16 patients not consenting did not differ from
the consenting patients in age, in male to female ratio, or in
capacity to consent.
Seventy-five patients were registered with type 2 diabetes,
five with type 1 diabetes, and for twenty patients information
about type of diabetes was not given in the nursing home
medical records.
3.2. Drug regime
Nearly half of the patients (n = 47) were prescribed insulin, 32
of which were prescribed insulin only and 15 of which were
prescribed insulin and oral antidiabetics (OADs). Of the
patients with only a prn ( pro re nata–as needed) prescription
for insulin (n = 11), eight were in the insulin + OAD group.
Patients were prescribed a range of eleven different drugs for
lowering blood glucose (Table 1). Insulins most frequently
prescribed were insulin aspart (n = 44) and insulin isophane
(n = 32). Metformin (n = 27) and glimepiride (n = 18) were the
most commonly prescribed OADs.
A quarter of the patients (n = 26) received no blood glucose
lowering drugs (Table 2). These did not differ from other
patients in mean age, male to female ratio or type of diabetes
registered in their medical records. However, the percentage
of patients being prescribed blood glucose lowering drugs was
significantly higher for patients with capacity to consent
compared to patients without capacity to consent (82.7% vs.
64.6%, P = 0.04). The patients who received medical treatment
for their diabetes had an average of 1.8 [CI: 1.6, 1.9] prescribed
drugs for lowering blood glucose (range 1–3). Two of the
patients registered with type 1 diabetes were prescribed an
OAD (metformin) in addition to insulin.
3.3. Glycemic control
Seventy-three of 100 patients had one or more capillary blood
glucose measurements (CBGM) in the last four weeks. Median
number of CBGM was significantly higher for patients
receiving regular insulin injections compared to the other
treatment groups (P < 0.01) (Table 2). Thirteen patients had
daily CBGM, twelve of which received regular insulin injec-
tions and one patient who received sulfonylurea as a regular
medication.
Of the patients who had a record of CBGM in the last four
weeks, 60% had recorded one or more measurements of blood
glucose concentrations in the range of hypoglycemia
(<4.0 mmol/L) and/or risk of hypoglycemia (fasting blood
glucose <6.0 mmol/L). Fifteen percent of all recorded CBGM
were in the range of hypoglycemia or risk of hypoglycemia
(Table 3).
All patients who were prescribed insulin had at least one
recorded episode of a CBGM <6.0 mmol/L (fasting), and 62%
of these patients also had a record of CBGM >11.0 mmol/L.
For the ‘‘OAD group’’ the numbers were 48% and 11%,
respectively. None of the patients in the ‘‘No drugs group’’
had a record of CBGM <6.0 mmol/L, whilst 8% had a record
of CBGM >11.0 mmol/L. A record of CBGM <6.0 mmol/L was
significantly associated with higher mean HbA1c value (7.8%
[CI: 7.3, 8.3] (61 mmol/mol [CI: 56, 67]) vs. 6.5% [CI: 6.1, 6.9]
(48 mmol/mol [CI: 44, 52])). Patients with a record of CBGM
>11.0 mmol/L also had a significantly higher mean HbA1c
value compared to those with no recordings >11.0 mmol/L
(8.3% [CI: 7.7, 8.9] (67 mmol/mol [CI: 60, 74]) vs. 6.8% [CI: 6.4,
7.2] (51 mmol/mol [CI: 46, 55])). We did not find significant
differences in mean HbA1c value between patients with a
record of CBGM <4.0 mmol/L and patients with no record-
ings <4.0 mmol/L (8.0% [CI: 7.1, 9.0] (64 mmol/mol [CI: 53,
75]) vs. 7.2% [CI: 6.8, 7.6] (56 mmol/mol [CI: 51, 60])), or
between patients with a record of CBGM compared to those
with no recordings of CBGM the last four weeks (7.5% [CI:
7.0, 7.9] (58 mmol/mol [CI: 53, 62]) vs. 6.9% [CI: 6.1, 7.8]
(52 mmol/mol [CI: 43, 61])). Neither did we find an associa-
tion between number of CBGM and last recorded HbA1c
value (data not shown).
Twenty-three patients had no record of HbA1c measure-
ments during the last 12 months, 14 of which were prescribed
blood glucose lowering drugs. Forty patients had one recorded
HbA1c value, and in 37 patients the number of measurements
Table 1 – Overview of drugs prescribed for regulating blood glucose (ATC-code: A10) divided into insulin injections and
oral antidiabetics (OADs) (n = 74).






Insulins A10A A10AB05 Insulin aspart 31 3 31
A10AC01 Insulin isophane 25 25 0
A10AD05 Insulin aspart 9 9 1
A10AB01 Insulin isophane 7 0 7
A10AB04 Insulin lispro 3 1 2
A10AE05 Insulin detemir 3 3 0
A10AE04 Insulin glargine 1 1 0
A10AD04 Insulin lispro 1 1 0
Other antidiabetics A10B A10BA02 Metformin 27 27 0
A10BB12 Glimepiride 18 18 0
A10BB07 Glipizide 1 1 0
a As some patients are prescribed the drug both regular and prn, this number will not always add up to the sum of regular prescriptions + prn
prescriptions.
b Prn = pro re nata/as needed medication.
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ranged from two to six. Last recorded value of HbA1c ranged
from 4.7% (28 mmol/mol) to 12.4% (112 mmol/mol), with an
average of 7.3% [CI: 7.0, 7.7] (57 mmol/mol [CI: 53, 60]).
Distribution of HbA1c values by treatment is shown in
Fig. 1. Mean value of HbA1c was significantly higher when
prescribed insulin (8.0% [CI: 7.4, 8.6] (64 mmol/mol [CI: 58, 70]))
compared to patients prescribed only OADs (6.7% [CI: 6.4, 7.4]
(52 mmol/mol [CI: 46, 57])) or patients who did not receive
blood glucose lowering drugs (6.4% [CI: 5.8, 7.0] (46 mmol/mol
[CI: 40, 53])).
Seven patients neither received CBGM in the last four
weeks nor HbA1c measurements in the last 12 months. Four
of these patients were prescribed blood glucose lowering
drugs; three patients with a prescription for OADs only, and
one patient with a prescription for a regular OAD and insulin
prn.
Capacity to consent was not associated with a record of
CBGM (58% vs. 37%, P = 0.08). Neither did we find an
association between capacity to consent and having HbA1c
measured the last twelve months (53% vs. 48% [P = 0.81]),
nor last recorded value of HbA1c (7.4% [CI: 6.9, 7.9]
(57 mmol/mol [CI: 51, 63]) vs. 7.3% [CI: 6.7, 7.8] (56 mmol/























































































































































































































































































































































































































































































































] Table 3 – Results of capillary blood glucose measure-






(n = 73) (n = 1006)
Blood glucose concentration n (%) n (%)
<4.0 mmol/La 10 (13.7) 31 (3.1)
<6.0 mmol/Lb 35 (47.9) 122 (12.1)
>11.0 mmol/La 34 (46.6) 367 (36.5)
a Random blood glucose concentration, not necessarily fasting.




















Including patients with regular and/or prn prescription for insulin.
a
a
Figure 1 – Distribution of last recorded HbA1c value (%,
mmol/mol) from 77 patients, sectioned into treatment
categories ‘‘Insulin’’, ‘‘OADs’’ and ‘‘No drugs’’.
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4. Discussion
Our results show that 16% of long-term care patients in
Norwegian nursing homes have a known diagnosis of
diabetes. This is consistent with findings from other European
countries [7,11–13], and also comparable with the prevalence
previously reported for the elderly population receiving
nursing care either at home or in an institution in the Tromsø
area in Norway [27]. The majority of the patients in our study
(71%) receive blood glucose regulating drugs regularly, but
frequency and level of glycemic control vary greatly among the
patients.
Patients with diabetes were prescribed a variety of blood
glucose lowering drugs (Table 1), and choice of drugs, average
number of prescribed drugs, and proportion of patients in the
different treatment groups are comparable to what are
reported in other nursing home studies [7,11,29].
Metformin was the drug of choice for patients prescribed
OADs, whilst a basal regime with NPH-insulin was common in
insulin-treated patients (Table 1). This is consistent with
current recommendations for older people with diabetes,
although these also state that newer therapies may benefit
selected patients [26]. Insulin detemir and insulin glargine
have shown to be more beneficial than NPH-insulin for
patients at higher risk of hypoglycemia [30]. The same is true
for incretin mimetics in obese patients and DPP-4 inhibitors in
malnourished patients [31]. However, limited knowledge of
effect and safety of the newer therapies in the population aged
"75 years, and higher costs may be an explanation for why
these drugs are seldom or never prescribed [30,31].
On average, the patients who received medical treatment
for their diabetes were prescribed more than one drug for
lowering their blood glucose, and almost half of them receive
regular insulin injections. The reason for this may be that
advanced age is associated with a decline in glucose tolerance
and b-cell function, leading to increased insulin resistance and
impaired insulin secretion [32]. Progressive loss of glycemic
control in type 2 diabetes with time, requiring several OADs
and ultimately insulin to achieve appropriate treatment, is
also well-known [33]. Although we do not have information
about duration of diabetes in these patients, it is reasonable to
believe that a number of them have had the disease for some
time. Jorde and Hagen reported the average duration of
diabetes to be 11.2 # 8.2 years [27]. They found that 46% of the
patients were treated with insulin compared to 47% of the
patients in our study. However, the majority of the Tromsø
patients received insulin together with OADs (35%), whilst in
our population patients mostly used insulin alone (32%). This
may be due to some demographic differences in our popula-
tions.
Low concentrations of fasting blood glucose (<6.0 mmol/L)
and/or hypoglycemic episodes (<4.0 mmol/L) were found for
60% of the patients with a record of CBGM (Table 3), which may
indicate overtreatment in these patients, but we do not know
if these patients experienced clinical symptoms of hypoglyce-
mia in these cases. However, as hypoglycemia is often
overlooked in these patients [20,21] and also associated with
an increased risk of cardiovascular events, dementia and
death [22,23], this number is worrying. Furthermore, number
of hypoglycemic episodes may be underestimated in our
study, as only one third of patients receiving regular insulin
have daily CBGM (Table 2). Frequent hypoglycemic episodes
among nursing home patients using insulin have also been
reported in other studies [9,11,34,35]. However, increased
CBGM may not be the solution for all patients to solve the
problem with hypoglycemia. Studies have shown that even
with regular CBGM in these patients, recommended glucose
targets were not met [36] and patients not at risk of
hypoglycemia experienced unnecessary measurements [35].
Furthermore, clinical symptoms that called for unscheduled
CBGM were overlooked [9], and the risk of hypoglycemic
episodes still was a considerable issue [9,35,36]. Shorter
periods, e.g. 24–72 h, with more frequent measurements, or
even continuous glucose monitoring, may give a better
understanding of the patient’s diurnal variation in blood
glucose than regular daily measurements.
Our study also showed that many patients who had
experienced low concentrations of blood glucose also had a
record of hyperglycemic episodes (>11.0 mmol/L). This glu-
cose variability suggests that management of nursing home
patients using insulin is challenging, and that hypoglycemic
episodes might be a problem even with higher levels of HbA1c.
It has been suggested that too much focus on treating a high
HbA1c, rather than individualizing the care for the patient is
the reason for this [21,37]. Guidelines recommend that HbA1c
should be taken at least every six months, regardless of
treatment and even if the patient’s glycemic control is stable
[25,38]. Over 60% of the patients in this study do not meet this
recommendation, possibly compromising initiation and fol-
low-up of treatment. Another worrying finding was that the
medical records of 26 patients receiving blood glucose
lowering drugs lacked information about level of glycemic
control, either in form of a CBGM record, an HbA1c value, or
both. Patients who receive medical treatment for their
diabetes should receive some sort of measurement to decide
their level of glycemic control, to make sure they receive the
appropriate treatment.
The newer guidelines have advocated less stringent HbA1c
goals (7.0–8.0% (53-64 mmol/mol)) for patients with advanced
age, one or several comorbidities and/or an increased risk of
hypoglycemia [25,26,38,39]. In our study, the levels of HbA1c
were not as low as reported in similar studies [11,12,34],
especially not for patients using insulin. Still, for 46% of the
patients with a record of HbA1c measurement the last 12
months, the last HbA1c value was below the recommended
limit of 7.0% (53 mmol/mol), whilst only a quarter of these
patients were within the recommended interval of 7.0–8.0%
(53–64 mmol/mol) (Fig. 1). Similar numbers were reported by
Jorde and Hagen [27]. Too tight glycemic control in aging
patients has been associated with adverse clinical outcomes
[40,41]. The Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study reported significantly higher frequency of
hypoglycemia requiring assistance, and also a significantly
higher risk of death in patients receiving an intensive drug
regime (mean HbA1c at study end 6.4% (46 mmol/mol))
compared with patients receiving standard therapy (mean
HbA1c at study end 7.5% (58 mmol/mol)) [40]. Currie et al.
showed that HbA1c values in the lower range (<7.5%
(58 mmol/mol)) were significantly associated with an
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increased risk of mortality in patients using insulin, com-
pared to HbA1c values between 7.5% and 9.0% (58 and
75 mmol/mol) [41]. Furthermore, a more intensive glycemic
control requires more drugs or more frequent dosing of drugs,
and it also increases the risk of drug–drug or drug–disease
interactions and adverse drug events. Norwegian nursing
homes should to a greater extent adjust their HbA1c
treatment goals according to the new recommendations, as
many of the patients in our study had an HbA1c in the lower
range. The high number of patients with a record of low blood
glucose concentrations in our study further demonstrates the
importance of less stringent HbA1c treatment goals for these
patients, especially if they have a limited life expectancy and
several comorbidities.
An interesting finding in our study was that lack of capacity
to consent was significantly associated with not receiving
blood glucose lowering drugs. However, we did not find any
significant differences in receiving CBGM or HbA1c measure-
ments, or average HbA1c results based on decisional capacity.
A lack of decisional capacity is associated with impaired
cognitive function [42], and differences in diabetes manage-
ment due to impaired cognitive function have been reported
[43–45]. However, in contrast to our findings, McNabney et al.
report no difference in choice of oral agents between nursing
home patients with different levels of both functional and
cognitive impairment, and do find lower intensity of both
CBGM and HbA1c measurements [45]. Less frequent HbA1c
measurements for patients with dementia is also reported by
Quinn et al. and Thorpe et al. [43,44]. None of these studies
investigated differences in HbA1c results. While it is difficult to
point out reasons for these differences, part of the explanation
may be that a recent patient safety campaign in Norway has
focused on minimizing drug treatment in nursing home
patients, especially those with dementia [46]. Restrictions in
both drug therapy and monitoring practices may be beneficial
for patients with cognitive impairment. A recent study
reported worsened cognitive performance for patients using
metformin compared to those who were not [47], suggesting
that excessive drug treatment may do more harm than good.
According to our study, glycemic control of patients without
capacity to consent is as good as that of patients with capacity
to consent, even if they do receive less blood glucose lowering
drugs.
To our knowledge, this is the first descriptive study of
Norwegian nursing home patients with diabetes residing in
long-term care. We included different sized nursing homes
from three counties, located in both urban and rural areas.
This should make the results representative for the general
nursing home population in Norway. Our results also support
findings in similar studies from other European countries,
strengthening the knowledge basis for this population. As we
did not collect information about length of stay, our results of
the HbA1c measurements may be biased. Patients with a stay
less than 12 months may have received HbA1c measurements
that are not documented in the nursing home medical records.
Transfer of medical information between care levels have
been shown to sometimes be inadequate [48], which also
raises concern about the validity of the treatment foundation.
However, three out of four patients did have at least one record
of an HbA1c result the last 12 months, giving a reasonable
estimate of glycemic control in this population. We did not
collect information about duration of diabetes, nutrition/diet,
weight/BMI, other diagnoses, drugs or laboratory values from
these patients, and hence could not investigate how these
aspects may have influenced blood glucose lowering treat-
ment and glycemic control. A more comprehensive diagnosis
and medication review for these patients should be included
in future studies, to gain a better understanding of the medical
challenges and needs for these patients. Future research
should also include a more thorough investigation of glycemic
control in these patients, as well as CBGM and HbA1c
measurement practices in nursing homes, as these aspects
of care are essential for initiation and follow-up of treatment.
In conclusion, the prevalence and blood glucose lowering
treatment of diabetes in Norwegian nursing homes is
comparable to other European countries. Special care seems
to be taken when choosing blood glucose lowering treatment
for patients with cognitive impairment. However, the high
number of insulin treated patients, together with several
recordings of low blood glucose concentrations and low HbA1c
values suggest that some patients are subject to overtreat-
ment. This may result in lower quality of life and increase the
risk of early death. Newer guidelines recommend less
stringent HbA1c limits for older patients [25,26,38,39] and
Norwegian nursing homes should adjust their treatment
targets for patients with diabetes accordingly. Individual care
planning should also be applied, especially for patients with
high variability in glucose concentrations.
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Abstract Background Type 2 diabetes is a common diag-
nosis in care home residents that is associatedwith potentially
inappropriate prescribing and thus risk of additional suffering.
Previous studies found that diabetes medicines can be safely
withdrawn in care home residents, encouraging further
investigation of the potential for deprescribing amongst these
patients.ObjectivesDescribe comorbidities and medicine use
in care home residents with Type 2 diabetes; identify number
of potentially inappropriate medicines prescribed for these
residents using a medicines optimisation tool; assess clinical
applicability of the tool. Setting Thirty care homes for older
people, East Anglia, UK. Method Data on diagnoses and
medicines were extracted from medical records of 826 resi-
dents. Potentially inappropriate medicines were identified
using the tool ‘Optimising Safe and Appropriate Medicines
Use’. Twenty percent of results were validated by a care home
physician. Main outcome measure Number of potentially
inappropriate medicines.ResultsThe 106 residents with Type
2 diabetes had more comorbidities and prescriptions than
those without. Over 90 % of residents with Type 2 diabetes
had at least one potentially inappropriate medication. The
most commonwas absence of valid indication. The physician
unreservedly endorsed 39 % of the suggested deprescribing,
and would consider discontinuing all but one of the remaining
medicines following access to additional information. Con-
clusion UK care home residents with Type 2 diabetes had an
increased burden of comorbidities and prescriptions. The
majority of these patients were prescribed potentially inap-
propriate medicines. Validation by a care home physician
supported the clinical applicability of the medicines optimi-
sation tool.
Keywords Care homes ! Deprescribing ! Medicines
optimisation tool ! Pharmacists ! Potentially inappropriate
medicines ! Type 2 diabetes mellitus
Impacts of practice
• The results from this study suggest that care home
residents with Type 2 diabetes have a higher burden of
comorbidities and polypharmacy than residents without
diabetes, thereby having increased risk for potentially
inappropriate prescribing.
• The evidence-based, pragmatic medicines optimisation
tool used in this study allows pharmacists to identify
medicines eligible for deprescribing for care home
residents with Type 2 diabetes, thus reducing polyphar-
macy and potentially adverse events following from it.
Introduction
In the UK, care homes for older people provide accom-
modation and nursing or personal care to those who need it.
These institutions are staffed 24 h a day, with or without
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qualified nursing staff, and are referred to as nursing homes
and residential homes respectively. Care home residents
generally have a limited life expectancy [1] and experience
high levels of disability, comorbidity and polypharmacy
[2]. Non-insulin-dependent diabetes, also known as Type 2
diabetes mellitus (T2DM), is reported to be among the ten
most common diagnoses, affecting 15 % of the care home
population [2].
T2DM is associated with a range of comorbidities and
complications [3, 4], deteriorating health and reducing
quality of life. In the general older population, diabetes has
been identified as a predictor of multiple medicine use [5]
and an independent risk factor for being prescribed
potentially inappropriate medicines or combinations of
these [6, 7]. Unnecessary or inappropriate medicines can
cause adverse events and additional suffering in this
already vulnerable group of patients. It is argued that
people with diabetes who suffer from multiple comor-
bidities, cognitive impairment or reside in a long-term
nursing facility may experience limited or uncertain benefit
from diabetes treatment [8, 9]. Concerns about overtreat-
ment with blood glucose lowering medicines have been
reported [10, 11] and a Swedish study suggests that dia-
betes medicines can be safely reduced or withdrawn in the
majority of these residents [11]. These findings indicate
that the potential for deprescribing should be investigated
to a greater extent in this population.
Deprescribing is defined by Reeve et al. [12] as «the
process of withdrawal of an inappropriate medication,
supervised by a health care professional with the goal of
managing polypharmacy and improving outcomes».
Deprescribing is increasingly acknowledged as an impor-
tant part of prescribing when managing patients with
multiple conditions and limited life expectancy [13–15].
Several tools exist to help determine medication appro-
priateness in older persons, the STOPP/START criteria
[16] perhaps being the most commonly used in UK set-
tings. However, it has been argued that whilst these criteria
are useful in aiding prescribing for healthier older persons,
they may be less suitable for use in settings where the
patients are frail, late in life, and suffer from multiple ill-
nesses [13]. Hence, there is a requirement for clearer
practical guidance that directly addresses appropriate
removal of medicines in these patients [13], that should be
founded on questions about whether the medicine is cur-
rently indicated, safe and beneficial considering comor-
bidities [17, 18]. The NHS PrescQIPP document
‘Optimising Safe and Appropriate Medicine Use’
(OSAMU), a pragmatic, evidence-based tool, developed to
allow for appropriately stopping or continuing medicines in
end of life, uses such an approach [19]. When used as a
resource in a care home setting, it has been shown to safely
contribute to a reduction in polypharmacy, inappropriate
medicines and potential adverse effects [20, 21]. In addi-
tion it contributed to a reduction in administration time,
waste and costs of medicines.
Aim of the study
This study aimed to investigate the potential for depre-
scribing in UK care home residents with T2DM. The
objectives set were (1) to describe the comorbidities and
medicine use in the residents with T2DM; (2) to describe
the number of potentially inappropriate medicines in these
residents using an evidence-based, pragmatic medicines
optimisation tool; and (3) to describe the clinical applica-
bility of the medicines optimisation tool used.
This study is a retrospective sub-analysis of data from
the CAREMED study, a cluster randomised controlled trial
investigating the impact of a multi-professional medication
review service (MMRS) within 30 care homes for older
people across East Anglia, UK between March 2011 and
March 2013 [22].
Details of inclusion and exclusion criteria, outcome
measures, data collection and ethical approval have been
described in a previous publication. Findings from the main
study have yet to be published.
Ethics approval
The CAREMED study was approved by the National
Health Service (NHS) Norfolk Research Ethics Committee
(REC reference 09/H0310/96).
Methods
Data extraction and analysis
CAREMED baseline data was extracted for all 826 resi-
dents living in the 30 care homes. Data included infor-
mation about the residents’ current medicines and active
medical problems, derived from their medical records at
the general practitioner’s (GP’s) surgery.
Demographics
Diabetes prevalence was determined by evidence of T2DM
documented as an active medical problem. Residents with
other types of diabetes were excluded from the study
population and further analysis. Comorbidity burden was
determined from the resident’s number of active medical
problems. All active medical problems in the dataset were
classified according to the 22 chapters of the International
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Statistical Classification of Diseases and Related Health
Problems 10th Revision (ICD-10) Version: 2010 [23].
Number of prescriptions was determined from the number
of unique medicines prescribed. Polypharmacy was defined
as prescription of C5 unique medicines. All medicines
were coded according to the Anatomical Therapeutic
Chemical (ATC) classification system [24].
Potential for deprescribing
The NHS PrescQIPP document OSAMU consists of 46
areas for medicine optimisation based on the drug classes
in the British National Formulary (BNF) chapters [19].
Based on the available CAREMED data, we identified that
35 of these areas were applicable to our population. For
counting purposes, one or several explicit criteria were
identified for each area by LMA in agreement with RLSK
(Online Resource 1). LMA and RLSK are pharmacists with
experience of clinical work and research in both commu-
nity pharmacies and care homes, with particular focus on
diabetes. Potentially inappropriate medicines (PIMs) were
identified by LMA based on the criteria derived from the
recommendations given in the OSAMU document (Online
Resource 2).
As a further validation of clinical applicability of the
OSAMU document a physician (CG) with clinical back-
ground from care homes, currently in involved in a large
multicentre-study on medicines optimisation in care homes
[25], assessed the identified PIMs for discontinuation for a
random sample of 20 % of the residents. Based on the
information available, the physician evaluated whether (1)
the medicine could be discontinued without further
question; (2) the medicine should potentially be discon-
tinued, but not before checking other parameters of
importance, e.g. laboratory values; (3) the medicine should
be changed to a more appropriate choice; or (4) the med-
icine should be continued.
Statistical analysis
Descriptive statistics were applied. Continuous variables
are presented as medians with range and/or 95 % confi-
dence intervals (CI), and categorical variables are pre-
sented as frequencies with percentages and/or 95 % CI.
The 95 % CI for the medians and percentages were esti-
mated by the 2.5 and 97.5 percentiles from a simple
bootstrap (10.000 datasets were randomly generated for
each CI). Non-overlapping CI was interpreted as significant
effects. The RAND function in Microsoft Excel 2010
(Microsoft, Redmond, WA, USA) was used to create the
random 20 % sample for validation. IBM SPSS Statistics
22.0 (IBM, Armonk, NY, USA) was used for all statistical
analysis, apart from bootstrapping, which was performed
using Python 2.7.
Results
Demographics, therapy and comorbidity burden
Of 826 residents, 109 had a registered diagnosis of DM.
Two residents with Type 1 DM and one resident with
steroid-induced diabetes were excluded, resulting in a total
study population of 823 residents, where 106 residents had
Table 1 Demographics, burden
of comorbidities and
prescriptions in care home
residents with and without
diabetes mellitus
Type 2 DM No DM
n = 106 n = 717
Median Range [95 % CI]a Median Range [95 % CI]a
Age, years 86 56–98 [84.5, 87.5] 88 39–104 [88.0, 89.0]
Age at admission, years 84 54–98 [81.0, 85.0] 86 36–103 [85.0, 86.0]
Number of active medical problems 6.5 2–16 [6.0, 7.0] 5 1–14 [4.0, 5.0]
Number of prescriptions 9 1–20 [8.5, 10.0] 7 0–27 [7.0, 7.0]
n % [95 % CI]b n % [95 % CI]b
Polypharmacyc 98 92.5 [86.7, 96.9] 534 74.5 [70.7, 78.1]
Nursing home residents 24 22.6 [8.3, 41.7] 170 23.7 [17.6, 30.0]
Women 70 66.0 [54.3, 77.1] 555 77.4 [73.9, 80.9]
DM diabetes mellitus
a Confidence intervals for median values. Non-overlapping confidence intervals are interpreted as statis-
tically significant differences
b Confidence intervals for percentages. Non-overlapping confidence intervals are interpreted as statistically
significant differences
c Polypharmacy is defined as prescription of C5 unique drug substances
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diagnosed T2DM (13 %). Table 1 compares residents with
T2DM to residents without DM. Residents with T2DM
were significantly younger and had a higher burden of both
comorbidities and prescriptions than residents without DM.
The top five ICD-10 classifications for residents with
T2DM, excluding diabetes, were I00-I99: circulatory dis-
eases (n = 82, 77.4 %), F00-F99: mental and behavioural
disorders (n = 52, 49.1 %), M00-M99: musculoskeletal
and connective tissue diseases (n = 43, 40.6 %), H00-H59:
eye diseases (n = 40, 37.7 %), and N00-N99: genitouri-
nary diseases (n = 37, 34.9 %). They were treated with the
following blood glucose lowering therapy: insulin only
(n = 10), insulin and oral antidiabetic drugs (OADs)
(n = 4), OADs only (n = 56), and no blood glucose low-
ering drugs (n = 36). The other most commonly prescribed
groups of medicines among these residents are listed in
Table 2.
Potential for deprescribing
Among the residents with T2DM, a total of 346 PIMs were
identified. The residents had from none to nine PIMs
(Table 3), with a median number of three PIMs. In total, 96
residents (90.6 %) were prescribed at least one PIM. Fre-
quency of PIMs by BNF classification is presented in
Table 4. The most frequent PIMs were (1) statins pre-
scribed without a valid indication (n = 50, 47.2 %); (2)
more than one antihypertensive prescribed (n = 43,
40.6 %); (3) laxatives prescribed without a valid indication
(n = 32, 30.2 %); (4) antidepressant prescribed without a
valid indication (n = 32, 30.2 %); and (5) H2 blockers/
proton pump inhibitors (PPI) prescribed without a valid
indication (n = 27, 26.5 %).
Within the 20 % random sample chosen for validation
by physician CG, a total of 67 PIMs were identified and 35
of these belonged to the top five frequent PIMs (Table 5).
Table 2 The most frequently
prescribed drug groups in care
home residents with Type 2
diabetes mellitus (n = 106)
ATC code Therapeutic group/substance Residents receiving therapy
N %
A10 Drugs used in diabetes 70 66.0
A10A Insulins and analogues 14 13.2
A10B Blood glucose lowering drugs, excl. insulins 60 56.6
A10BA02 Metformin 45 42.5
A10BB09 Gliclazide 26 24.5
N02 Analgesics 65 61.3
C10 Lipid modifying agents 61 57.5
B01 Antithrombotic agents 60 56.6
A06 Drugs for constipation 48 45.3
C03 Diuretics 46 43.4
D02 Emollients and protectives 45 42.5
N06 Psychoanaleptics 43 40.6
A02 Drugs for acid related disorders 41 38.7
C09 Agents acting on the renin-angiotensin system 38 35.8
B03 Antianaemic preparations 29 27.4
C01 Cardiac therapy 26 24.5
N05 Psycholeptics 26 24.5
C07 Beta blocking agents 25 23.6
A12 Mineral supplements 24 22.6
H03 Thyroid therapy 24 22.6
Table 3 Total frequency of
potentially inappropriate
medicines in care home resi-
dents with Type 2 diabetes
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Out of the total of 67 PIMs the physician agreed that 26 of
these could be discontinued without further question
(38.8 %). A common example of this was statins without a
valid indication. In the case of a further 40 PIMs (59.7 %)
the physician indicated that medicine discontinuation
should be considered, following access to other clinical
data. An example here was to check blood pressure before
deciding whether or not to discontinue excess antihyper-
tensives. The physician recommended that one PIM
(1.5 %) be changed to a different medicine. In this par-
ticular case, the combination of an SSRI with low-dose
aspirin gave the resident an increased risk of gastroin-
testinal bleeding and hence the physician recommended
keeping the ulcer prophylaxis, but replacing the H2 blocker
with a proton pump inhibitor. None of the PIMs were
considered for direct continuation.
Discussion
This study found that UK care home residents with T2DM
were younger and had a greater burden of active medical
problems, prescriptions and polypharmacy than residents
without diabetes. Using the NHS PrescQIPP document
OSAMU, PIMs were identified for nine out of ten residents
with T2DM, with the absence of a valid indication as the
most common reason. Based on the available data, a
physician with experience of care homes and medicines
Table 4 Frequency of potentially inappropriate medicines by classification of the British National Formulary, in residents with Type 2 diabetes
mellitus (n = 106)




Chapter 1—gastrointestinal system 4 70 20.2
Chapter 2—cardiovascular system 10 111 32.1
Chapter 3—respiratory system 3 1 0.3
Chapter 4—central nervous system 15 89 25.7
Chapter 5—infections 3 10 2.9
Chapter 6—bisphosphonates 1 9 2.6
Chapter 7—obstetrics, gynaecology and urinary
tract disorders
5 7 2.0
Chapter 9—nutrition and blood 2 24 6.9
Chapter 10—musculoskeletal and joint diseases 4 13 3.8
Chapter 11—eye 1 0 0.0
Chapter 12—ear, nose and oropharynx 1 1 0.3
Chapter 13—skin 1 11 3.2
Total 50 346 100.0
BNF British National Formulary
a Chapters omitted indicated that these were not applicable to our population
Table 5 Validation of deprescribing potential for the top five frequently prescribed potentially inappropriate medicines









Statin, no valid indication (107)a 50 12 12 0 0 0
Antihypertensive, more than one (105)a 43 7 0 7 0 0
Laxative, no valid indication (103b)a 32 7 0 7 0 0
Antidepressant, no valid indication (120a)a 32 4 0 4 0 0
H2 blocker/PPI, no valid indication (102)a 27 5 4 0 1 0
Total 184 35 16 18 1 0
PIM potentially inappropriate medicine, PPI proton pump inhibitor
a Numbers in parentheses indicate the assigned criteria number (Online resource 1)
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optimisation confirmed that 39 % of the PIMs could be
directly discontinued, and acknowledged a potential for
deprescribing in all but one of the remaining cases.
Our findings concur with previous studies showing that
older persons with diabetes have higher rates of comor-
bidities [26] and prescriptions [5, 27, 28] compared to the
general older population, thereby having increased risk for
potentially inappropriate prescribing. The proportion of
residents with at least one PIM is similar to that found for
the general UK care home population when using a similar
pragmatic approach for medicines review. The Northum-
bria Shine 2012 project, a prospective medicines optimi-
sation study involving both clinicians and residents, used
OSAMU as a resource in the shared decision making
process [21]. When performing an extensive medicine
review for 422 residents in 20 care homes in North
Tyneside, UK, they found that 90.5 % of the residents
required an intervention to their medicines [17, 21]. Stop-
ping medicines was the most common intervention,
required for seven out of ten residents [17, 21].
Failure to integrate comorbidities into clinical practice
guidelines, and limited guidance on treatment for frail
older patients are presented as leading reasons for the
prescribing cascade so often seen in this population
[29, 30]. Furthermore, frail elderly are normally excluded
from randomised controlled trials and other robust studies
that guidelines are built upon. Consequently, practitioners
have little or no evidence-based guidance for how to pre-
scribe for this vulnerable group of patients, and sometimes
feel pressured to follow guidelines not developed based on
the needs of these patients [30, 31].
It has been demonstrated that many medicines can be
safely discontinued in older patients without causing
adverse effects [11, 14, 17]. Still, concerns about with-
drawal effects and lack of guidance on how and when to
discontinue a medication discourage clinicians from
attempting to do so [31, 32]. Several healthcare practi-
tioners have expressed a need for deprescribing guidelines,
especially for prevention-oriented medicines, as they may
be less appropriate in the care home population [32]. In
particular, statins have even been considered harmful in
older patients, as low total cholesterol (\5.5 mmol/l) is
associated with increased total mortality in those aged
C80 years [18]. GPs sometimes choose not to follow rec-
ommended guidelines and refrain from prescribing statins
in patients with T2DM. Questions about whether statins
lead to improved quality of life, and concerns regarding
frailty, multimorbidity and short life expectancy, are listed
as the main reasons for this [33]. In our study, the physician
who evaluated the PIMs agreed to stop all statins in the
sample cases examined, for the same reasons.
In addition to evaluation of risk versus benefit of con-
tinued use of a medicine, the existence of a current
indication is of particular concern for healthcare practi-
tioners when considering deprescribing [32]. Four out of
the five most common PIMs in our population involved
medicines not having a valid indication. Similarly, no
current indication was reported as the top reason for
stopping medicines in the Northumbria Shine 2012 project
[17], and according to Barber et al. [34] incomplete
information in medical records is the prescribing error most
frequently occurring in UK care homes. Many care homes
receive prescribing services from multiple GPs, making
clear and complete information crucial for adequate fol-
low-up of the residents. A lack of information on indication
may increase the potential for medication errors, and may
also hamper deprescribing, as it adds to the uncertainty of
whether the medicine is appropriate or not, especially if it
is prescribed by a GP different to the one reviewing it. GPs
often feel reluctant to change or stop medicines prescribed
by colleagues, and also report to lack knowledge of geri-
atric pharmacotherapy [31].
In general, a lack of communication and team work
between the GP practice, the pharmacy and the care home,
and hence no integrated system for medicines management,
is the reality for many UK care homes [34]. Appointing a
lead GP for each care home and involving a pharmacist
overseeing and regularly reviewing medicines use, are
recommended to improve this [34]. Pharmacist involve-
ment is valued by both GPs and care home staff [17] and
can contribute to increased knowledge and awareness
around medicines, as well as improve quality of medicine
use [35]. The Northumbria Shine 2012 project demon-
strated that a review process led by a prescribing phar-
macist, where interventions were made available in the
electronic medical notes for the GPs to challenge after-
wards, was a cost-efficient approach. However, they
debated that involving the GP during rather than after the
review may result in even more interventions and greater
savings [17]. This may be difficult to achieve at all care
homes, and several clinical studies have shown that the
GPs’ acceptance rate for medicine interventions suggested
by pharmacists is generally high [17, 36, 37]. Although our
approach was theoretical rather than clinical, the physician
who evaluated the PIMs fully agreed with the pharmacist’s
suggestions for deprescribing in 39 % of the cases, and
acknowledged a potential for deprescribing in all but one of
the remaining cases.
As this study was a cross-sectional and retrospective
review of a selection of resident data from an RCT dataset,
it has its limitations. For instance, we did not have infor-
mation about the sequence of prescribing, information
about duration of active medical problems, or previous
medical problems and prescriptions. Neither did we have
access to clinical data, such as blood pressure, lipids,
weight and fluid intake. These data could have shed light
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on the appropriateness of even more therapies than we
included as part of our analysis, and thus have facilitated a
consideration of optimisation of therapy, not just the
potential for deprescribing. We know from previous studies
that blood glucose lowering therapy is not always optimal
in the care home population [10, 11]. Additional clinical
data could also have provided a better foundation for
assessing the applicability of the criteria, and thus have
given room for involving a more extensive team of clini-
cians to validate them. With a limited set of medical
information, we identified 346 medicines as potentially
inappropriate, where in a random sample a large proportion
was directly endorsed for discontinuation by an experi-
enced care home physician. If applied by clinical phar-
macists or GPs with full access to all necessary medical
information, maybe an even greater number of PIMs could
have been identified and discontinued, and other therapies
could also have been considered for optimisation.
We used a relatively new tool for evaluating appropri-
ateness of medicines in the care home population. As such,
comparison with other studies using other tools should be
done with care. However, we have only compared our
results to studies using similar, pragmatic approaches. In
addition, more well-known tools, such as the STOPP/
START criteria, have been considered less suitable when
seeking to optimise drug therapy in the very frail old [13].
The tool used in this study is evidence-based, takes into
account the complexity of care home residents and has
proven to be efficient in this population [20]. Even though
the sample size is small and performed in a limited geo-
graphical area, the resident population is comparable to
that of other studies investigating different aspects of
health status of care home residents both with and without
DM in other parts of the UK [2, 38]. Hence, there is no
reason to believe that the residents in this study are sig-
nificantly different from the overall UK care home
population.
The results of this study indicate that there is an
unfulfilled potential for deprescribing in care home resi-
dents with T2DM. A more clinical approach with com-
plete access to all relevant information and involvement
of a team of clinicians, assessing relevant outcomes such
as impact on glycaemic control and quality of life, should
be the goal for future studies. It would be interesting to
see if such a study gives similar results to those reported
here. As a final note, when targeting care home medicines
management, involvement of the resident should also be
considered. Together with the best current research evi-
dence and clinical expertise, the patient’s values and
preferences make up the triad for evidence-based medi-
cine [39].
Conclusion
UK care home residents with T2DM have an increased
burden of comorbidities, prescriptions and polypharmacy.
Using an evidence-based, pragmatic medicines optimisa-
tion tool, we identified that the majority of these residents
were prescribed at least one PIM. Validation of the PIMs
by an experienced care home physician supports the clin-
ical applicability of the ‘Optimising Safe and Appropriate
Medicines Use’ document.
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Abstract
Background: Capillary blood glucose measurements are regularly used for nursing home residents with diabetes.
The usefulness of these measurements relies on clear indications for use, correct measurement techniques, proper
documentation and clinical use of the resulting blood glucose values. The use of a regular, invasive procedure may
also entail additional challenges in a population of older, multimorbid patients who often suffer from cognitive
impairment or dementia. The aim of this study was to explore the perspectives of physicians, registered nurses and
auxiliary nurses on the use, usefulness and potential challenges of using capillary blood glucose measurements in
nursing homes, and the procedures for doing so.
Methods: This was a qualitative study that used three profession-specific focus group interviews. Interviews were
transcribed in modified verbatim form and analysed in accordance with Malterud’s principles of systematic text
condensation. Five physicians, four registered nurses and three auxiliary nurses participated in the focus groups.
Results: All professional groups regarded capillary blood glucose measurements as a necessity in the management
of diabetes, the physicians to ensure that the treatment is appropriate, and the nurses to be certain and assured
about their caring decisions. Strict glycaemic control and excessive measurements were avoided in order to promote
the well-being and safety of the residents. Sufficient knowledge of diabetes symptoms, equivalent practices for glucose
measurement, and unambiguous documentation and communication of results were determined to be most helpful.
However, all professional groups seldom involved the residents in managing their own measurements and stated that
guidelines and training had been inconsistent or lacking.
Conclusion: Inadequate procedures and training in diabetes care may compromise the rationale for capillary blood
glucose measurements in nursing homes, and hence the residents’ safety. These concerns should be addressed
together with the possibility of involving and empowering residents by exploring their ability and wish to manage
their own disease.
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Background
Nursing home residents with diabetes are medically
complex, with a high level of disability, many complica-
tions and medicines [1–3]. Feeding or swallowing diffi-
culties, acute illnesses or infections, or use of insulin and
other hypoglycaemic medicines can cause detrimental
fluctuations in blood glucose levels. Symptoms are
sometimes confused with other age-related changes or
are less marked compared to symptoms in younger
adults [4, 5]. Regular capillary blood glucose measure-
ments (CBGM) are therefore recommended for these
patients [6–8].
For CBGM to be useful, it requires a clear purpose,
correct sampling and good analytical performance of the
device used, as well as appropriate documentation, inter-
pretation and use of the result. However, studies have re-
ported findings such as: that CBGM is not always
performed according to individual needs [9–11]; patho-
gen transmission due to incorrect sampling [12–14];
insufficient blood glucose logs [15, 16]; uncertainty con-
cerning physician involvement [15] and actual use of test
results [17]; lack of procedures and inconsistent instruc-
tions [15, 18, 19]. In addition, training and guidance
about symptoms requiring additional measurements are
not always adequate [19, 20].
Incorrect sampling or unnecessary use of CBGM puts
residents at risk, adds costs and is associated with a higher
burden of depression, distress and worries [21, 22]. In
Norway, CBGM is the standard method for day-to-day
monitoring of diabetes in nursing homes, and three quar-
ters of nursing home residents with diabetes regularly re-
ceive CBGM [23]. Clinical procedures recommend that an
individual plan for CBGM should be decided in collabor-
ation between the physician, nursing staff and the resident
[7]. However, two recent focus group studies among
nurses in Norwegian nursing homes, revealed deficiencies
in work procedures for diabetes care, differences of opin-
ions about who should decide the frequency of CBGM,
and poor inter-professional collaboration [24, 25].
This study is part of LMA’s PhD project on diabetes in
nursing homes. In a previous study we investigated dia-
betes therapy and glycaemic control. One of our findings
was that 60 % of the nursing home residents had at least
one CBGM reading that was consistent with risk of
hypoglycaemia [23]. Together with observations during
data collection indicating that CBGM was an area of
concern to the healthcare professionals, this led us to
question whether the practices relating to CBGM were
adequate to ensure the residents’ safety and well-being.
This study therefore seeks to gain a better understanding
of CBGM practices by exploring the perspectives of phy-
sicians, registered nurses and auxiliary nurses on the
use, usefulness and potential challenges of using CBGM
in nursing homes, and the procedures for doing so.
Methods
Design of the study
We conducted profession-specific focus group inter-
views with physicians, registered nurses and auxiliary
nurses employed in nursing homes. Through a series of
open ended-questions, focus groups interviews use the
interaction between the participants to investigate their
common experiences, priorities and attitudes [26].
Participants
Three focus groups with a total of 12 participants were
held in June and September 2014. Nurses were recruited
in May and June 2014 through nursing home managers
at two different, but geographically adjacent nursing
homes. The managers received written information
about the study and predetermined dates for the inter-
views, which they distributed to eligible employees. They
then informed us how many of each professional group
had agreed to participate. Physicians were recruited by
visiting continuing professional education meetings for
nursing home physicians in June and September 2014.
In Norway, registered nurses have a bachelor’s degree
in nursing, which requires a minimum of three years
education and practical training at a university college.
Auxiliary nurses are licensed practical nurses, who have
two years of vocational education followed by a two-year
apprenticeship. Auxiliary nurses work under the guid-
ance of registered nurses. They are also known as
healthcare assistants or nursing assistants. The nursing
home physicians are either full-time employed or part-
time contracted general practitioners working at a nurs-
ing home once or twice a week.
For all professional groups, men and women with a
licence to practice and with work experience from a
nursing home were invited. No limits were set as regards
the length of work experience, but it was specified in the
invitation that the participants should have experience
of performing or managing CBGM in a nursing home
setting.
Three auxiliary nurses (AN) and four registered nurses
(RN), all women from two geographically adjacent nurs-
ing homes, participated in two separate focus groups.
Another two auxiliary nurses were originally recruited,
but failed to show up. Five physicians (P) participated in
the final focus group, two men and three women. They
were employed at different nursing homes, but knew
each other from regular continuing professional educa-
tion meetings.
Setting
The focus group interviews with the nurses were con-
ducted in a meeting room at one of the nursing homes
after the participants’ working hours. The focus group
interview with the physicians was conducted after a
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continuing professional education meeting, in an adja-
cent meeting room. Each interview lasted between 60
and 75 min and was audiotaped. Researcher LMA mod-
erated all interviews, and UØS, GBBK and RLSK took
turns as co-moderators. The interview guide was semi-
structured with open-ended questions about experience
of the use, documentation, interpretation and conse-
quences of CBGM in a nursing home setting, as well as
potential challenges for patients or personnel (Table 1).
Participants received a complimentary gift voucher
worth EUR 45.
Analysis
All interviews were transcribed in modified verbatim
form by LMA. The analysis followed the principles for
systematic text condensation (STC) [27]. We did not use
a theoretical framework for this study, as we emphasised
a more descriptive approach. Even though a theoretical
framework can support STC analysis, STC is also often
used without additional theory. STC is founded on phe-
nomenology and the theory that knowledge is con-
structed through joint understandings of the world. STC
offers a pragmatic, but systematic approach that safe-
guards transparency, inter-subjectivity, reflexivity and
the feasibility of the study [27].
STC is a four-step process, defined by Malterud as 1)
from chaos to themes – obtaining an overview of initial
themes; 2) from themes to codes – identifying and sorting
units of meaning; 3) from code to meaning – condensa-
tion of the meaning units into an abstracted text; and 4)
from condensation to descriptions and concepts – synthe-
sising the contents of the condensates. In detail, all au-
thors first read all the transcripts in order to identify
initial themes, which were used as starting categories for
coding. The four themes agreed on were: needs and bene-
fits of CBGM; glycaemic control – target values, purpose
and challenges; professional knowledge, clinical skills and
understanding of roles; and documentation and inter-
action. Secondly, LMA analysed the material iteratively
based on these initial themes, searching for units of mean-
ing. Related units were grouped under the same code
heading, which was developed from the initial theme and
adjusted during analysis. A fifth code group emerged dur-
ing analysis: the patient perspective. In the third step, all
the authors came together to sort the content of the five
code groups into subgroups. LMA then condensed and
abstracted the content of each subgroup into an artificial
quote. In the final step, the artificial quotes within each
code group were transformed by LMA into an analytical
text accompanied by authentic illustrative quotes. Com-
paring these analytical texts to the original material, all
authors searched for additional perspectives and, lastly,
defined the following categories for presenting the results:
1) Premises for CBGM, 2) Professional competence and
understanding of roles, 3) Record keeping. The analysis
process was facilitated by the text analysis software NVivo
version 10 (QSR International Pty Ltd).
Literature search
A systematic literature search was conducted to obtain
an overview of existing literature on capillary blood glu-
cose measurements in nursing homes. The databases
PubMed (EMBASE), CINAHL and MEDLINE (Ovid)
were searched for relevant publications. The following
search terms were used in different combinations: dia-
betes mellitus; nursing homes; homes for the aged; long-
term care; health knowledge, attitudes, practice; attitude
of health personnel; employee attitudes; professional
practice; quality of health care; blood glucose; blood
glucose measurement; blood glucose monitoring.
Ethical considerations
The Norwegian Social Science Data Services (NSD) is
the advisory body on privacy and research ethics for re-
search involving healthcare professionals. NSD was con-
sulted, but, since no personal data were registered or
stored as part of the data collection, the study was not
subject to notification. However, the study complied
with ethical principles for research in order to protect




Tell us about what triggered measurement the last time you
performed CBGM.
Physicians
Tell us about your approach for deciding if and when a resident with
diabetes should receive CBGM
Quality, documentation and communication of CBGM readings
Nurses/Physicians




Tell us about an episode where you experienced either a high or a
low blood glucose reading in a resident with diabetes.
Physicians
Tell us about an episode where you experienced or were called upon




Tell us about the training you have received on diabetes care and
CBGM.
Physicians
Please describe what type of training or education initiatives that
exist/are given at your place of work on diabetes care and CBGM.
In this table “Nurses” refer to both registered nurses and auxiliary nurses;
the key questions were identical for these two professional groups
CBGM = capillary blood glucose measurements
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the privacy of the participants. Specifically, the names of
the participants or their workplace were not linked to
the interview data, and audio recordings of the inter-
views were deleted once the transcripts were completed.
No individual participant or nursing home could be
identified in the transcripts or the finalised study results.
Furthermore, all participants were given an information
leaflet prior to the focus group interviews. It described
the study aims, what participation entailed and the stor-
age of data, and stated that participants could withdraw
their consent at any time up until after participation
without providing any reason. The leaflet also stressed
the importance of professional confidentiality, reminding
the participants not to identify names of patients, their
families or colleagues during the interviews. This infor-
mation was repeated before the interviews. Volunteering
for and participation in the focus group interviews was
understood as entailing consent.
Results
Premises for CBGM
Frequency and benefit of measurements
All groups expressed the view that measurements
should be kept to a minimum in order to ease the
strain of blood sampling (finger pricking) on the resi-
dents. The participants explained that most residents
had established a relaxed and consistent CBGM re-
gime, based on drug treatment and previous record-
ings of glucose levels. Physicians and registered
nurses stressed the HbA1c value as central when de-
ciding on the frequency, a decision that was made
jointly according to the nurses.
‘It varies a lot depending on [the resident’s] condition
and treatment target. I try not to bother the residents
too much, you know. Not to bother them more than
necessary to achieve whatever treatment target I’ve
set.’ P3.
The registered nurses emphasised that a change in
the resident’s situation, such as an infection, de-
creased food intake or exhibiting unusual symptoms,
usually led them to perform more frequent measure-
ments for a period. Both groups of nurses regarded
CBGM as an easy and accessible way of confirming
or disproving that a change in the residents’ cognitive
or physical behaviour was due to fluctuations in their
blood glucose. They trusted the readings from the
CBGM devices, as the nursing homes were enrolled
in an external quality assurance programme.
‘Well, in any case, if a resident with diabetes falls
ill in any way whatsoever, our first thought is,
okay, we should at least check the blood sugar level,
to rule it out, you know. Even if we suspect that it
may be due to something completely different, we
always check it, because it is such an easy and
quick thing to do.’ RN2.
All participants, but especially the physicians, regarded
the measurements as essential for following up and
adjusting diabetes treatment, but they admitted that they
were most useful for residents with unstable blood glu-
cose levels, or for residents in need of rapid-acting
insulin.
Avoiding discomfort
The physicians stressed that maintaining quality of life
for the residents and avoiding hypoglycaemia were the
main aims when deciding the level of glycaemic control.
All groups perceived the risk of long-term complications
as low due to short remaining life expectancy for most
residents. Hence the blood glucose levels were permitted
to lie around 10 mmol/l. In their experience, this did not
result in discomfort for the residents, and the registered
nurses stated that a higher rather than lower blood glu-
cose level made them feel safer as well.
‘I’m used to them being a bit liberal, that around 10
[mmol/l] is appropriate for older persons, since they do
not have that risk of long-term complications, if
they’re ninety years old, you know? (…) It is safer
and the residents feel fine, so if they’re in good
shape and all that… But, otherwise, somewhere
between 5 and 10 [mmol/l].’ RN2.
The nurses explained that most residents achieved
better glycaemic control after admission to the nurs-
ing home, probably due to regular meals and physical
activity. They sometimes worried about the residents’
nocturnal blood glucose, due to the long time that
elapsed between the evening meal (~7 p.m.) and
breakfast (~9 a.m.). In contrast, all groups said that
treats from visiting relatives often explained deviant
CBGM results. However, they were ambivalent about
food restrictions or preventing residents from eating
what they wanted. Especially the physicians were
sceptical about diets, as different-looking food made
some residents feel insecure.
‘We do not know what they eat at any given time. The
wife shows up with grapes and chocolate and sugary
yoghurts, and you know. That’s a bit of a challenge, to
be honest.’ AN1.
‘In residents with dementia, I often observe that when
they’re given different-looking food at mealtimes, they
feel insecure and start wondering what’s wrong with
them.’ P3.
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The resident perspective
Residents rarely measured blood glucose themselves. Ac-
cording to the physicians, many residents would have
been able to do so, but the task was assigned to the
nurses. The auxiliary nurses said that they involved the
residents in the measurements to some extent, either by
assisting those able to do it themselves, or by talking the
residents through the process.
‘Yes, [we’ll say] “this might be a bit sharp”, “ok, now
you will feel a little prick”, like that, but then we’re
allowed to do the measurement, as some of the
residents don’t perform the measurement themselves.
Some are allowed to measure themselves, those
who are able to of course, yes. They perform
the measurement themselves, and they adjust
[the insulin] themselves, but you’re with them,
observing and double-checking.’ AN3.
The nurses were concerned that the CBGM sometimes
bothered the residents. They nonetheless stated that the
residents, even those with dementia, seldom or never
expressed concern or objected to measurement. The
physicians shared the same experience, reflecting that
most residents were used to the routine after living with
diabetes for years.
Professional competence and understanding of roles
Training and responsibility
The auxiliary nurses were given CBGM training by the
registered nurses, but did not experience this as entirely
appropriate. In their experience, the registered nurses
had no consistent method of performing CBGM and
very seldom received further training after graduating
from nursing college. The registered nurses said that
training in performing correct CBGM had been given by
an external quality improvement programme managed
by Norwegian Quality Improvement of Primary Health
Care Laboratories (Noklus) [28], but they confirmed that
few courses were provided after graduation. They stated
that they were expected to acquire and maintain the ne-
cessary knowledge about caring for residents with dia-
betes. The physicians confirmed this. They expected the
registered nurses to be able to differentiate between
high, normal and low levels of blood glucose, to be
knowledgeable about different insulins and antidiabetic
medicines and to provide appropriate management of
hypoglycaemia. The nurses followed up this responsibil-
ity by engaging in self-study and discussing experiences
and questions with colleagues.
‘You look it up if you encounter a challenge while
at work. You will go home, look into it, then discuss
it with the physician, and then you gain knowledge
in that way. Discussing with colleagues, your
experiences. That is something you learn from
all the time.’ RN3.
The nurses expressed a wish for mandatory, inter-
professional courses to ensure that everyone has the
same information and follows the same guidelines. The
physicians supported this, and felt that they had a great
responsibility to monitor and tailor the training, as it
was often them who discovered that it was inadequate.
However, they also emphasised the nurses’ responsibility
for giving feedback on lacking procedures or insufficient
courses, and that responsibility ultimately rested with
the employer.
‘In my experience, it is often very useful to attend
[the nurses’] training. (…) There are often totally
different approaches for the nurses compared to the
physicians, you know. And they often benefit from
seeing it from both angles. And my opinion is that it
is a joint responsibility, that you as a physician have
a great responsibility to oversee the training given at
the nursing home, because you work so closely with
the staff and the others involved in the training
programme.’ P3.
Awareness and assessment of symptoms
The nurses knew which symptoms would call for an
additional measurement or would require notification of
the physician, also among residents not diagnosed with
diabetes. The registered nurses said that they found it
easier to spot hypoglycaemia than hyperglycaemia, while
the auxiliary nurses admitted that they sometimes found
it difficult to distinguish between the symptoms of these
conditions. Physicians thought that registered nurses
interpreted diabetes symptoms appropriately, but found
that they deviated from their set orders for CBGM and
insulin injections due to concerns about potential
hypoglycaemia. The registered nurses admitted a ten-
dency to perform CBGM more often than the physician
had recommended, and that borderline low or high
values made them feel uncertain. However, the physi-
cians emphasised that diabetes is a complicated disease
and that residents’ symptoms of hypoglycaemia could
cover a surprisingly wide spectrum. They further under-
lined that proper management depended a lot on precise
orders and the opportunity to get regular practice or
training in these matters.
‘Maybe if a resident’s blood glucose is low in the
morning, but not very low, more borderline low,
somewhat under what’s normal for that resident, you
start to think “should I inject insulin, should I not
inject insulin?”, because that’s not specified anywhere,
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you know? (…) And most times they need [insulin]
anyway. When they have eaten, [the blood glucose
level] will become too high if they don’t get [insulin].
But then, OK, you will still stand there assessing
these things, so…’ RN2.
‘It’s not a diagnosis that’s based on a blood test,
it’s a diagnosis based on a clinical assessment.
And it’s a surprisingly wide spectrum for, you know,
what is the lower [limit], or when do they
experience hypoglycaemia? Some will not
experience it before their value is around 2
[mmol/l], while others may experience it
around 4 [mmol/l], you know?’ P2.
Record keeping
Single or double documentation? A two-sided argument
The responsible nurse logged all information about the
CBGM, e.g. the time, value, site of pricking, units of in-
sulin given, or food intake, in the resident’s records.
Some would record the information on paper in the resi-
dent’s medical records, then later, preferably the same
day, transfer it to the electronic patient records system,
where the physician could examine it at any time. The
physicians regarded this as unnecessary double docu-
mentation. However, to the nurses, the paper sheets,
which were easily accessible in the medicine room or
trolley on the ward, made it easier to keep an eye out for
deviations, both in the residents’ blood glucose levels
and each other’s documentation routines.
‘Strictly speaking, it is double documentation, but
we do also have a paper form where we register [the
values]; it’s kept in the resident’s kardex. But we also
register it in the electronic patient records system that
we use. (…) It makes it easier on the physician’s round
to be able to access the results from there, but we do
register it both places, and that’s also because we need
it to be available on the ward, easily accessible, you
know? To look back at how [the blood glucose levels]
have been earlier.’ RN3.
Official guidelines or common procedures?
None of the participating nurses was aware of any
written template or procedure for how to carry out a
CBGM. While the auxiliary nurses expressed concern
that this led to staff performing CBGM in many dif-
ferent ways, the registered nurses seemed less con-
cerned about this because they felt that they had a
good understanding of the practical aspects of CBGM.
The nurses were not familiar with any written proce-
dures for how to manage acute glycaemic events. This
surprised the physicians, who stated that local author-
ity guidelines for managing hypo- and hyperglycaemia
existed and should be well-known.
‘I believe that they have been given some written
guidelines, or teaching or, but yes. That they have
them available and can look it up somewhere,
but I’d better look into it again.’ P2.
Despite differences in familiarity with guidelines, com-
mon procedures did exist. The registered nurses used
the individually set blood glucose limits for residents
who needed rapid-acting insulin as guidance, where
these existed. However, they stated that orders given by
a physician familiar with the resident made them feel
much safer than instructions given by an ambulatory
physician. In a serious acute event, the physician was
always called upon, while smaller deviations in blood
glucose and how they had been handled were communi-
cated between shifts and during the physician’s round.
The physicians were dependent on this, since no warn-
ing would pop up in the electronic system if a resident’s
values were deviant. A possible cause was always sought
when unexpected symptoms or CBGM results occurred,
and the action taken was based on the information
available.
‘Yes, if we’ve taken a blood glucose [measurement]
in the morning, you know, then we almost always
inform the afternoon shift nurse about the result.
Especially if it’s an unusual one, if it’s a low or a high.
So that’s part of the verbal report, in addition to it
being registered in the medical records.’ RN3.
Discussion
Principal findings
The results from this study indicate that the healthcare
professionals tried to provide patient-centred care by
minimising strict glycaemic control and excessive
CBGM. However, the rationale for CBGM in these nurs-
ing homes may be somewhat expanded due to inadequa-
cies in formal policies and training in diabetes care.
Hence, the basis for how the healthcare professionals
make decisions about care could be skewed towards
blood glucose testing rather than clinical assessment. In
addition, few opportunities existed for resident em-
powerment, since residents seldom took part in deci-
sions concerning the management of their own care.
CBGM – a safety measure or a source of additional worry?
The participants in our study revealed that training in
diabetes management was sparse and inconsistent, and
the nurses also felt that clear instructions and written
procedures were lacking. This sometimes contributed to
Andreassen et al. BMC Nursing  (2016) 15:7 Page 6 of 9
a feeling of uncertainty and created fear of inducing
hypoglycaemia in residents. Hence, CBGM was used to
reassure both staff and residents. The participants had
also created systems for preventing and managing acute
events, including good communication and thorough
documentation procedures.
In a focus group study from the UK addressing
healthcare professionals’ concerns about diabetes care
in care homes and domiciliary care, the participants
stated that, even though regular CBGM and detailed
communication between shifts are helpful, knowing
your patients well is the key to preventing
hypoglycaemia [29]. And, as the physicians in our
study pointed out, even though the range of values
where residents experience hypoglycaemia can be ex-
tremely wide, the registered nurses managed acute sit-
uations well. This could be due to good knowledge of
signs and symptoms and the fact that they were con-
stantly attentive to their patients. However, the nurses
would still confirm their suspicions using CBGM.
Similar findings have been reported by Graue et al.,
who found that nurses working in nursing homes
lacked confidence when interpreting and managing
changes in residents with diabetes. Here, the authors
point to little time to keep up-to-date about diabetes,
few resources that could be consulted, and limited
support within and between professions as sources of
uncertainty [24]. In our study, the nurses did not
seem to lack support from their peers or the phys-
ician, but there was a lack of systematic training and
common procedures. Performing CBGM not ordered
by the physician and keeping glucose logs on paper
sheets in the residents’ medical records were therefore
used to support their clinical assessments. However,
borderline glucose values contributed to further un-
certainty about how to handle the situation. Even
though the physicians stressed that clinical compe-
tence is more important than CBGM, they admitted
that inadequate instructions and training probably
contributed to this practice.
Several studies have observed inappropriate care to be
a consequence of deficiencies in guidelines [15, 19, 30]
or formal training in diabetes care for healthcare pro-
fessionals working in long-term care [25, 29]. Accord-
ingly, a need for training in diabetes care has also
been pointed out [10, 24, 25, 29, 31], highlighting
areas such as which signs and symptoms to look for,
recognising when to perform a CBGM and managing
hypoglycaemia. Others have emphasised how contin-
ued education in diabetes care could enhance the
nursing staff ’s knowledge, confidence and professional
competence, and lead to improved patient outcomes
[11, 31–33]. These findings seem to be transferable to
our study population.
The resident – the centre of attention but not part of the
team?
Even though the residents’ quality of life was the partici-
pants’ main concern, they seldom or never talked about
including the resident in decisions about their diabetes
care or CBGM. The registered nurses stated that deci-
sions about CBGM were made jointly between them and
the physicians, but they never mentioned the resident as
part of the team. This was also reflected in the fact that
very few residents performed CBGM themselves.
Two recent studies found that, even though healthcare
professionals wanted to provide patient-centred care,
several barriers existed that made them take a more
traditional approach and carry out activities on behalf of
the patient [33, 34]. In Huber et al., the nurses described
how complications and comorbidities limited older
patients’ ability to manage their diabetes care [33]. Asi-
makopoulou et al. reported that healthcare professionals
had the impression that the concept of empowerment
was unfamiliar to older patients, and that they regarded
making decisions about treatment as the healthcare pro-
fessionals’ job [34]. This could perhaps explain the situ-
ation our participants find themselves in: wanting to
empower the residents, but finding that they are neither
willing nor able to take this responsibility.
Asimakopoulou et al.’s study also revealed that most
healthcare professionals interpreted the term empower-
ment to mean giving the patients informed choice about
their treatment and that meeting biochemical targets
was an indicator of successful empowerment [34]. This
stands in contrast to the findings of Huang et al., who
reported that community-dwelling older adults with dia-
betes described their goals in global, functional terms,
instead of focusing on biomedical goals [35]. This prag-
matic view seems to be mirrored by statements made by
the healthcare professionals in our study, as they strive
to ensure minimal discomfort for the residents, for in-
stance by accepting a slightly raised blood glucose level
and attempting to avoid excessive measurements. This
sober-minded approach to care could also be part of the
reason why the residents seldom or never protested
about nursing staff performing CBGM or managing their
treatment. However, in a previous study, we found that
60 % of nursing home residents with diabetes had expe-
rienced one or several worryingly low CBGM readings,
and 46 % had an HbA1c under 7.0 % (53 mmol/mol)
[23]. This discrepancy could reflect the possibility that
the healthcare professionals in our focus groups are par-
ticularly up-to-date about current recommendations for
diabetes management. It is also likely, however, that
what one strives for in theory may not be so easy to
achieve in practice. This could also be true as regards in-
cluding the resident as part of the team. While the
healthcare professionals we interviewed individualised
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management as best as they could, they did it based on
their own preconceptions of what was considered appro-
priate and seldom seemed to involve the resident. Huang
et al. argue that providers’ awareness of how older
people define their goals for managing their diabetes
should be improved in order to enable better and more
individualised plans to be developed [35]. “Patient-cen-
teredness”, placing the patient or the resident at the
centre of the consultation, is the very foundation for
achieving empowerment, Asimakopoulou et al. states
[36]. Identification of the resident’s wishes and capacities
for self-care, as well as any concerns and issues related
to their diabetes care, should be done on admission to
the nursing home and the care plan should be revised
on a regular basis [37]. Often residents are hesitant or
anxious to express their wishes or needs to nursing staff,
as they fear it will be perceived as conflict behaviour and
ultimately will have a negative effect on the care they re-
ceive. Hence, it is important to ensure the residents that
their opinion matters and that conveying your wishes to
the nursing home staff will improve rather than reduce
quality of care [37]. To offer the resident to take an ac-
tive role in their own care, through discussing their
views on measurement frequency and CBGM results, as
well as providing training or guidance in performing
CBGM, may be ways to empowerment. Education and
empowerment of nursing staff is also vital to further fa-
cilitate resident autonomy [37, 38]. Building professional
competence and a healthy and positive work culture
among nursing staff will help the staff to be more
aware of the residents’ needs and enhance nursing
care [37, 38]. This requires access to guidelines, op-
portunity to attend courses and seminars, as well as
an open and positive work environment where discus-
sion of care situations is encouraged.
Strengths and limitations of the study
Keeping the focus groups profession-specific was both a
strength and a necessity. The professional hierarchy
could have proved limiting for group dynamics in a
mixed group, and the different professionals might have
felt that they were not given an opportunity to stress
what was important to them. Profession-specific groups
and the use of open-ended questions help the partici-
pants to share what they see as important, in their own
language, concepts and framework for understanding
the topic [26]. Even though the researchers belong to
different professional groups than those interviewed, the
systematic analysis method stays true to the participants’
perspectives and phrasing by creating a condensate in
the form of an artificial quote. It also validates the find-
ings and interpretations against the original transcripts,
and thus helps to preserve the individual context [27].
The greatest limitation of the study is the difficulty we
experienced in recruiting nurses. This resulted in a lim-
ited sample size in these two focus groups. The goal was
to recruit five to eight participants in each group, as rec-
ommended by Malterud [39], but this was only achieved
for the physician group. We could have attempted to
organise additional focus groups to obtain more mater-
ial, but we found the interaction between participants to
be adequate to elucidate our objectives. Our ambition
was not to provide an extensive description of every
aspect of CBGM practices in nursing homes, but to ex-
plore the breadth of experiences and opinions of the
different healthcare professionals involved in this aspect
of diabetes care. It is likely, however, that we have in-
cluded healthcare professionals who are most receptive
to the topic. According to Malterud, this may not be a
disadvantage, since, with respect to external validity, the
number of relevant episodes presented in the focus
groups is more important than the number of groups or
participants [39].
Conclusion
We found that the aim of protecting the residents’ safety
and well-being may be compromised by systematic inad-
equacies in procedures and training. The participants in
our study focused more on the residents’ quality of life
than on glycaemic goals and individualised management
as best they could. In nursing homes, it may not always
be possible or reasonable to let the residents manage
their own treatment, but it is still important to evaluate
whether they are able to, and wish to, manage their own
disease.
As a follow-up of this study, it would be interesting to
use quantitative methods to explore what guidelines,
procedures and training opportunities exist for diabetes
care in Norwegian nursing homes, and how they are be-
ing used. Future studies should also investigate the resi-
dents’ perspective on self-care in diabetes management,
and efforts should be made to include the residents’
wishes and needs in their care plans.
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Appendix 4. Consent form, Study I   
I 
 
Forespørsel om deltakelse i forskningsprosjektet 
 
 ”Diabetespasienter i norske sykehjem og deres behandling” 
 
Bakgrunn og hensikt 
Dette er et spørsmål til deg om å delta i en forskningsstudie for å kartlegge behandlingen av diabetes 
hos beboere på norske sykehjem. Vi kjenner per i dag ikke til hvor mange beboere i norske sykehjem 
som har diagnosen diabetes, og hvilken behandling og oppfølging de får. For å kunne tilby 
diabetespasienter i sykehjem best mulig pleie og behandling, er det nødvendig å først kartlegge 
omfanget av diabetes i norske sykehjem og hvilken behandling diabetespasientene får.  
 
Pleiepersonell ved sykehjemmet du bor på har blitt bedt om å spørre alle beboere på langtidsopphold (3 
måneder eller lengre) som har en diabetesdiagnose om å delta i studien. 
 
Forskningsprosjektet utføres av forskere fra Universitetet i Bergen. 
 
Hva innebærer studien? 
For å få tilgang til informasjonen beskrevet ovenfor, trenger vi å hente ut opplysninger fra journalen din 
om eventuelle medisiner du bruker for regulering av ditt blodsukker, om du måler blodsukker og 
eventuelt hvor ofte blodsukkeret ditt er blitt målt de siste 4 uker. Vi ønsker også å hente ut opplysninger 
om ditt langtidsblodsukker (HbA1c-verdi) de siste 12 måneder. Vi kommer ikke til å registrere 
personlige opplysninger, som fødselsnummer, navn eller bosted om deg. Informasjonen vi ønsker å 
hente ut vil dermed ikke kunne spores direkte tilbake til deg. 
 
Pleiepersonellet har også på forhånd blitt spurt om å registrere om du har en demensdiagnose – dette er 
for å vurdere om informasjon om deltagelse i studien også skal gis til dine pårørende. Dette er viktig for 
å ivareta personvernet ditt, slik at du kan få hjelp til å vurdere hva studien innebærer og om det vil være 
av interesse for deg/dine pårørende å la deg delta. 
 
Studien vil også undersøke hvordan blodsukkermåling foregår ved sykehjemmet der du er beboer. 
Dersom blodsukkeret ditt blir målt med jevne mellomrom, kan du komme til å bli spurt om forskeren 
kan observere en av disse målingene. Om du samtykker til dette, vil det for deg innebære et ekstra stikk 
i fingeren, til en kontrollmåling på et annet instrument. 
 
Mulige fordeler og ulemper 
Ved å undersøke hvilken behandling diabetespasienter får i norske sykehjem, vil en få et grunnlag for å 
vurdere hva som er den beste pleien og behandlingen for denne gruppen. Studien vil således være 
fordelaktig for pasienter med diabetes i norske sykehjem. 
 
Studien bruker kun opplysninger om deg som er samlet inn fra før, og du vil ikke måtte gjennomgå nye 
undersøkelser. Det vil ikke bli notert ned navn eller fødselsnummer, men journalen din vil ikke være 
anonym når forskeren ser den. 
 
Dersom du samtykker til at en av dine blodsukkermålinger blir observert, vil dette innebære ett ekstra 
stikk i fingeren, til en kontrollmåling. Samtykke til deltakelse i prosjektet vil ikke innebære ekstra 
målinger av ditt blodsukker, utover dette. 
 
Appendix 4. Consent form, Study I   
II 
 
Hva skjer med informasjonen om deg? 
Informasjonen som registreres om deg fra journalen skal kun brukes slik som beskrevet i hensikten med 
studien. Alle opplysningene vil bli behandlet uten navn og fødselsnummer eller andre direkte 
gjenkjennende opplysninger. En kode knytter deg til dine opplysninger gjennom en navneliste.  
 
Det er kun autorisert personell knyttet til prosjektet som har adgang til navnelisten og som kan finne 
tilbake til deg. Opplysningene vil bli slettet når prosjektet er ferdig (senest desember 2014). 
 
Det vil ikke være mulig å identifisere deg i resultatene av studien når disse publiseres.  
 
Hvis en av dine blodsukkermålinger blir observert, vil ingen av opplysningene som samles inn kunne 
spores tilbake til deg som pasient.  
 
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke 
til å delta i studien. Dette vil ikke få konsekvenser for din videre behandling. Dersom du ønsker å delta, 
undertegner du samtykkeerklæringen på siste side. Om du nå sier ja til å delta, kan du senere trekke 
tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom du senere ønsker å trekke deg 
eller har spørsmål til studien, kan du kontakte  
 
Lillan Mo Andreassen (prosjektleder) 
Telefon: 55 58 61 62 
Mobil: 993 86 849 
 
Ytterligere informasjon om studien finnes i kapittel A – utdypende forklaring av hva studien 
innebærer. 
 
Ytterligere informasjon om biobank, personvern og forsikring finnes i kapittel B – Personvern, 
biobank, økonomi og forsikring.  
 
Samtykkeerklæring følger etter kapittel B.
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Kapittel A- utdypende forklaring av hva studien innebærer 
 
Antall mennesker med diabetes er stadig økende, særlig i den eldre delen av befolkningen, noe som 
gjør at en antar at stadig flere pasienter i sykehjem vil være diagnostisert med denne sykdommen. 
Det er ikke tidligere gjort forskning på beboere med diabetes i sykehjem, og vi vet derfor ikke hvor 
mange sykehjemsbeboere som har denne diagnosen, eller hvilken oppfølging de får for sykdommen. 
For å kunne tilby deg som diabetespasient i sykehjem best mulig pleie og behandling, er det nødvendig 
å først kartlegge omfanget av diabetes i norske sykehjem og hvordan diabeteskontrollen, herunder 
legemiddelbehandling og blodsukkermåling, fungerer.  
 
Kriteriene for deltakelse i studien er at du er en sykehjemsbeboer på langtidsopphold (3 måneder eller 
lengre), som har diagnosen diabetes. Det blir lettere å planlegge tiltak for å forbedre behandlingen av 
pasienter med diabetes på sykehjem hvis vi vet hvor mange dette gjelder og hvilken behandling de får 
i dag. Studien er del av et doktorgradsprosjekt ved Universitetet i Bergen som løper ut 2014. 
Registrering av opplysninger til denne studien vil skje fra høsten 2011 og fremover. Analyser og 
publisering av resultater vil skje fortløpende etter dette. Alle opplysninger som samles inn til denne 
studien vil kun være tilgjengelig for forskergruppen og personidentifiserbare opplysninger slettes når 
prosjektet er ferdig – senest i desember 2014.  
 
Skulle det fremkomme ny informasjon under studieforløpet som kan tenkes å påvirke din villighet til å 
delta i studien, vil du eller din verge bli orientert om dette så raskt som mulig. Du kan, som tidligere 
nevnt, når som helst velge å trekke tilbake ditt samtykke. Allerede registrerte opplysninger om deg vil 
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Kapittel B - Personvern og finansiering  
 
Personvern 
Opplysninger som registreres om deg er: 
• Fødselsår. 
• Kjønn. 
• Type diabetes (type 1, type 2, annen). 
• Hvilke legemidler du eventuelt bruker for regulering av ditt blodsukker. 
• Hvor ofte blodsukkeret ditt er målt innenfor de siste 4 ukene. 
• Hvor ofte langtidsblodsukkeret (HbA1c-verdi) ditt er målt innenfor de siste 12 måneder og 
eventuelle registrerte verdier av denne. 
• Om du har en demensdiagnose og i så fall hvilken grad (mild, moderat, alvorlig). 
 
Hvis en av dine blodsukkermålinger blir observert, vil ingen av opplysningene som samles inn kunne 
spores tilbake til deg som pasient. Kontrollprøven vil analyseres umiddelbart etterpå og vil deretter 
destrueres. 
 
Universitetet i Bergen ved administrerende direktør er databehandlingsansvarlig. 
 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver  
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er registrert om 
deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har registrert. Dersom du 
trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og opplysninger, med mindre 
opplysningene allerede er inngått i analyser eller brukt i vitenskapelige publikasjoner.  
 
Økonomi  




Appendix 4. Consent form, Study I 
V 
 
Samtykke til deltakelse i studien 
 
 




(Signert av prosjektdeltaker, dato) 
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CODEBOOK PAPER II 05.10.2015 
Additional material to codebook: 
Attachment 1: Generic names of medicines prescribed in our population. Each generic 
medicine has an assigned number. 
Attachment 2: Anticholinergic medicines UK. All medicines with anticholinergic properties 
that are licensed in the UK. Classified into high-potency anticholinergics and low-potency 
anticholinergics. 
Attachment 3: List of anticholinergic medicines prescribed in our population. All medicines 
with anticholinergic properties prescribed in our population. 
Attachment 4: Classified conditions, numbers and ICD. Excel spreadsheet with overview of 
all classified conditions, their assigned numbers and ICD codes. 
Deprescribing criteria based on Ipswich MI document.docx 
 
The following SPSS-files are used for analysis of this codebook: 
Datasets: 
Dataset aiding deprescribing analysis T2DM 2015-10-05.sav 
Dataset aiding deprescribing analysis T2DM POST ANALYSIS 2015-10-05.sav 
Deprescribing T2DM 2015-10-05.sav 
Syntax: 
Syntax recode medicine variables 2015-10-05.sps 
Syntax analysis category 1 2015-10-05.sps 
Syntax analysis category 2 2015-10-05.sps 
Syntax analysis category 3 2015-10-05.sps 
Syntax analysis category 4 2015-10-05.sps 
Syntax deprescribing analysis 2015-10-07.sps 
 
  




Category 1: Inappropriate choice of drug 
101: Antispasmodics: Avoid long-term use, highly anticholinergic preparations, 
uncertain effectiveness. 
Check antispasmodics use, Yes = 1, No = 0.  
Make variable (Antispasmodics) in SPSS by counting the numbers 6, 93, 124 and 149 in 
‘Medicine_1new … Medicine_20new’ in SPSS. The following drugs are listed as 
antispasmodics in BNF: 
Alverine citrate (6) 
Atropine sulphate (not prescribed) 
Dicycloverine hydrochloride (not 
prescribed) 
Hyoscine butylbromide (93) 
Mebeverine hydrochloride (124) 
Peppermint oil (149) 
Propantheline bromide (not prescribed) 
 
102: H2 blockers / PPI: Check if there is a valid indication for prescribing e.g. NSAID 
still being taken, diagnosis of peptic ulcer, GI bleeding or dyspepsia. Continued use may 
contribute to C. difficile infection.  
Check for valid indication for use of H2 blockers / PPI; No valid indication = 1, Valid 
indication = 0.  
Make variable for H2 blockers / PPI (A02BA + A02BC) in SPSS. For residents receiving 
these, check for evidence of prescribed NSAID by making variable (M01 + N02BA01) in 
SPSS OR diagnoses that can justify use by counting the numbers 20, 70, 73, 88, 98 and 134 in 
‘Condition1-16’ in SPSS. The following diagnoses have by the researchers been identified as 
valid indications: 
Barrett’s oesophagus (20) 
Gastric haemorrhage (70) 
Gastro-oesophagal reflux (73) 
Hiatus hernia (88) 
Indigestion (dyspepsia) (98) 
Oesophagitis (134) 
 
103: Laxatives: Check if there is a valid indication for prescribing e.g. opioid analgesics 
still being taken, diagnosis of constipation. Also check if >1 laxative is being used. 
103a: Check if there is more than one laxative being prescribed; Yes = 1, No = 0.  
Make variable for laxatives (A06A) in SPSS. Run frequency analysis.  




103b: Check for valid indication for use of laxatives; No valid indication = 1, Valid 
indication = 0.  
For residents receiving laxatives, visually check for evidence of prescribed opioid analgesic 
(N02A) OR the diagnosis of constipation or other diagnosis that could justify use in medical 
records. Disorders affecting colon, like diverticular disease, cancer, hernia of colon etc. have 
by the researchers been identified as valid indications. 
104: Antiarrhytmics: Amiodarone is associated with multiple toxicities (thyroid, 
pulmonary, QT prolongation), should not be prescribed. 
Check for use of amiodarone; Yes = 1, No = 0. 
Make variable (Amiodarone) in SPSS by counting the number 8 in ‘Medicine_1new … 
Medicine_20new’ in SPSS.  
105: Antihypertensives - ACE inhibitors, beta blockers, A2RB, diuretics, calcium 
channel blockers: Check if >1 antihypertensive is being used. 
Check if there is more than one antihypertensive agent being prescribed; Yes = 1, No = 0.  
Make variable for antihypertensives (C03: diuretics, C07: beta blockers, C08: calcium 
channel blockers, C09: ACEI + A2RB) in SPSS. Run frequency analysis.  
106: Nitrates: Check if there is a valid indication for prescribing e.g. chest pain/angina.  
Check for valid indication for use of nitrates; No valid indication = 1, Valid indication = 0. 
Make variable for nitrates (C01DA) in SPSS. For residents receiving these, check for 
diagnosis of angina or other diagnoses that can justify use in medical records. The following 
diagnoses have by the researchers been identified as valid indications: 
Angina pectoris 
Heart failure 
Ischaemic heart disease (IHD) 
Myocardial infarction 
 
107: Statins / lipid lowering drugs: Re-evaluate the patients risk profile for primary and 
secondary prevention of cardiovascular disease – is there a valid indication for 
prescribing? Not sufficient data to recommend in the population aged 80+, with or 
without CVD (Petersen et al 2010). 
Check for valid indication for use of statins; No valid indication = 1, Valid indication = 0. 
Make variable (80+ yes/no) in SPSS. Using this as an ‘if’-condition (=1), check how many 
receive prescription for lipid lowering drugs (C10), using already available variable for this. 
108: Aspirin: Check if there is a valid indication for prescribing e.g. re-evaluate the 
patients risk profile for primary prevention. Do the known possible adverse drug 




reactions (risk of bleeding) outweigh the possible benefits (cardiovascular endpoints)? 
Recent studies on patients with high baseline risk, such as those with T2DM, have not 
found the expected benefits of aspirin on cardiovascular endpoint, and elderly patients 
are also more vulnerable to major haemorrhage.  
Check for valid indication for use of aspirin; No valid indication = 1, Valid indication = 0. 
Check which residents are prescribed aspirin by making variable (B01AC06) in SPSS. Then 
visually check each of these resident’s diagnoses to see if use can be justified (sign of 
secondary prevention). The following diagnoses have by the researchers been identified as 
valid indications for secondary prevention: 
Angina pectoris 
Atrial fibrillation and flutter 




Ischaemic heart diseases (IHD) 
Myocardial infarction 
Stroke 
Transient cerebral ischaemic attack 
 
109: Dipyridamole: Clopidogrel is now preferred over dipyridamole as more clinically 
and cost effective. 
Check for use of dipyridamole; Yes = 1, No = 0. 
Make variable (Dipyridamole) by counting the number 61 in ‘Medicine_1new … 
Medicine_20new’ in SPSS.  
110: Digoxin: Check if there is a valid indication for prescribing, e.g. heart failure or 
arrhythmias. 
Check for valid indication for use of digoxin; No valid indication = 1, Valid indication = 0. 
Make variable for digoxin (C01AA05) in SPSS. For residents receiving this, check for 
diagnosis of heart failure or atrial fibrillation/flutter or other diagnoses that can justify use in 











111: Theophylline: monotherapy in COPD is not appropriate – safer, more effective 
alternatives available. 
Check for theophylline as monotherapy in COPD; Yes = 1, No = 0. 
Make variable for COPD, counting the number 45 in ‘Classified condition 1-16’ in SPSS. For 
residents with this diagnosis, visually check for evidence of theophylline as monotherapy in 
medical records. 
112: Oral corticosteroids: Prednisolone maintenance in COPD is not usually 
recommended. Gradual withdrawal should be considered for those who have received 
more than 3 weeks treatment, those who have received more than 40 mg prednisolone 
daily (or equivalent) or have other possible causes of adrenal suppression. 
Check for prednisolone as long term therapy (>3 weeks) in COPD; Yes = 1, No = 0. 
For residents with COPD diagnosis (use SPSS-variable from 111), visually check for 
evidence of long term use (>3 weeks) of prednisolone (or daily prednisolone doses >40 mg 
daily) in medical records. 
113: Antihistamines (first generation): Highly anticholinergic, clearance is reduced with 
advanced age, tolerance develops when used as a hypnotic, greater risk of confusion, dry 
mouth, constipation. 
Check for use of first generation antihistamines; Yes = 1, No = 0. 
Visually check for use of first generation antihistamines in the medical records. The following 











Promethazine hydrochloride/promethazine teoclate 
Trifluoperazine  
 
114: Chloral hydrate: Tolerance occurs within 10 days, risk outweighs benefits as 
overdose is only 3 times the recommended dose; avoid use, avoid prolonged use (and 
abrupt withdrawal thereafter). 
Check for use of chloral hydrate; Yes = 1, No = 0. 




Make variable for chloral hydrate (N05CC01) in SPSS. 
115: Meprobamate: High rate of physical dependence, very sedating, avoid use, avoid 
prolonged use, abrupt withdrawal may precipitate convulsions. EMEA recommended 
the suspensions of marketing authorisations in Jan 2012 as the risks of serious CNS side 
effects outweigh the benefits. 
Check for use of chloral hydrate; Yes = 1, No = 0. 
Make variable for meprobamate (N05BC01) in SPSS. 
116: Barbiturates: Intermediate acting preparations should only be used in severe 
intractable insomnia, avoid use in the elderly. High rate of physical dependence, 
tolerance to sleep benefits, risk of overdose at low doses. 
Check for use of intermediate acting barbiturates; Yes = 1, No = 0. 
Make variable for barbiturates (N05CA) in SPSS. 
117: Benzodiazepines (including ‘Z’ drugs): With long term use, risk of adverse effects 
including falls, exceeds therapeutic benefit of continued use. 
117a: Check for benzodiazepines as long term therapy (>3 months); Yes = 1, No = 0. 
Make variable for benzodiazepines (N05CD) in SPSS. For residents using these, visually 
check for evidence of long term use in medical records. 
117b: Check for benzodiazepines as long term therapy (>3 months); Yes = 1, No = 0. 
Make variable for ‘Z’ drugs (N05CF) in SPSS. For residents using these, check for evidence 
of long term use in medical records. 
118: Levodopa – carbidopa: Check if there is a valid indication for prescribing, i.e. 
Parkinson’s disease. 
Check for valid indication for use of digoxin; No valid indication = 1, Valid indication = 0. 
Make variable for levodopa/carbidopa (N04BA) in SPSS. For residents receiving these, check 
for diagnosis of Parkinson’s disease in medical records by counting the number 141 in 
‘Condition1-16’ in SPSS. 
119: Antipsychotics: Check if there is a valid indication for prescribing. Do the known 
possible adverse drug reactions outweigh the possible benefits? In dementia patients 
with behavioural and psychological symptoms, review and discontinue, particularly if 
there has been no response and symptoms are mild, unless there is extreme risk or 
distress for the patient. Standardized symptom evaluations and drug cessation attempts 
should be undertaken at regular intervals.  
Check for antipsychotics by making variable (N05A) in SPSS. For residents using these, 
check for evidence of schizophrenia or other diagnoses that can justify use (e.g. delirium, 




agitation, hallucination, dementia). For other diagnoses than schizophrenia, the prescription 
should be PRN/short term to be justified!  
120: Antidepressants – Selective serotonin reuptake inhibitors (SSRIs), tricyclic 
antidepressants (TCADs), others e.g. MAOIs, agomelatine, duloxetine, reboxetine, 
venlafaxine, mirtazapine: Check if there is a valid indication for prescribing, e.g. 
depression. Dosulepin should not be prescribed. 
120a: Check for valid indication for use of antidepressants; No valid indication = 1, Valid 
indication = 0. 
Make variable for for antidepressants (N06A) in SPSS. For residents using these, check for 
evidence of depression in medical records. 
120b: Check for use of dosulepin; Yes = 1, No = 0. 
Check for dosulepin by visually looking through medical records. 
121: Opioid analgesics: Is a regular opioid still required? The risk of falls/constipation 
can outweigh the benefits. Consider non-drug options, switch to regular paracetamol. 
Review laxatives. 
121a: Check for justified use of regular opioids; No diagnosis justifying use = 1, Diagnosis 
justifying use = 0. 
Check for opioid analgesics by making variable (N02A) in SPSS. For residents using these, 
visually check for regular use in medical records. Where regular use is documented, check if 
use may be justified AND if paracetamol is also prescribed. The following diagnoses have by 
the researchers been identified (in this population) as valid indications of regular opioid use: 
Gout 
Osteoarthritis 
Osteoporosis / Paget’s disease 
Sudek’s atrophy 
 
121b: Check for prescription of laxative in residents prescribed regular opioids, No laxative ) 
1, Laxative = 0. 
For residents using regular opioids, visually check for prescription of laxative in medical 
records.  
122: Metoclopramide: Check if there is a valid indication for prescribing. How long has 
it been prescribed? Can cause extrapyramidal effects including tardive dyskinesia, risk 
greater in frail older adults. 
Check for valid indication for use of metoclopramide; No valid indication = 1, Valid 
indication = 0. 




Make variable for metoclopramide (A03FA01) in SPSS. For residents using this, check for 
evidence of diagnoses that can justify use in medical records. The following diagnoses have 
by the researchers been identified as valid indications: 
Cancer 
GI disorders (not specified) 
Migraine 
 
123: Antibacterials: Check if there is a valid indication for prescribing. Inappropriate 
uses – a bacterial infection has resolved; a viral infection has been diagnosed; 
prophylactic treatment prescribed but no pathogen isolated. Treatment of asymptomatic 
bacteriuria (ASB) in older patients and diabetes patients has no beneficial effects. 
Nitrofurantoin has potential for pulmonary toxicity; avoid long term use. 
123a: Check for valid indication for use of antibacterials; No valid indication = 1, Valid 
indication = 0. 
Check for antibacterials (systemic) by making variable (J01) in SPSS. For residents using 
these, visually check for diagnoses that can justify use, e.g. bacterial infections, or conditions 
putting resident at risk of bacterial infection. 
123b: Check for long term use (>3 weeks) of nitrofurantoin; Over 3 weeks = 1, Under 3 
weeks = 0. 
Make variable for nitrofurantoin by counting the number 138 in ‘Medicine_1new … 
Medicine_20new’ in SPSS. For residents using these, check for evidence of long term use in 
medical records. 
124: Antifungals: When a course of treatment of appropriate length has been finished, 
do not continue indefinitely e.g. oral and topical nystatin. 
Check for long term use (>3 weeks) of antifungals with no valid indication; No valid 
indication = 1, Valid indication = 0. 
Make variable for antifungals (oral + topical) by counting the numbers 52, 90, 91, 106, 130 
and 139 in ‘Medicine_1new … Medicine_20new’ in SPSS. For residents using these, visually 
check for evidence of long term use (>3 weeks) and no valid indication in medical records. 


























125: Bisphosphonates: Check if there is a valid indication for prescribing.  
Check for valid indication for use of bisphosphonates; No valid indication = 1, Valid 
indication = 0. 
Make variable for bisphosphonates (M05BA) in SPSS. For residents using these, visually 
check for diagnoses that can justify use in medical records. The following diagnoses have by 
the researchers been identified as valid indications: 
Osteoporosis 
Paget’s disease of bone 
 
126: Alpha blockers: Check if there is a valid indication for prescribing.  
Check for valid indication for use of alpha blockers; No valid indication = 1, Valid indication 
= 0. 
Make variable for alpha blockers (G04CA + C02CA) in SPSS. For residents using these, 
visually check for diagnoses that can justify use in medical records. The following diagnoses 
have by the researchers been identified as valid indications: 
Hyperplasia of prostate 
Overactive bladder 
 
127: Antimuscarinics (for bladder/urinary tract symptoms): Check if there is a valid 
indication for prescribing.  
Check for valid indication for use of antimuscarinics for bladder/urinary tract symptoms; No 
valid indication = 1, Valid indication = 0. 
Make variable for antimuscarinics (G04BD) in SPSS (no one in our population uses 
propantheline). For residents using these, visually check for a diagnosis that can justify use in 









128: NSAIDs: Check if there is a valid indication for prescribing. Is an NSAID still 
needed/appropriate e.g. long term treatment of gout but no prophylaxis prescribed? If 
topical NSAIDs are continued indefinitely, review the need for use; short courses are 
generally advised. 
128a: Check for valid indication for use of oral NSAIDs; No valid indication = 1, Valid 
indication = 0. 
Check for NSAIDs (oral only) by using variable from 102 (M01A + N02BA) in SPSS. For 
residents receiving these, visually check for a diagnosis that can justify use in their medical 
records. NB! If used for long-term treatment, GI prophylaxis should also be prescribed! The 
following diagnoses have by the researchers been identified as valid indications: 
Gout 
Musculoskeletal diseases (not specified) 
 
128b: Check for topical NSAIDs as long term therapy (>3 months); Yes = 1, No = 0. 
Make variable for NSAIDs (topical only) (M02AA) in SPSS. For residents receiving these, 
visually check for long term use (>3 months) in their medical records (preparations prescribed 
prn are considered short term use). 
129: Skeletal muscle relaxants: Often poorly tolerated because of anticholinergic 
adverse effects, sedation, risk of fracture, avoid use. 
Check use of skeletal muscle relaxants; Yes = 1, No = 0. (even if valid indication!) 
Make variable (SMR) in SPSS by counting the numbers 19 and 164 in ‘Medicine_1new … 
Medicine_20new’ in SPSS. The following drugs are listed as skeletal muscle relaxants in 
BNF: 
Baclofen (19) 
Carisoprodol (not prescribed) 
Dantrolene (not prescribed) 
Diazepam (not prescribed) 
Methacarbamol (not prescribed) 
Quinine (164) 
Tizanidine (not prescribed) 
 




130: Sodium, potassium & iron supplements: Check if there is a valid indication for 
prescribing. 
Check for valid indication for use of sodium, potassium & iron supplements; No valid 
indication = 1, Valid indication = 0. 
Make variable (Na_K_Fe) by counting the numbers 71, 72, 73 and 157 in ‘Medicine_1new … 
Medicine_20new’ in SPSS. For residents receiving these, visually check for valid indication 
in their medical records. The following diagnoses have by the researchers been identified as 
valid indications. The following diagnoses have by the researchers been identified as valid 
indications: 
Anaemia 
Vitamin B12 deficiency 
 
131: Vitamins: Check if there is a valid indication for prescribing, e.g. does the patient 
have a disorder which requires vitamin & mineral supplements. 
Check for valid indication for use of vitamins; No valid indication = 1, Valid indication = 0. 
Make variable (Vitamins) by counting the numbers 15, 79, 92, 134 and 191 in 
‘Medicine_1new … Medicine_20new’ in SPSS. For residents receiving these, visually check 
for valid indication in their medical records, e.g. ‘vitamin/mineral deficiency’ or use of 
methotrexate if receiving folic acid. 
132: Eye drops/ointments: Have antibiotic preparations been continued without a 
review or stop date? 
Check for long term use of antibiotic preparations without valid indication; No valid 
indication = 1, Valid indication = 0. 
Visually check for antibiotic preparations for eye. If found, check for evidence of valid 
diagnosis, e.g. bacterial infections.  
133: Ear, nose and oropharynx: Drops, sprays, solutions etc.: Have antibiotic / steroid / 
sympathomimetic preparations been continued without a review or stop date? 
Check for long term use of antibiotic / steroid / sympathomimetic preparations without valid 
indication; No valid indication = 1, Valid indication = 0. 
Visually check for antibiotic / steroid / sympathomimetic preparations for ear, nose and 
oropharynx. If found, check for evidence of valid diagnosis, e.g. bacterial infections etc.  
134: Skin: Creams, ointments: Has the condition resolved and continued use may cause 
adverse effects or exacerbate the condition e.g. preparations containing antibacterials or 
corticosteroids? 




Check for antibiotic / steroid  preparations without valid indication; No valid indication = 1, 
Valid indication = 0. 
Visually check for antibiotic / steroid preparations for skin. If found, check for evidence of 
valid diagnosis, e.g. bacterial infections, skin disorders.  
  




Category 2: Inappropriate dosage of drugs 
201: Spironolactone: If dose >25 mg/day, the risk of hyperkalaemia is higher in older 
adults with heart failure. 
Check for dose of spironolactone >25mg/day in residents with heart failure; Yes = 1, No = 0. 
In SPSS make variable for spironolactone (C03DA01), and check for heart failure by making 
variable for heart failure, counting the number 84 in ‘Classified condition 1-16’ in SPSS. 
Combine these two to check if any residents with heart failure receive spironolactone. For 
residents with this combination, visually check for doses >25mg/day in medical records.  
202: Aspirin: Is a dose of >150 mg/day being used for a cardiovascular indication? 
Check for dose of aspirin >150mg/day; Yes = 1, No = 0. 
Check which residents are prescribed aspirin (B01AC06) in SPSS. Then visually check each 
of these resident’s dose of aspirin in the medical records. 
203: Digoxin: Long-term digoxin at >125 mcg/day in patient with impaired renal 
function can lead to an increased risk of toxicity. 
Check for dose of digoxin >125mcg/day in residents with renal failure; Yes = 1, No = 0. 
Check for digoxin by making variable (C01AA05) in SPSS. For residents receiving this, 








Category 3: Inappropriate drug-drug combinations 
301: Antipsychotics: Are chlorpromazine or trifluoperazine being taken with other 
medicines that have anticholinergic activity and can increase risk of cognitive 
impairment e.g. TCADs, oxybutynin, chlorphenamine? 
Check for combination of antipsychotics (on anticholinergic list) with other anticholinergic 
drugs; Yes = 1, No = 0. 
Make variable (N05A_anticholinergic) by counting the numbers 140, 163 and 167 in 
‘Medicine_1new … Medicine_20new’ in SPSS. Make variable for anticholinergic drugs in 
general according to list (see other document). Combine the two variables, and visually check 














302: Antidepressants: Are TCADs being taken with other medicines that have 
anticholinergic activity and can increase risk of cognitive impairment e.g. 
chlorpromazine, oxybutynin, chlorphenamine? Reduce dose of antidepressants 
gradually to avoid withdrawal effects. 
Check for combination of antidepressants (on anticholinergic list) with other anticholinergic 
drugs; Yes = 1, No = 0. 
Make variable (N06A_anticholinergic) by counting the numbers 10, 46, 65, 78, 131, 148 and 
186 in ‘Medicine_1new … Medicine_20new’ in SPSS. Combine with variable for 
anticholinergic drugs in general according to list (see other document), and visually check for 




















303: Antimuscarinics (for bladder/urinary tract symptoms): Are antimuscarinics being 
taken with other medicines that have anticholinergic activity and can increase risk of 
cognitive impairment e.g. chlorpromazine, TCADs, chlorphenamine? 
Check for combination of antimuscarinics for bladder/urinary tract symptoms (on 
anticholinergic list) with other anticholinergic drugs; Yes = 1, No = 0. 
Make variable (G04BD_anticholinergic) by counting the numbers 144 and 184 in 
‘Medicine_1new … Medicine_20new’ in SPSS. Combine with variable for anticholinergic 
drugs in general according to list (see other document), and visually check for duplicates in 












 Category 4: Inappropriate drug-disease combinations  
401: Antidepressants: Do the known possible adverse drug reactions outweigh the 
possible benefits? E.g. TCADs can worsen dementia, glaucoma, constipation, urinary 
retention; SSRIs may induce clinically significant hyponatremia.  
Check for use of TCADs in residents with diagnoses of dementia, glaucoma, constipation or 
urinary retention; Yes = 1, No = 0. 
Make variable for TCADs (N06AA) in SPSS. Also check for drugs related to TCADs 
(mianserin, trazodone) (N06AX03 + N06AX05). For residents using these, visually check for 
evidence of diagnoses that could worsen from use. The following diagnoses have by the 




Urinary retention (or related diagnoses, e.g. BPH) 
 
402: Antimuscarinics (for bladder/urinary tract symptoms): Do the known possible 
adverse drug reactions outweigh the possible benefits? E.g. postural hypotension, 
urinary retention, constipation. Oxybutynin will decrease MMSE score in patients with 
dementia. 
402a: Check for use of antimuscarinics for bladder/urinary tract symptoms in residents with 
diagnoses of hypotension, urinary retention or constipation; Yes = 1, No = 0. 
Visually check if any resident receiving antimuscarinics for bladder/urinary tract symptoms 
have diagnoses that could worsen from use. The following diagnoses have by the researchers 
been visually searched for: 
Constipation 
Hypotension 
Urinary retention (or related diagnoses, e.g. BPH) 
 
402b: Check for use of oxybutynin in residents with dementia; Yes = 1, No = 0. 
Visually check if any resident receiving oxybutynin have a diagnosis of dementia in their 
medical records. 
403: NSAIDs: Do the known possible adverse drug reactions outweigh the possible 
benefits e.g. use in patients with severe hypertension/heart failure/chronic renal failure. 
Check for use of oral NSAIDs in residents with heart failure or chronic renal failure; Yes = 1, 
No = 0. 




Check which residents use oral NSAIDs (M01A + N02BA) in SPSS. For residents receiving 
these, visually check for a diagnosis that may contra-indicate use in their medical records, e.g. 
heart failure or chronic renal failure. 
 
  




OSAMU criteria not applied 
Antihypertensives - ACE inhibitors, beta blockers, A2RB, diuretics, calcium channel 
blockers: Check if there is a valid indication for prescribing, is the BP at a normal level 
or too low? Do the known possible adverse drug reactions outweigh the possible benefits 
e.g. orthostatic hypotension, CNS effects, risk of falls, loop diuretic for ancle oedema – 
would compression hosiery be more appropriate? 
Limited access to clinical data, need to make too many assumptions to evaluate. 
Statins: Stop in metastatic disease. 
Do not have access to data that can tell whether resident has metastatic disease. 
Anticoagulants – oral and injected: Are LMWHs/oral anticoagulants prescribed 
following hip/knee replacement surgery still required? Stop warfarin if the risk of falls 
outweighs the benefits. Long term warfarin use (>6 months) is not recommended when 
the VTE was provoked by surgery, non-surgical trigger factors or the VTE occurred in 
the calf only. 
Limited access to clinical data, unable to evaluate. 
Peripheral vasodilators: Check if there is a valid indication for prescribing. Clinical 
effectiveness often not established. Do the known possible adverse drug reactions 
outweigh the possible benefits? 
Peripheral vasodilators are not prescribed in our population. 
Inhaled corticosteroids: In asthma – review every 3 months, has control been achieved, 
if yes; reduce dose slowly (by 50% every 3 months). In COPD – if an inhaled 
corticosteroid is not appropriate, a long acting abtimuscarinic bronchodilator can be 
used with a long acting beta2 agonist. 
No access to clinical data that is needed to evaluate this. 
Benzodiazepines (including ‘Z’ drugs): Is use required if physical and psychological 
health and personal circumstances are stable? If the patient is willing, committed and 
compliant, and has adequate social support, refer to a withdrawal clinic. 
No access to the information necessary to evaluate this. 
Drugs for dementia: If MMSE <10, medicines may be continued if they help with 
behavior. NICE recommends memantine if MMSE <10. Review benefit, use should only 
continue if the MMSE score is ≥10 and treatment has an effect on the global, functional 
or behavioural symptoms. 
No access to MMSE scores. 




Antibacterials: Nitrofurantoin, lack of efficacy in patients with CrCl <60 ml/min due to 
inadequate drug concentration in the urine. 
No access to clinical data that is needed to evaluate this. 
Oestrogens ± progestogens: There is no mandatory limitation on the duration of HRT. 
Whether or not to continue therapy is dependent on an objective estimation on ongoing 
benefits and risks. Evidence of carcinogenic potential in breast and endometrium, lack 
of cardioprotective effect and cognitive protection in older women. Topical low dose 
oestrogen intravaginal cream safe and effective for dyspareunia and other vaginal 
symptoms. 
Not complete access to all information needed to make this evaluation. 
Bisphosphonates: Has treatment been taken for 5 years or more? Do the known possible 
adverse drug reactions outweigh the possible benefits? If the patient is at low risk of 
falls, are these still needed? Prolonged immobility is a risk factor for BMD. 
Do not have access to information necessary to evaluate this. 
Alpha blockers: Use is generally not indicated if a patient has a long term (>2 months) 
catheter in situ. 
Do not have access to information necessary to evaluate this. 
Antimuscarinics (for bladder/urinary tract symptoms): Check if continence pads are 
also used, is concomitant use necessary? 
Do not have access to information necessary to evaluate this. 
Cytotoxics, immunosuppressants: What outcome is expected, do the known possible 
adverse drug reactions outweigh the possible benefits? Refer to doctor who initiated 
treatment. 
Do not have access to information necessary to evaluate this. 
Calcium + vitamin D: Does the patient have adequate levels through diet/sunlight 
exposure? If the patient is not mobile, is this still needed? 
Do not have access to information necessary to evaluate this. 
Sip feeds: Check if there is a valid indication for prescribing. Has a dietician recently 
reviewed the patient; is the patient able to prepare, or have someone else prepare 
fortified food and therefore does not need sip feeds. 
Do not have access to information necessary to evaluate this. 
DMARDs: Discontinue penicillamine if there is no improvement within 1 year. Consider 
withdrawal of azathioprine and ciclosporin if there is no improvement within 3 months 
of use. Refer to doctor who initiated treatment. 




Do not have access to information necessary to evaluate this. 
TNF inhibitors: Psoriatic arthritis/Ankylosing spondylitis – discontinue adalimumab, 
etanercept and infliximab if there is inadequate response after 12 weeks. Rheumatoid 
arthritis/Juvenile idiopathic arthritis – withdraw adalimumab, etanercept and 
infliximab if response is not adequate within 6 months. 
Do not have access to information necessary to evaluate this. 
Eye drops/ointments: Review need for preservative free eye drops – is there a valid 
indication for prescribing (e.g. previous preservative toxicity), are eye drops instilled 
more than 4 times per day? 
Do not have access to information necessary to evaluate this. 
Creams, ointments: Is the patient using sufficient emollient to avoid use of steroids or 
development of ulcers? 
Do not have access to information necessary to evaluate this. 
Dressings: Wounds should be reviewed before prescribing to ensure correct dressing 
chosen. Chronic wounds change over time – refer difficult to treat wounds to a tissue 
viability nurse. Wounds should reduce in size over time. Address underlying problems 
e.g. soiling from incontinence, wrong choice of dressing etc. Larger dressings are more 
expensive than the smaller sizes. Query large size dressings on repeat prescriptions. 
Query quantities over 10 units per month, most dressings can stay in place for 3-5 days 
except on infected wounds, although some patients may have multiple wound sites. 
Avoid waste – prescribe the actual number of dressings needed rather than “1OP”. 
Not relevant. 
  




Attachment 1. Generic names of medicines prescribed in our population 
1 Alendronic acid 




6 Alverine citrate 






13 Amoxicillin + clavulanic acid 
14 Anastrozole 





20 Barrier preparation 
21 Beclomethasone dipropionate 
22 Beclomethasone + formoterol 
23 Bendroflumethiazide 
24 Benzerazide hydrochloride + levodopa 
25 Betamethasone dipropionate 
26 Betamethasone valerate 








35 Calcipotriol + betamethasone 
36 Candesartan 
37 Carbidopa + levodopa 
38 Carbimazole 
39 Carbomer 980 (eye lubricant) 




44 Cinchocaine hydrochloride + fluocortolone 




45 Cinchocaine hydrochloride + prednisolone 
46 Citalopram 
47 Clobetasol propionate 
48 Clobetasone butyrate 
49 Clonazepam 
50 Clopidogrel 
51 Cloral betaine 
52 Clotrimazole 
53 Coal tar 





59 Dihydrocodeine tartrate 
60 Diltiazem 
61 Dipyridamole 
62 Disodium etidronate 
63 Domperidone 
64 Donepezil 
65 Dosulepin hydrochloride 
66 Doxazosin 
67 Emollient 
68 Enalapril maleate 
69 Felbinac 
70 Fentanyl 
71 Ferrous fumarate 
72 Ferrous gluconate 




77 Fluticasone propionate 
78 Fluoxetine 









88 Glyceryl trinitrate 
89 Hydrocortisone topical 
90 Hydrocortisone + clotrimazole topical 




91 Hydrocortisone + miconazole topical 
92 Hydroxocobalamin (vit B12) 
93 Hyoscine 
94 Hypromellose (eye lubricant) 
95 Ibuprofen 
96 Indoramin 
97 Insulin (human) 
98 Insulin aspart 
99 Insulin detemir 
100 Insulin glargine 
101 Insulin lispro 
102 Ipratropiumbromid 
103 Isosorbide dinitrate 
104 Isosorbide mononitrate 
105 Isphagula husk 










116 Liquid paraffin 






123 Magnesium salt + liquid paraffin 





129 Metoprolol tartrate 
130 Miconazole 
131 Mirtazapine 



























155 Piroxicam topical 
156 Polyvinyl alcohol (eye lubricant) 














171 Silver sulfadiazine 
172 Simvastatin 
173 Sodium chloride topical 
174 Sodium citrate rectal 


















189 Warfarin sodium 
190 Zuclopenthixol 










Attachment 2. Anticholinergic medicines UK.  
High-potency anticholinergics 
Generic name ATC code 
Amitriptyline N06AA09 
Atropine A03BA01 































Both lists based on Duran CE et al (2013). "Systematic review of anticholinergic risk scales in 
older adults." Eur J Clin Pharmacol 69(7): 1485-1496. 
  























































Attachment 3. List of anticholinergic medicines prescribed in our 
population 
No Generic name Potency 
10 Amitriptyline H 
19 Baclofen L 
43 Cetirizine L 
46 Citalopram L 
49 Clonazepam L 
54 Codeine + paracetamol L 
55 Codeine L 
63 Domperidone L 
65 Dosulepin hydrochloride L 
70 Fentanyl L 
74 Fexofenadine L 
78 Fluoxetine L 
93 Hyoscine H 
102 Ipratropiumbromid H 
119 Loperamide L 
120 Loratadine L 
131 Mirtazapine L 
133 Morphine L 
140 Olanzapine L 
144 Oxybutynin H 
145 Oxycodone L 
148 Paroxetine L 
160 Procyclidine H 
163 Quetiapine L 
166 Ranitidine L 
167 Risperidone L 
180 Temazepam L 
181 Theophylline L 
184 Tolterodine H 
185 Tramadol hydrochloride L 
186 Trazodone L 
 
  




Attachment 4. Classified conditions, numbers and ICD. 
No Name ICD 1 ICD 2 ICD 3 
1 Cancer (neoplasms - other)       
2 Abnormal weight loss R00-R99     
3 Acute bronchitis       
4 Aggressive personality       
5 Alcohol misuse       
6 Allergic rhinitis       
7 Alzheimer's disease G00-G99 G30-G32 G30 
8 Anaemia D50-D89     
9 Angina I00-I99 I20-I25 I20 
10 Anxiety F00-F99 F40-F48   
11 Anxiety with depression F00-F99 F40-F48   
12 Aortic aneurysm I00-I99 I70-I79 I71 
13 Aortic valve disorder I00-I99 I30-I52   
14 Apnoea G00-G99 G40-G47   





M00-M25   
17 Asthma J00-J99 J40-J47 J45 
18 Atrial fibrillation and flutter I00-I99 I30-I52 I48 
19 




20 Barrett's oesophagus K00-K93 K20-K31 K22 
21 Behavioural management       
22 Bone pain       
23 Bronchiectasis       
24 Bronchitis (recurrent)       
25 Cancer (neoplasms - benign)       
26 Cancer (neoplasms - in situ)       
27 Cancer (neoplasms - malignant) C00-D48 C00-C97   
28 Cancer (neoplasms - unknown behaviour) C00-D48 D37-D48   
29 Candidal intertrigo A00-B99 B35-B49   
30 Candidal vulvovaginitis A00-B99 B35-B49   
31 Cardiac enlargement I00-I99 I30-I52 I51 
32 Cardiac pacemaker Z00-Z99 Z80-Z99 Z95 
33 Carpal tunnel syndrome       
34 Cellulitis L00-L99 L00-L08 L03 
35 Cerebral atrophy       
36 Cerebrovascular disease I00-I99 I60-I69   
37 Cervical myelopathy & cord compression       
38 Chest infection       
39 Cholesterol E00-E90 E70-E90 E78 
40 Chondrocalcinosis       




41 Cirrhosis of liver K00-K93 K70-K77   
42 Coeliac disease K99-K93 K90-K93   
43 Congenital malformations       
44 Constipation K00-K93 K59 K59.0 
45 COPD J00-J99 J40-J47 J44 
46 Coronary artery disease       
47 Cryptogenic fibrosing alveolities       
48 Cystitis       
49 Degeneration of lumbar spine       
50 Dementia F00-F99 F00-F09   
51 Depression F00-F99 F30-F39   
52 Depression (recurrent)       
53 Dermatitis L00-L99 L20-L30   
54 Diabetes Mellitus (Type 1) E00-E99 E10-E-14 E10 
55 Diabetes Mellitus (Type 2) E00-E90 E10-E14 E11 
56 Diplegia/Hemiplegia       
57 Diverticular disease K00-K93 K55-K63 K57 
58 Duodenal ulcer       
59 DVT I00-I99 I80-I89   
60 Ear problems H60-H95     
61 Eczema L00-L99 L20-L30 L20 
62 
Electrolyte disorders (eg sodium, potassium) E00-E90 E70-E90 E87 
63 Emphysema J00-J99 J40-J47 J43 
64 Endocrine disorders (other) E00-E90 E20-E35   
65 Epilepsy G00-G99 G40-G47 G40 
66 Excessive salivation       
67 Factor VIII inhibtor activity       
68 Fractures S00-T98     
69 Gall bladder, biliary tract and pancreas K00-K93 K80-K87   
70 Gastric haemorrhage K00-K93 K90-K93   
71 Gastric ulcer       
72 Gastritis and duodenitis       
73 Gastro-oesophageal reflux K00-K93 K20-K31 K21 
74 
Giant cell arteritis 
M00-
M99 






76 Haematemesis       
77 Haematoma       
78 Haematuria (recurrent & persistent) N00-N99 N00-N08   
79 Haemopericardium       
80 Haemorrhoids I00-I99 I80-I89 I84 
81 Hay fever J00-J99 J30-J39 J30 
82 Heart block       
83 Heart defect (electrical)       




84 Heart failure I00-I99 I30-I52 I50 
85 Hemiplegia       
86 Hernia K00-K93 K40-K46   
87 Herpes zoster       
88 Hiatus hernia K00-K93 K40-K46   
89 Hydrocele       
90 Hydrocephalus       
91 Hyperplasia of prostate N00-N99 N40-N51 N40 
92 Hypertension I00-I99 I10-I15 I10 
93 Hypertensive heart disease I00-I99 I10-I15 I11 
94 Hyperthyroidism E00-E90 E00-E07   
95 Hypopituitarism       
96 Hypotension I00-I99 I95-I99 I95 
97 Hypothyroidism E00-E90 E00-E07   





M00-M25   
100 Injury and poisoning       
101 Insomnia G00-G99 G40-G47 G47 
102 Intentional self harm       
103 Interstitial lung disease       
104 Intestinal obstruction       
105 Intracerebral haemorrhage       
106 Intracranial haemmorrhage       
107 Irritable bladder       
108 Irritable bowel       
109 Ischaemic colitis       
110 Ischaemic heart diseases (IHD) I00-I99 I20-I25   
111 Joint pain       
112 Kyphosis       
113 Lacerations       
114 Learning difficulties F00-F99     
115 Lewy body dementia       
116 Lymphoedema (chronic)       
117 Metabolic disorders E00-E90 E70-E90   
118 Microalbuminuria R00-R99     
119 Migraine G00-G99 G40-G47 G43 
120 Mild cognitive disorder       
121 Mood (affective) disorders F00-F99 F30-F39   
122 MRSA L00-L99     





M60-M63   
125 Myocardial infarction I00-I99 I20-I25 I21 
126 Nail disorders       




127 Nasal polyp J00-J99 J30-J39 J33 
128 Neuralgia       
129 Neutropenia       
130 Non-compliance       
131 Not specified       
132 Nutritional deficiencies E00-E90 E50-E64   
133 Obesity E00-E90 E64-E68   
134 Oesophagitis K00-K93 K20-K31 K20 
135 Oral thrush A00-B99 B35-B49   










M80-M85   
139 Overactive bladder N00-N99 N30-N39   
140 
Paget's disease of bone 
M00-
M99 
M80-M94   
141 Parkinson's disease G00-G99 G20-G26   
142 Patulous oesophagus       
143 Pericardial effusion       
144 Peripheral vascular disease I00-I99 I70-I79 I73 
145 Personality disorder       
146 Phemphigoid       
147 Phimosis       
148 Phlebitis       
149 Pleural effusion       
150 Pleural plaque       
151 Pneumonia       





M30-M36   
154 Psychosis       
155 Pulmonary heart disease I00-I99 I26-I28   
156 Rectal bleeding       
157 Rectal prolapse       
158 Recurrent UTIs N00-N99 N30-N39   
159 Renal failure N00-N99 N17-N19 N18 





M05-M14   
162 Schizophrenia F00-F99     
163 Scoliosis       
164 Seizures G00-G99 G40-G47   
165 Sepsis       
166 Shy drager syndromes       
167 Skin conditions L00-L99     




168 Solar keratosis       
169 Spinal stenonsis       











M80-M94   
174 
Symptoms and signs not elsewhere classified R0-R99     
175 Tachycardia       
176 Transient cerebral ischaemic attack G00-G99 G40-G47 G45 
177 Tricuspid regurgitation       
178 Ulcerative colitis K00-K93 K50-K52   
179 Upper respiratory traction infection       
180 Urinary incontinence R00-R99     
181 Urinary reflux       
182 Urinary tract infection N00-N99 N30-N39   
183 Urosepsis       
184 Uterine prolapse       
185 Vaginal prolapse       
186 Varicose veins I00-I99 I80-I89 I83 
187 Vascular dementia F00-F99 F00-F09 F01 
188 Vasomotor rhinitis       
189 Venous insufficiency I00-I99 I80-I89   
190 Vision impairment/eye conditions H00-H59     










Kva forbinder du med ordet blodsukkermåling? 
 
Korleis føregår blodsukkermåling ved sjukeheimen du arbeidar? 
Kven måler, har de mange pasientar som får målt blodsukker, er det pasientar som 
måler sjølve, kor ofte blir blodsukker målt 
Nøkkelspørsmål 1: Årsak til måling 
Fortel om sist gong du utførte ei blodsukkermåling – kva utløyste målinga? 
 
Kva avgjer om måling skal gjerast (årsaker til måling: legemiddel, HbA1c-verdien, 
økonomi, ernæring, infeksjon, innkomst-målingar, screening)?  
Kven og kva bestemmer hyppigheit av målingar? Når/kor ofte måler de?  
Er det enkelte pasientar med diabetes som får ekstra oppfølging / ein tar ekstra omsyn 
til (i høve til legemiddelbruk (insulin, OAD), hjartesvikt, nyresvikt, KOLS, demens, 
smerte)? Korleis følgjer ein opp desse? 
Finst individuelle planar for kvar enkelt pasient?  
Nøkkelspørsmål 2: Kvalitet, dokumentasjon og kommunikasjon av resultat 
Fortel kva som skjer med resultata av blodsukkermålingane? 
 
Korleis dokumenterast målingane og resultatet og kor god er praksis for dette? 
Korleis og med kven samhandlar/kommuniserer dykk om resultata (tilsette, pasientar, 
legen)? Kor ofte? 
Kva blir konsekvensane av målingane? Kor ofte får målinga konsekvensar for 
pasientane / justering av behandling (også kost/mosjon, ikkje berre legemiddel)? Kva 
verdiar krev ikkje tiltak? 
Kva rutinar eksisterer for når ein skal setje i verk tiltak / når ein skal kontakte lege? 
Settast eigne «grenser» for blodsukkerverdiar for når ein skal gjere dette? 
Korleis vurderer de nytteverdien av målingane?  
Er de trygg på resultata de får? Kvifor/kvifor ikkje? Korleis sikrar dei kvaliteten på 
målingane?  
 




Nøkkelspørsmål 3: Akuttsituasjonar 
Fortel om ein gong du opplevde ein akuttsituasjon med høgt eller lågt blodsukker hjå ein 
pasient med diabetes. 
 
Korleis kjenner de att ein akuttsituasjon? Pasientar som har høg risiko for føling eller 
høgt blodsukker? 
Kva trening har de i å kjenne att hyperglykemi og hypoglykemi? 
Korleis skil de mellom forventa høge verdiar (ein pasient som har blitt dårlegare), og 
uventa høge verdiar?  
Kor ofte opplev de akuttsituasjonar? 
Kva retningslinjer brukast i akuttsituasjonar? Er desse skriftlege og generelle, eller 
pasientspesifikke? 
Kva tiltak finst for akuttsituasjonar, både på kort og lang sikt (særskilt om det er for 
høgt)? Er desse godt kjent? Er desse skriftlege og generelle, eller pasientspesifikke? 
Kven har utarbeida tiltak? 
Kva blir gjort for å finne årsaka til akuttsituasjonen? Kva retningslinjer finst for dette? 
Kva gjer de for å unngå akuttsituasjonar? 
Kva andre problematiske situasjonar kan oppstå i samband med blodsukkermåling (t.d. 
pasientnekt)? 
Nøkkelspørsmål 4: Opplæring 
Fortel om kva opplæring du har fått innanfor diabetes og blodsukkermåling? 
 
Kva opplæring har blitt gitt – om blodsukkermåling, om diabetes, om akuttsituasjonar? 
Når? Kor ofte? Kor mykje? Av kven? 
Kven kan måle blodsukker og kva opplæring krevjast? 
Kva ressursar eksisterer – diabetessjukepleiar, Noklus-kontakt, farmasøyt? Er det 
nokon hos dykk som er spesielt god på dette? Kven kan du spørje om du er usikker eller 
lurer på noko i samband med måling av blodsukker eller diabetes? 
Kva opplæring er ønskja? Kven ønskjer de at skal gi denne?  
Kva forventningar har de til legane? 
Er sjukeheimen med i Noklus? Kva ønskjast frå Noklus? 
Avslutning/Oppsummering 
Alt i alt, føler de at vi har oppsummert dei viktigaste punkta i diskusjonen? Er det noko vi 
ikkje har fått drøfta, andre ting de har tenkt på? 
 
  






Kva forbinder du med ordet blodsukkermåling? 
 
Korleis føregår blodsukkermåling ved sjukeheimen du arbeidar? 
Kven måler, har de mange pasientar som får målt blodsukker, er det pasientar som 
måler sjølve, kor ofte blir blodsukker målt 
Nøkkelspørsmål 1: Årsak til måling 
Fortel om kva vurderingar du gjer i høve til om og når ein pasient med diabetes skal få målt 
blodsukker? 
 
I kva situasjonar og på kva for nokre pasientar måler de blodsukker? Kvifor 
(legemiddel, økonomi, ernæring, infeksjon, innkomst-målingar, screening)?  
Korleis speler HbA1c-verdien inn, og kor viktig opplev dykk blodsukkerverdiane i høve 
til HbA1c? 
Pleiarane spør gjerne om det skal målast før eller etter alle måltid eller insulindosar – 
kva tenkjer de om dette? Er det tvil om når det skal målast? 
Fortel om korleis de går fram når de lagar planar/ordinasjonar for måling av 
blodsukker. Finst individuelle planar for kvar enkelt pasient? 
Korleis og kor ofte følgjer de opp planen/ordinasjonen for blodsukkermålingar? Blir 
denne følgt (hyppigheit av målingar? Når / kor ofte måler dei?) 
Korleis følgjer de opp pasientane med diabetes som er eldre og skrøpelege (har 
tilleggsutfordringar som til dømes demens, hjartesvikt, nyresvikt, KOLS, smerte) i høve 
til behandlingsmål og målehyppigheit? Tenkjer over konsekvensar? 
Kor strenge er de i høve til ernæring med tanke på målehyppigheit? 
I kva grad opplev de at blodsukkermåling er ei belastning? For dykk sjølve, pleiarane 
og pasientane? 
Nøkkelspørsmål 2: Kvalitet, dokumentasjon og kommunikasjon av resultat 
Fortel kva som skjer med resultata av blodsukkermålingane? 
 
Korleis dokumenterer de målingane og resultatet og kor god er praksis hos dykk for 
dette? (Pleiarane seier at dei passar på kvarandre slik at det blir dokumentert «før eller 
seinare» - kva er dykkar erfaring?) 
Kva med pasientar som måler sjølve – kva skjer med desse målingane? 
Korleis og med kven samhandlar/kommuniserer dykk om resultata? Kor ofte?  
Fortel om kva konsekvensar resultata av målingane får hoss dykk? Kor ofte får målinga 









Fortel om kva rutinar som eksisterer hos dykk for når ein skal setje i verk tiltak / når ein 
skal kontakte lege? Settast eigne «grenser» for blodsukkerverdiar for når ein skal gjere 
dette (individuelt eller generelt)? Kva verdiar krev ikkje tiltak? 
Korleis vurderer de nytteverdien av målingane?  
Er de trygg på resultata de får? Kvifor/kvifor ikkje? Korleis sikrar de kvaliteten på 
målingane? 
Nøkkelspørsmål 3: Akuttsituasjonar 
Fortel om ein gong du opplevde eller blei kontakta om ein akuttsituasjon med høgt eller lågt 
blodsukker hjå ein pasient med diabetes. 
 
Kor ofte opplev de (å bli kontakta om) akuttsituasjonar på dykkar sjukeheim? 
Kva opplev de oppstår oftast, hypoglykemi eller hyperglykemi? Korleis vurderer de dei 
ulike situasjonane? 
Kva inntrykk har dykk av kva trening / erfaring pleiarane har i å kjenne att 
hyperglykemi og hypoglykemi? 
Korleis skil de / pleiarane mellom forventa høge verdiar (pasient har blitt dårlegare), 
og uventa høge verdiar? 
Fortel om kva retningslinjer dykkar sjukeheim brukar i akuttsituasjonar? Kven har 
utarbeida desse? Er desse skriftlege og generelle, eller pasientspesifikke? Er dei godt 
kjent? (pleiarane kjenner ikkje til slike). 
Fortel om kva tiltak de gjer ved akuttsitasjonar, både på kort og lang sikt (særskilt om 
de er for høgt)? 
Kva gjer de som legar for å finne årsaka til akuttsituasjonen? Har de retningslinjer for 
dette? 
Kva strategiar har de eller sjukeheimen dykkar for å unngå akuttsituasjonar? 
Fortel om de har opplevd å bli kontakta om andre problematiske situasjonar i samband 
med blodsukkermålingar? 
Nøkkelspørsmål 4: Opplæring 
Fortel om kva opplæring som finst og blir gitt innanfor diabetes og blodsukkermåling, ved 
din sjukeheim? 
 
Kva opplæring har blitt gitt – om blodsukkermåling, om diabetes, om akuttsituasjonar? 
Når? Kor ofte? Kor mykje? Av kven?(Pleiarane fortalte at denne var usystematisk – 
kva er dykkar inntrykk?) 
Kven kan måle blodsukker hos dykk og kva opplæring krevjast? 
Kva ressursar eksisterer hos dykk – diabetessjukepleiar, Noklus-kontakt, farmasøyt? Er 
det nokon hos dykk som er spesielt god på dette? Kjenner de til fagprosedyren for 
diabetes i sjukeheimar og brukast denne? 
Kva forventningar har de til pleiarane? 
------------> 
 





Kva opplæring ønskjer de at pleiarane skal ha? Kven ønskjer de at skal gi denne? Kven 
skal ha ansvar for at denne blir gitt?Kva opplæring har de behov for sjølve?? 
Er sjukeheimen med i Noklus? Kva ønskjast frå Noklus? 
Avslutning/Oppsummering 
Alt i alt, føler de at vi har oppsummert dei viktigaste punkta i diskusjonen? Er det noko vi 








Førespurnad om deltaking i prosjektet 
Helsepersonell sine erfaringar, tankar og haldningar til 
blodsukkermålingspraksisar i sjukeheimar – ein kvalitativ studie 
 
Bakgrunn og formål 
Blodsukkermåling er eit verktøy innanfor diabetesomsorga som brukt riktig kan bidra til å gi 
informasjon om kor godt pasienten sin diabetes er kontrollert og på bakgrunn av dette 
optimalisere behandlinga. Det er gjort lite forsking blodsukkermålingspraksisar i sjukeheimar, 
og meir kunnskap trengs for å kunne vere trygg på at denne delen av diabetesomsorga møter 
behova til både pasientar og sjukeheimspersonell. 
Formålet med denne studien er å undersøke erfaringar, tankar og haldningar til 
blodsukkermåling i sjukeheimar gjennom profesjonsspesifikke gruppeintervju med tilsette 
legar, sjukepleiarar og hjelpepleiarar/helsfagarbeidarar. Det er viktig at vi får ei betre 
forståing av dei ulike profesjonsgruppene sine perspektiv på blodsukkermålingspraksisar, då 
dei er involvert på ulike måtar i handteringa av og ansvaret for desse praksisane. 
 
Kva inneber deltaking i studien? 
Dersom du seier deg villig til å delta i studien vil dette innebere at du deltar på eit 
gruppeintervju saman med 4-7 andre helsearbeidarar frå same yrkesgruppe. Gruppeintervjua 
vil vare i 60-75 minutt [tidspunkt og stad]. Vi ha lett servering ved intervjuet og deltakarane 
vil òg motta eit gåvekort på 400 kr som takk for innsatsen.  
Spørsmåla vil omhandle erfaring med og praktisk handtering av blodsukkermålingar, 
dokumentasjon, tolking og konsekvensar av resultat, og potensielle utfordringar for pasientar 
og/eller personalet. Vi vil ikkje stille spørsmål om eller be deg uttale deg om enkeltpasientar.  
Stipendiaten og ein eller fleire av rettleiarane vil leie intervjuet. Intervjuet vil bli tatt opp på 
lydband, og forskarane vil òg ta støttenotater undervegs. Dette utgjer grunnlaget for seinare 
omsetjing av lydmaterialet til tekst. Opplysningane som kjem fram vil bli anonymisert, og 
opptaka vil bli sletta når studien er ferdig, seinast desember 2014. Ingen enkeltpersonar vil 
kunne kjenne seg igjen i den ferdige artikkelen, som vil bli publisert i eit internasjonalt 
helsetidsskrift.  
 
Kva skjer med informasjonen om deg? 
Opplysningar om namn, stilling, arbeidsstad og kontaktinformasjon vil bli behandla 
konfidensielt og ikkje bli kopla opp mot intervjumaterialet. Denne informasjonen vil vere 




papirbasert, oppbevarast i ein låst skuff, berre vere tilgjengeleg for stipendiaten, og vil bli 
sletta straks etter intervjuet er ferdig.  
Lydopptaka vil bli overførte til og krypterte på ein pc og ein ekstern harddisk direkte etter 
intervjuet er avslutta. Lydfilene på minnekorta i opptakarane vil deretter slettast, så snart vi 
har forsikra oss om at overføringa til pc og ekstern harddisk har vore vellukka. Vi må høyre 
gjennom lydopptaka for å sjekke dette. Lydopptaka vil berre vere tilgjengeleg for dei 
involverte forskarane i studien.  
 
Frivillig deltaking 
Deltakinga er frivillig og du kan trekkje deg når som helst undervegs, utan å måtte grunngje 
dette nærare. 
 
Meir om studien 
Studien er del av eit doktorgradsprosjekt om diabetesomsorg i sjukeheimar, som utførast ved 
Universitetet i Bergen (UiB). I tillegg til stipendiaten, Lillan Mo Andreassen, er følgjande 
personar involvert i prosjektet: Førsteamanuensis Reidun Kjome (hovudrettleiar, UiB), 
professor Sverre Sandberg (birettleiar, UiB og Noklus), førsteamanuensis Una Sølvik 
(birettleiar, UiB og Noklus), Gunn Kristensen (birettleiar, Noklus og NKK), og professor 
Anne Gerd Granås (ressursperson kvalitativ metode, Høgskolen i Oslo og Akershus). 
Studien er ikkje søknadspliktig hjå Regional komité for medisinsk forskingsetikk (REK) eller 
hjå Norsk samfunnsvitskapleg datateneste (NSD), då vi ikkje samlar inn korkje 
helseopplysningar eller personopplysningar. 
 
Dersom du ønskjer å delta, eller har spørsmål til studien, ta kontakt med Lillan Mo 
















I løpet av datainnsamlinga til Paper I, kor eg reiste rundt til ulike sjukeheimar på Vestlandet 
for å samle inn data om medisinsk behandling av diabetespasientar, skreiv eg ein feltlogg. Eg 
skreiv blant anna korleis eg opplevde besøket på sjukeheimen, og i samtalar med 
kontaktpersonane mine ved sjukeheimen og dei andre tilsette, kom det også fram ein del 
generelle opplysningar om diabetesomsorga ved kvar enkelt sjukeheim. Enkelte var veldig 
opptatt av å fortelje om kva dei hadde av retningslinjer og kunnskap, og kor opptatt dei var av 
dette området etc., medan andre fokuserte meir på kva som ikkje fungerte og uttrykte ønske 
om meir kunnskap, betre tilrettelegging, betre forståing av feltet etc. Sidan ein del av 
datainnsamlinga involverte deltakande observasjon av blodsukkermålingar ved sjukeheimen, 
blei sjølvsagt fokuset i feltloggen mykje retta mot dette (kva fungerte, kva var vanskeleg, 
korleis opplevdes det eigentleg), for å kunne ha eit tillegg til å supplere dei meir 
standardiserte skjema som eg brukte under observasjonen.  
 
Eg fann eigentleg informasjonen om HbA1c-målingar mest interessant til å byrje med, fordi 
det verka som om praksisen for dette var den som var minst standardisert, og det var 
mulegvis på bakgrunn av dette at ideen om vidare utforsking av blodsukkermålingspraksis 
gjennom kvalitativ forskingsmetode kom i stand. På bakgrunn av det eg hadde sett, høyrt og 
blitt fortalt ila. feltarbeidet, i tillegg til kva eg hadde lest frå tidlegare i artiklar om 
blodsukkermålingspraksisar i sjukeheimar, satt eg igjen med inntrykket av at dette var eit 
område som hadde betra seg dei siste åra, særskilt i høve til førebuing og gjennomføring av 
målingane av pleiepersonalet (sjukepleiarar og hjelpepleiarar/helsefagarbeidarar). 
Samstundes fekk eg inntrykk av at det var lite refleksjon rundt kvifor enkelte pasientar fekk 
målt/ikkje målt, kor ofte dei fekk målt og kvifor ein gjorde det på dei tidspunkta ein gjorde 
det (for den enkelte pasient). Det verka meir som at blodsukkermåling var noko som var 
bestemt på avdelingsnivå heller enn på pasientnivå. Og det verka òg som om det var ein del 
av den daglege/vekevise rutina (på same måte som stell, frukost etc.), heller enn ei bevisst 
handling som hadde tydning for pasientens helse og sjukdomsoppfølging (med mindre 
verdien var svært unormal, og pasienten svært ustabil). Somme stader avdekka eg også brist i 
rutinane for dokumentasjon av resultata, og somme gonger blei resultata lagt inn i det 
elektroniske systemet når ein fekk tid seinare på dagen, men utan å korrigere tidspunktet i 
loggen. Somme stader var det også brist i rutinane for å innhente informasjon om HbA1c-
verdien. Ein tok gjerne å kryssa av for HbA1c når ein likevel skulle ta blodprøver, men 
gløymde gjerne å få den tilbake frå legekontoret slik at den kunne leggast inn i journalen. No 
skal det seiast at eg ytterst sjeldan snakka med legen på staden, så det kan vere at HbA1c-
verdiane blir sendt direkte til ho/han, men det mangla gjerne informasjon om dette i 
sjukeheimen/sjukepleiejournalen. Somme gonger verka det som om HbA1c-målingane var ei 
"legesak", medan dei vanlege kapillære blodsukkermålingane var ei "sjukepleiesak" fram til 
det eventuelt skjedde noko uvanleg.  
 
Eg tar derfor meg sjølv i å lure, og dette er ein frykteleg fordom mot 
pleiepersonalet/sjukepleiarane, om desse verdiane berre blir rapportert om det skulle "vere 
noko", om legen faktisk får sjå sjølve målingane/verdiane, eller om det blir rapportert i ord 
som "stabilt", "inga endring", "jamnt nivå" etc.? Kor trygge er dei på dei verdiane dei får i 
målingane, og kor trygg er legen på at desse er riktige? Og er legen sjølv aktiv med å spørje 
etter verdiane, setje eigne mål for kvar enkelt pasient og gjere vurderingar utifrå 
funksjonsnivå, samtidig sjukdom, behandling (både diabetes og anna), ikkje berre når 




pasienten kjem inn på sjukeheimen, men også undervegs? Og blir dette reflektert over blant 
pleiepersonalet, altså at "måleregime" til pasienten trengs å tilpassast både frå starten og 
undervegs? Og gir dei isåfall tilbakemelding til legen om dette? Mykje spørsmål rundt 
interaksjonen mellom lege-pleiepersonell når det gjeld oppfølging av pasienten altså. Kor ligg 
ansvaret, og kven kjenner på dette? Kunne det òg ha vore aktuelt å spørje om korleis dei 
vurderer måling/medisinsk behandling versus matrestriksjonar (som ikkje er anbefalt)? Blir 
dette for mykje? Kor mykje er det greit å inkludere, og kor like skal intervjuguidane til dei 
ulike helsepersonellgruppene vere? 
 
Om eg skulle formulere kva eg trur på førehand, må det bli at ein har ei haldning om at 
sjukeheimspasientar med diabetes for det meste er stabile, og at bestemming av måling blir 
gjort på "systemnivå", altså generelt for avdelinga, med 1-2 dagar i veka/månaden "for syns 
skuld", og at ein er mindre bevisst på kliniske symptom som kan medføre at ein må måle 
oftare (i alle fall på pleienivå - særskilt hjelpepleiarar/helsefagarbeidarar). Eg trur ikkje 
pleiarane rapporterer nok særleg tilbake til legane om kor ofte ein bør måle/kva som er best 
for pasienten, eller kanskje berre dette ikkje er eit samtale-emne? Eg trur at det som regel 
eksisterer retningslinjer for sjølve målinga (teknisk sett), men at retningslinjer for kva for 
nokre pasientar, kor ofte, og vidare dokumentasjon av resultata (til dømes når ein skal varsle 
lege) finst i mindre grad/ er i mindre grad kjent/utarbeida. Eg trur også det er for stort fokus 
på hyperglykemi istadenfor hypoglykemi, og at ein i mindre grad reagerer på om 
blodsukkeret er litt lågt, men dette er mest i høve til HbA1c. Spørsmålet er om dette skal med 
i intervjuguiden til legane - altså spørsmål om vurdering av HbA1c-målingar (kva? kvifor? 
kor ofte? tolking/vurdering? kva er for høgt/for lågt?). Eg trur også at det ikkje reflekterast så 
mykje rundt kvifor ein gjer målingane og kva ein faktisk bruker resultata til. Når det gjeld 
belastning for pasientane trur eg pleiepersonalet er meir obs på dette enn legane. Eg trur også 
legane har ei haldning til at pasientane i hovudsak er stabile og at dei får tilbakemelding frå 
sjukepleiarane skulle det skje endringar, men kor bevisst er sjukepleiarane dette ansvaret? Eg 
trur sjukepleiarane og også hjelpepleiarane/helsefagarbeidarane tenkjer at dei får beskjed av 
legen dersom ein skal måle oftare. Eg trur somme sjukepleiarar har reflektert over 
kvalitetsbiten av sjølve målinga, men ikkje nødvendigvis at dei elles betraktar denne som 
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